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Abstract: 
The Non-Wnt related functions of APC: the link between APC and apoptosis. 
 
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the 
UK and Western world. More than 90% of sporadic CRCs harbour mutations in the multi-
functional tumour suppressor gene Adenomatous polyposis coli (Apc).  The most commonly 
studied function of APC is its role as a scaffold for the β-catenin destruction complex 
involved in Wnt signalling. However, APC binds many other proteins. For example, it directly 
binds to and stabilises microtubules and actin. These non-Wnt related functions of APC are 
poorly understood. 
My PhD examines non-Wnt functions of APC. To this end, I created degron-tagged APC in 
DT40 cells that allowed for the rapid, conditional degradation of endogenous APC.  The 
aim was to identify the immediate effects on cellular processes. Then, to identify the 
contribution of different APC domains by measuring the ability to rescue any defects when 
reintroducing fragments of APC.  However, creation of these degron-tagged Apc knock-in 
cell lines resulted in hypomorphic phenotypes and auxin-associated off-target effects.  
Nonetheless, I compared the response of APChigh, APClow, and APCminimal cells to DNA 
damaging agents and Taxol® but found no significant differences.  
Subsequently, I focused on the relationship between APC and apoptosis. Previous 
observations suggested that deficiency in Apc rendered cells less sensitive to low doses of 
Taxol®.  However, Apc deficient cells were more readily killed when Taxol® was combined 
with the Bcl-2 inhibitor, ABT-737.  One possible explanation is the increase in Bcl-2 protein 
upon Apc depletion. However, I found that ABT-737, Taxol® and Apc depletion each cause 
activation of the unfolded protein response. This suggests that these treatments elicit a 
stress response that can stimulate apoptosis.  Moreover, the same treatments also cause 
changes in mitochondria.  Importantly, all of these effects do not require an increase in the 
β-catenin protein. Together, my data reveal novel links between APC and apoptosis that 
could be exploited clinically. 
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Chapter 1 - Introduction 
 
1.1 Background on colorectal cancer 
Nearly ten percent of all cancer diagnoses in the world are colorectal cancers (CRC). This 
makes CRC the third most common cancer in the world (according to the World Cancer 
Research Fund, 2012). Colorectal cancer is also the second most common cause of cancer 
death cancer in the UK (CRUK data, 2012). Currently, bowel screening is available 
biennially to anyone over the age of fifty in Scotland and 60 years of age in England. This 
is by means of the faecal occult blood test (FOBS) to detect blood traces in a stool sample 
(Hardcastle et al., 1980). However, more effective means of CRC testing is needed, ideally, 
a method(s) to detect bowel polyps (pre-cancerous growths). Over and above this, an 
understanding is needed of the genotypic and phenotypic initiating events that cause polyps 
and subsequent carcinomas, to develop. Prevention or destruction of a polyp may be able 
to circumvent the downstream accumulation of mutations and consequential physiological 
changes that lead to adenocarcinomas in the intestinal tract. Thus, decreasing the tumour 
burden and potentially alleviating the condition. Adenomatous polyposis coli (Apc) is the 
most mutated gene in human cancers (Polakis, 2012) and Apc mutations have been found 
in >90% of sporadic colorectal cancers (CRCs). This makes Apc an attractive target for 
cancer research, in understanding the first changes in normal intestinal tissues that leads 
to polyp development. 
  
1.2 Development of colorectal Cancer 
Mutation of Apc is the first step in the development of CRC (fig 1.1). It causes a change in 
intestinal epithelia leading to aberrant crypt foci. Further accumulation of mutations can lead 
to the development of polyps, which through the accumulation of subsequent mutations can 
progress into cancerous tissue (fig 1.1). The progression of CRC is clinically subdivided 
into stages (fig 1.2), referring to the size and metastasis of the tumour, that give an outlook  
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on the prognosis; TNM Stages (tumour, nodes, metastasis). Firsty, the T (tumour stage), 
T1 refers to a tumour still within the bowel epithelia. Stage T2 is a tumour that has grown 
into the muscle layer of the bowel. T3 means the tumour has grown into the outer lining of 
the bowel wall. T4 refers to a tumour that has grown through the outer wall of the bowel 
and as such much have grown into another part of the bowel, into other nearby structures 
or it may have broken through the peritoneum (fig 1.2). To classify the node(s) involvement 
of CRC progression, N0 means that there are no CRC cells contained within lymph nodes. 
Whereas, node stage N1 refers to up to 3 lymph nodes close to the bowel containing CRC 
cells. The last node stage N2 means there are CRC cells in more than 4 lymph nodes close 
to the bowel. Lastly the stages of metastasis can be classified in two groups. M0 means the 
cancer has not spread to other organs, whereas M1 means the cancer has spread to other 
parts of the body. All three results of the TNM stages are then put together, such as T2, N1, 
M0 to provide the clinical classification. 
 
Fig 1.1 The development of colorectal cancer. The. Image edited from Fodde, Smits and 
Clevers (2001). In wild-type (normal) intestinal epithelia there is a clear boundary between crypts 
and crypts remain largely linear structures. Loss of Apc is the first step towards the decelopment 
of CRC and leads to aberrant crypt foci. The accumulation of other mutations such in genes such 
as Kras, or Apc LOH leads to adenoma/polyp development. Subsequent mutations in genes such 
as the tumour suppressos Tp53 lead to the cancerous development into a (malignant) carcinoma. 
Image edited from Fodde, Smits and Clevers (2001). 
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Treatment for CRC is dependent on the stage and location of the cancer (information taken 
from CRUK, 2016). In those with early CRC surgery is usually the first option as up to all of 
the tumour can be removed. Radiotherapy is usually given in those with rectal tumours 
rather than those with bowel cancers. To treat T3 cancer, chemotherapy drugs such as 
Fluoracil are usually used after surgery. Combination therapy of two or more 
chemotherapeutic agents are currently in clnical trials. In advanced CRC (T4 cancer), the 
prognosis is poor with a terminal outlook and treatments are usually provided in an attempt 
to extend the life od the patient (rather than cure the disease).Surgery may be an option to 
remove blockages, slow the progression of the cancer, or remove a secondary cancer. 
Chemotherapy is the main course of treatment and if the first course was not successful, 
second and third courses – using different drugs can be administered. External beam 
radiotherapy may be used to shrink tumours, but is more likely to be used for a rectal 
tumour. An additional treatment for advanced bowel cancer is biological treatments – drugs 
that help to control the growth of the tumour(s). When used in combination with 
chemotherapy it can prolong life and importantly, improve the quality of life of the patient. 
Unfortunately, late stage CRC is very difficult to treat. The key in CRC treatment is in early 
detection. 
 
Fig 1.2 The TNM staging of colorectal 
cancer. The classification of a tumour 
depends on its TNM staging. T1 
tumours remain within the inner lining of 
the bowel. T2 tumours have grown 
throught the inner lining. T3 means the 
tumour is growing through the muscle 
layer and T4 tumours have grown 
through the outer wall of the bowel. 
Imaged taken from CRUK.  
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1.3 Physiology of the human intestine 
Maintaining the normal physiology of the intestine is key in preventing polyp and 
subsequent adenocarcinoma development. Therefore, an understanding of gut physiology 
is needed. The human intestine is the site of nutrient absorption and faecal matter creation 
in the body. The intestine is lined with an absorptive epithelial sheet, folded to form crypts 
of Lieberkühn that house the intestinal stem cells (fig 1.3). The intestinal stem cells are 
interspersed with anti-microbial secreting Paneth cells (Porter et al., 2002), whom protect 
the crypt niche (reviewed by Clevers, 2013). These stem cells produce cells (Cheng and 
Leblond, 1974) that migrate upwards through the crypt and transit-amplifying compartment. 
These cells then terminally differentiate into the cell types found in that region of the 
intestinal tract (Bjerknes and Cheng, 1981). Once cells reach the villus tip (small intestine) 
or the surface of the colonic epithelium (colon) they are shed into the lumen.This migration 
takes three to five days (see a review by Barker, 2014), so cell numbers need to be 
frequently replenished. Due to this high rate of cell turnover, the only cells likely to harbour 
genetic changes for long enough to change gut physiology, are the intestinal stem cells 
(Potten and Loeffler, 1990). Mutation of Apc specifically in stem cells is thought to be the 
initiating event in intestinal tumorigenesis (Kinzler and Vogelstein, 1996; Rowan et al., 
2000; Radulescu et al., 2010) – loss of APC in non-stem cells of the intestinal crypts does 
not result in tumorigenesis (Barker et al., 2009). Loss of APC precedes changes in crypt 
biology indicated by the presence of polyps. This suggests that it APC is required for the 
correct maintenance of intestinal and colonic epithelia (Su et al., 1992; Fodde et al., 1994; 
Oshima et al., 1995). 
 
 
1.4 Adenomatous polyposis coli (APC) 
The change from normal gut epithelium to a pre-cancerous polyp happens by mutation of 
the tumour suppressor gene Adenomatous polyposis coli (Apc) (Kinzler and Vogelstein, 
1996; Rowan et al., 2000; Radulescu et al., 2010). Its gene product is a large (312kDa, 
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2843 amino acid), multi-domain tumour suppressor protein with many binding partners and 
interactors (fig 1.4). Known binding sites at the N-terminus (N-APC) consist of an 
 
 
 
 
 
 
 
 
 
 
 
 
oligodimerisation domain (Su et al., 1993) 
and 7 Armadillo repeats that bind multiple 
partners (Hirschl, Bayer and Muller, 1996). 
The middle portion of APC (M-APC) contains 
3-15 amino acid (15R) and 7-20 amino (20R) 
repeats that bind axin and β-catenin, each 
with varying affinity - although when 
phosphorylated by axin, the 20mers have increased β-catenin affinity (Rubinfeld et al., 
1993; Rubinfeld, Tice and Polakis, 2001; Tickenbrock et al., 2003; Liu et al., 2006). These 
15R and 20R regions (fig 1.4) are key for the function of APC in the Wnt pathway (see Xing 
et al., 2004 for crystal structure detail of APC-β-catenin interaction). M-APC also has SAMP 
sites for axin binding, so-called after their consensus motif (serine, alanine, methionine, 
proline). The APC C-terminus (C-APC) has a basic domain for microtubule (MT) binding as 
well as a site for the MT binding protein EB1.  The extreme C-terminus contains a PDZ.
Fig 1.3 Crypt/Villus structure. The 
intestinal epithelium is invaginated. 
Folds create crypt structures that 
house the intestinal stem cells (SC) 
interspersed with anti-microbial 
secreting Paneth cells that protect 
the crypt niche. SCs produce 
progenitor cells that proliferate and 
migrate up through the transit 
amplifying region of the crypt where 
they will eventually terminally 
differentiate. In the small intestine 
these cells continue to migrate up 
through finger-like projections of the 
epithelium called villi. The villi 
protrude out into the lumen of the 
intestine. It takes 3-5 days for a cell 
to reach the villus tip before it is shed 
into the lumen.  
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Fig 1.4 Apc. The top panel shows the intron/exon structure of the Apc gene found on 5q21-22 (Kinzler et al., 1991). The 
black boxes represent exons and the arrow indicates the direction of transcription. The bottom panels shows the various 
binding domains within Apc. Exon 15 (top panel) contains the coding information for more than two thirds of Apc, as indicated 
by the dashed lines. Close to 75% of all Apc mutations occur in the mutation cluster region (MCR) resulting in an N-terminally 
truncated Apc (N-Apc) lacking most/all of the β-catenin, axin and microtubule binding domains.  
 
 
domain (fig 1.4) allowing interaction with other PDZ-domain-containing proteins such as 
DLG1/SAP97 (Matsumine et al., 1996). Importantly, APC binding to β-catenin and 
microtubules is mutually exclusive – APC can only bind one or the other (Penman, Leung 
and Näthke, 2005; Dikovskaya et al., 2007). 
 
Loss of Apc usually occurs through a nonsense mutation that falls within the mutation 
cluster region (MCR) (fig 1.4) (Mori et al., 1992). This results in a truncated APC (N-APC) 
that lacks many binding sites including those for -catenin, axin and microtubules (Su et al., 
1993). These N-terminal fragments cause dominant effects in the crypt. For instance, they 
induce aberrant cell migration (Nelson et al., 2012). This results in the basal extrusion of 
epithelial cells instead of the apical extrusion seen in Apc WT cells (Marshall et al., 2011). 
Thus heterozygous Apc is sufficient to create a dominant effect over the remaining wild type 
Apc allele and this is not correlated with large changes in the transcriptional activity of -
catenin. When both Apc alleles are lost, constitutive activation of proliferative pathways 
ensues through β-catenin, which accumulates in the nucleus and binds transcriptional 
coactivators TCF/LEF (Behrens et al., 1996; van de Wetering et al., 1997). This activates 
Wnt pathway gene transcription (for a list of Wnt target genes see appendix A). 
Understanding the entire spectrum of APC functions is key for understanding the changes 
that characterise Apc mutant cells and in treating CRC patients. 
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1.4.1 APC and Wnt signalling 
Aberrant regulation of the Wnt signalling pathway due to mutant Apc is the best understood 
link between APC and cancer. This is because APC acts as a negative regulator of β-
catenin as part of the Wnt signalling pathway (fig 1.5). Loss of function mutations in Apc, 
such as nonsense mutations found in CRC, abolish this function. APC is fundamental in the 
Wnt signalling pathway (fig 1.3) as it forms part of the -catenin destruction complex (DC) 
along with the scaffold protein axin (Nakamura et al., 1998) and kinases CK1 and GSK3 
(Rubinfeld et al., 1996; Behrens et al., 1998; Ideka et al., 1998). Axin may be the limiting 
step in DC formation as it is the least abundant member of the complex (Lee et al., 2003).  
. 
In the absence of a Wnt signal (fig 1.5 - WNT OFF), the DC targets -catenin for degradation 
by phosphorylation. CK1 phosphorylates -catenin at serine 45 and this acts as a priming 
kinase for GSK3 (Liu et al., 2002; Sakanaka, 2002), which subsequently phosphorylates 
serines 33, 37 and 41 (Winston et al., 1999). Phospho--catenin is recognised by the F-box 
protein -TrCP (Kitagawa et al., 1999; Latres, Chjaur and Pagano, 1999; Winston et al., 
1999) and is subsequently degraded by the 26S proteasome (Hart et al., 1999). 
 
The 3-15R and 7-20R regions (fig 1.5) are key for the function of APC in the DC as they 
bind axin and -catenin. This allows –catenin to be phosphorylated at its N-terminus, 
targeting it for its ultimate destruction by the proteasome. Loss of this pathway plays an 
important role in tumorigenesis as an increase in -catenin leads to its cytoplasmic 
accumulation and subsequent nuclear translocation. Here, it alters gene expression profiles 
upon binding the transcriptional coactivators TCF/LEF (Behrens et al., 1996; Korinek et al., 
1997; van de Wetering et al., 1997). (For a list of Wnt target genes see appendix A). This 
leads to an upregulation of oncogenes such as c-Myc (He et al., 1998), Cyclin D1 (Shtutman 
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et al., 1999; Tetsu and McCormick, 1999) and other genes thought to be involved in 
proliferation. 
 
 
 
 
 
 
 
 
 
1.4.2 APC and microtubules 
Other than Wnt signalling, APC has also emerged as a key regulator of microtubules (MTs). 
This is another link between APC and cancer as loss of Apc leads to chromosome instability 
(CIN) due to MT defects (Green and Kaplan, 2003). Microtubules are dynamic tubulin 
Fig 1.5. The β-catenin destruction complex in Wnt signalling. Beta-catenin is found at 
various locations within the cell; it binds E-cadherin at the membrane to form adherens 
junctions, it is found in the cytosol and in the nucleus. APC forms part of the β-catenin 
destruction complex (DC) with the scaffold protein Axin and kinases CK1 and GSK3β.  In the 
absence of a Wnt ligand (WNT OFF) the DC binds cytosolic β-catenin through APC and Axin. 
CK1 phosphorylates β-catenin and is the priming kinase for subsequent GSK3β 
phosphorylation. Phosphorylated β-catenin is targeted for proteasomal degradation. However, 
upon a Wnt ligand binding (WNT ON) to the receptor LRP5/6 and its co-receptor Frizzled 
(Fzd), it is thought that the receptors recruit the adaptor protein Dishevelled (Dsh), which binds 
to the DC. This prevents the DC from phosphorylating β-catenin and targeting it for 
degradation. Subsequently, β-catenin accumulates in the cytosol, translocates to the nucleus 
and binds the transcriptional co-activators TCF/LEF. This induces transcription of Wnt target 
genes. 
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polymers (consisting of α-β tubulin heterodimers) used by eukaryotes for cellular structure, 
a means of intracellular transport, mitotic spindles and together with actin and intermediate 
filaments they form the cytoskeleton. The APC C-terminus harbours a MT binding domain 
(Deka et al., 1998) and a site to interact with the microtubule-binding protein EB1 (Berrueta 
et al., 1998). Loss of Apc leads to chromosome instability (CIN). There are several reasons 
why this can occur. 
 
APC binds to MT plus-ends, stabilising them (Mimori-Kiyosue, Shiina and Tsukita, 2000; 
Zumbrunn et al., 2001; Mogensen et al., 2002; Kroboth et al., 2007). In Apc mutant cells 
MTs are less stable (Kita et al., 2006; Kroboth et al., 2007) meaning mitotic spindles may 
not form correctly, leaving unattached centrosomes. APC is also found at kinetochore-
microtubule attachment sites during mitosis (Fodde et al., 2001; Kaplan et al., 2001), and 
Apc depleted cells show reduced kinetochore tension in mitosis (Dikovskaya et al., 2007).  
Hence, Apc deficient cells may lack appropriate attachments required to pull apart sister 
chromatids appropriately. Indeed, Apc mutant cells are defective in chromosome 
segregation (Fodde et al., 2001; Kaplan et al., 2001; Dikovskaya, Newton and Näthke, 
2004; Draviam et al., 2006).  
 
Fodde et al., (2001) used FISH analysis on 2 ES cell lines, each containing differently 
truncated Apc (nonsense mutations). Both cell lines produced karyotypes with near-
tetraploid genomes and more structural rearrangements than WT ES cells. This again 
indicates that a lack of WT Apc leads to problems with mitotic spindles. This results in a 
failure to maintain euploidy and chromosomal translocations (CIN). 
 
1.4.2.1 Microtubule poisons 
Microtubule poisons are commonly used chemotherapeutic agents used to disrupt MT 
dynamics. This results in altered spindle fibres in mitosis and functional changes in 
microtubules during interphase. The toxic effect of microtubule poisons is caused by 
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apoptosis due to a prolonged mitotic arrest (Ellis et al., 1999). The MT poisons Nocodazole 
and Vinorelbine prevent MT polymerisation (Lobert, Vulevic and Correia, 1996). Taxol® 
stabilises MTs and prevents their depolymerisation (Schiff and Horwitz, 1980). APC-bound 
microtubules are stabilised and more resilient against depolymerising agents (Zumbrunn et 
al., 2001). However, cells with mutant Apc arrest much less readily in mitosis in response 
to Taxol® (Radulescu et al., 2010). Conversely, Vinorelbine kills Apc deficient cells more 
effectively than cells with WT Apc because it can kill cells in interphase, irrespective of a 
mitotic arrest (Klotz et al., 2012). Investigating a means to kill Apc deficient cells using 
Taxol® means killing proliferating cells such as cancer cells. This would leave cells in 
interphase untouched, unlike Vinorelbine treatment. 
 
1.4.2.2 Taxol® mechanism of action 
Taxol® was the microtubule poison used for experiments in this thesis. Taxol® works as a 
microtubule poison because it binds the microtubule ‘plus’ ends, stabilising them, meaning 
they are resistant to depolymerisation induced by Ca2+, cold temperatures and dilution 
(Schiff, Fant and Horwitz , 1979). Specifically, Taxol® binds to the β-tubulin subunit of 
microtubules (Diaz, Menendez and Andreu, 1993; Rao et al., 1994). Therefore, 
microtubules are unable to remain dynamic because they can no longer remodel 
themelves. 
 
1.4.2.3 Microtubules and the spindle assembly checkpoint 
One reason why Apc deficient cells do not arrest in response to Taxol® is a defective 
spindle assembly checkpoint (Fodde et al., 2001; Kaplan et al., 2001; Dikovskaya et al., 
2007). Disrupted mitotic spindles should activate the spindle assembly checkpoint during 
prometaphase in eukaryotic cells. This happens when chromosomes are misattached to 
cell poles by the mitotic spindle or through the use of MT poisons to disrupt MT dynamics. 
Checkpoint activation results in mitotic arrest (Hoyt Totis and Roberts, 1991). Activation of 
the spindle assembly checkpoint should therefore prevent CIN. Thus, Apc depleted cells 
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harbour CIN as a result of defective MTs and inactivation of the spindle assembly 
checkpoint that should detect spindle problems (Dikovskaya et al., 2007). The lethality of 
MT poisons is due to apoptosis resulting from a prolonged mitotic arrest. However, Apc 
deficient cells do not efficiently undergo apoptosis in response to Taxol® treatment. 
Developing a means to kill Apc deficient cells is of great clinical benefit in treating CRC. 
 
1.5 Cell death 
Killing Apc deficient cells is important in treating CRC. Therefore, understanding the 
mechanisms that lead to cell death is key in activating these pathways. In 2005 the 
Nomenclature Committee on Cell Death (NCDD) proposed new criteria to define cell death. 
They stated that for a cell to die there must be irreversible loss of plasma membrane 
integrity (Kroemer et al., 2005). There are many processes that lead to loss of membrane 
integrity (cell death). I will now introduce apoptotic cell death because that is what this thesis 
looked at. 
 
1.5.1 Apoptosis 
The best characterised and most studied form of programmed cell death is apoptosis, first 
described by Kerr, Wyllie and Currie, (1972). A more in depth understanding of its function 
came from later work done on the nematode worm Caenorhabditis elegans. Importantly, 
this showed that apoptosis is a key component during development and in maintaining 
healthy cells and tissues (Horvitz, 1999). According to the NCDD in 2009, the cellular 
changes leading to apoptotic cell death are: chromatin condensation, cell shrinkage 
(pyknosis), little to no modifications to organelles, nuclear fragmentation (karyorrhexis), 
membrane blebbing and the separation of these fragments into apoptotic bodies, with 
subsequent engulfment by phagocytes (Kroemer et al., 2009). Additionally, a hallmark of 
apoptosis is caspase activation. There are two separate apoptotic pathways – the intrinsic 
mitochondrial pathway and extrinsic death receptor pathway. Both pathways converge on 
executioner caspase 3.   
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1.5.1.1 The extrinsic pathway 
The extrinsic pathway of apoptotic cell death (fig 1.6) involves plasma membrane receptors 
relaying a death message to the cell. Death ligands such as CD95L, TRAIL or TNFα, bind 
to death receptors in the plasma membrane. The receptors have a cytoplasmic death 
domain (DD) that binds a cytosolic adaptor protein, which can transmit the death signal 
(Tartaglia et al., 1993). This results in the activation of pro-caspase 8, which in turn activates 
the downstream effector caspase 3 (fig 1.6).  
 
1.5.1.2 Bcl-2 family proteins 
The Bcl-2 family of proteins (table 1.1) govern intrinsic apoptosis. The interaction of Bcl-2 
proteins with each other controls the life/death fate of a cell (fig 1.7). Binding of proteins 
within the Bcl-2 family are well understood, but their regulation by signals out-with the family 
are poorly understood.  The family is comprised of proteins that share between one and 
four BH (Bcl-2 homology) domains (fig 1.8) and is split into three subgroups (table 1.1).  
 
 
 
Pro-life proteins, such as Bcl-2 contain all four BH domains and are the “guardians” of the 
cell against apoptosis (fig 1.8). They bind to pro-death proteins, neutralising their capacity 
to induce apoptosis (Zha et al., 1996). Their pro-life function is evident as overexpression  
TABLE 1.1 
Bcl-2 Family Proteins 
Pro-life “Guardians” Pro-death “Effectors” BH3-only “Initiators” 
Bcl-2 BAX Activators Sensitizers 
Bcl-XL BAK PUMA NOXA 
Mcl-1 BOK BIM BAD 
Bcl-w/Bcl2L2 Bcl-XS tBID BIK 
A1   BMF 
Bcl-B/Bcl2L10   HRK 
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Fig 1.6. The extrinsic and intrinsic apoptotic pathways. Both pathways converge on the executioner 
caspases 3, 6 and 7. The intrinsic pathway. Extracellular apoptotic stimuli such as cytokine deprivation are 
passed across the plasma membrane. Intracellular stimuli such as increased ROS and intracellular Ca2+, hypoxia 
or glucose deprivation transduce intracellular signals. Both intra and extracellular stimuli are thought to activate 
p53, which results in the transcription and post-translational modification of sensitizer BH3 proteins Pums, Noxa 
and Bim. These BH3 only proteins bind pro-life proteins Bcl-2, Bcl-XL and Mcl-1. This binding prevents them 
from heterodimerising with the pro-death proteins. This enables BAX and BAK to form a pore in the mitochondrial 
outer membrane from which cytochrome c can escape into the cytosol. Cytochrome c binds APAF-1 and 
caspase 9 to form the apoptosome, which can then activate the executioner caspases 3, 6 and 7. DIABLO is 
also released from the mitochondrial pore, inhibiting the executioner caspases inhibition by IAPS. The extrinsic 
pathway. A death ligand such as CD95L or TRAIL bind to its transmembrane death receptor such as CD95 or 
TRAIL-R1/2. This activates the death domain (DD) within the receptor, which then recruits an adaptor protein 
such as FADD, resulting in transduction of the apoptotic signal. Procaspase 8 is cleaved into the active caspase 
8 (inhibiting the pro-survival C-FLIP). Caspase 8 then cleaves the executioner caspases 3, 6 and 7 and apoptosis 
ensues.   Pathway cross-talk. The intrinsic and extrinsic pathways can cross-talk through the BH3-only protein 
BID, which is cleaved by caspase 8 in the extrinsic pathway. Activated Bid (tBid) then binds the mitochondrial 
outer membrane and forms a pore allowing the release of mitochondrial components such as cytochrome c.  
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studies have shown that they confer resistance to apoptosis (McDonnell et al., 1989; 
Strasser, Harris and Cory, 1991). Pro-death proteins such as Bax are the “effectors” of 
apoptosis and contain 3 BH domains (fig 1.8). They can both homodimerize and 
heterodimerize, which induces a conformational change from inert monomers to allow the 
exposure of the apoptotic BH3-domain (Czabotar et al., 2013). Once bound to the 
mitochondrial outer membrane (MOM), the complex of pro-death proteins forms a pore in 
the membrane. This allows the release of cytochrome c (Jürgensmeier et al., 1998) for 
subsequent assembly of the apoptosome and the execution of apoptosis (fig 1.6). However, 
the exact mechanism for BAX and BAK induced membrane permeabilisation is still 
unknown. BH3-only proteins are the “initiators” of apoptosis, conveying the message to 
start apoptosis. As the name suggests they contain just the BH3 domain (fig 1.8). They are  
Fig 1.7. Bcl-2 family proteins life/death balance. (a) The relationship between the life and 
death of a cell relies on intricate partnerships between Bcl-2 proteins. The balance between 
life and death is shown schematically as a set of scales. (b)  In order for a cell to live, the 
balance of the scales must tip in favour of the formation of pro-life protein interactions. The pro-
life set of Bcl-2 proteins (green) must bind the pro-death proteins (red) to prevent them for 
executing apoptosis. (c) If the balance is to be tipped towards death, there needs to be more 
binding between protein partnerships that favour apoptosis. The BH3 proteins (purple) bind the 
pro-life proteins (green) and this frees up the pro-death proteins (red) to homo and 
heterodimerize, and illicit the apoptotic programme. 
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induced either transcriptionally or post-translationally by cytotoxic stress signals (see review 
by Adams and Cory, 2007). BH3-only proteins can initiate apoptosis in two ways and as 
such are further classified into two subgroups (table 1.1). The “activators” directly bind pro-
death proteins causing a conformational change that exposes their BH3 apoptotic domains 
(Letai et al., 2002; Certo et al., 2006). The “sensitizers” bind to pro-life proteins, preventing 
them from binding and neutralising pro-death proteins (Letai et al., 2002; Chen et al., 2005). 
Thus the BH3-only proteins both free-up and activate the pro-death proteins, to execute 
apoptosis. 
 
1.5.1.3 The intrinsic pathway 
The intrinsic/or mitochondrial pathway results in apoptosis induced by the release of 
cytochrome c from mitochondria (fig 1.6). It is carried out by Bcl-2 family proteins,  
stimulated by such factors as ER stress, UV-radiation, growth serum deprivation, increased 
ROS, increased intracellular Ca2+ and DNA damage (Galluzzi, Blomgren and Kroemer, 
2009). Many factors of intrinsic pathway regulation are still unknown. However, cytotoxic 
stimuli are known to activate the tumour suppressor protein p53, which upregulates BH3-
only proteins such as PUMA and NOXA (Villunger et al., 2003) (fig 1.6). These BH3-only 
proteins bind to pro-life proteins such as Bcl-2, Bcl-XL and Mcl-1. This frees up pro-death 
Fig 1.8. Structure of Bcl-2 family proteins. Representative examples of the BH domains 
in Bcl-2 family proteins. Different proteins within each group vary in size. (a) Pro-life proteins 
contain all 4 BH domains and a transmembrane domain TM. (b)  Pro-death proteins express 
BH domains 1-3 and a TM domain. (c) BH3-only proteins lack BH 1, 2 and 4 but still possess 
a TM domain. Note that gene structures are not to scale.  
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proteins BAX and BAK from their neutralising pro-life partners. In healthy cells BAK is 
constituently bound to the mitochondrial outer membrane (MOM) by its C-terminal 
transmembrane domain (Griffiths et al., 1999). However, cytotoxic stimuli leads to the 
translocation of BAX from the cytosol to the MOM (Wolter et al., 1997; Smaili et al., 2001). 
BAK and BAX then homooligomerise via their BH3 domains (Dewson et al., 2008). 
Subsequently, BAX and BAK are activated and form a pore in the MOM – the mechanism 
for which is unknown (see a detailed review by Czabotar et al., 2014 discussing different 
models of BAX and BAK activation). This pore allows the release of cytochrome c, which 
binds with caspase 9 and APAF-1 to form the apoptosome (fig 1.6). The mitochondrial pore 
also allows the release of DIABLO (also known as SMAC), which binds and inhibits IAPs, 
preventing their inhibition of executioner caspases 3, 6 and 7 (fig 1,6)  (Du et al., 2000; 
Verhagen et al., 2000). Together, the apoptosome and DIABLO allow the activation of 
procaspases 3, 6 and 7 and subsequent execution of apoptosis.  
 
1.5.1.4 Crosstalk between the intrinsic and extrinsic pathways 
Although the intrinsic and extrinsic apoptotic pathways are separate mechanisms that 
induce cell death, activation of caspase 8 as part of the extrinsic pathway can lead to 
mitochondrial damage and subsequent cytochrome c release (fig 1.6). After death receptor 
activation, caspase 8 can cleave the BH3-only protein Bid (Li et al., 1998). The truncated 
and activated Bid (tBid) then translocates from the cytosol to mitochondria. This leads to 
cytochrome c release from the mitochondria (by an unknown mechanism) and apoptosis 
ensues (Luo et al., 1998). Activation of Bid happens under specific circumstances such as 
non-steroidal anti-inflammatory (NSAID) drugs (Leibowitz et al., 2014). 
 
1.5.1.5 Small molecule inhibitors against pro-life proteins 
Members of the pro-life Bcl-2 family of proteins are often over-expressed in cancer. This 
over-reliance of pro-life proteins makes it difficult to kill these cells and provides resistance 
to certain chemotherapeutics (Oltersdorf et al., 2005). Inhibiting the pro-life proteins in these 
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cancer cells may enable them to be killed, paving the way for a new type of cancer therapy. 
Small molecule inhibitors are organic molecules of low molecular weight (usually below 
750Da) meaning they are practical and cost-effective. Several small molecule inhibitors of 
pro-life Bcl-2 proteins have been produced, one of which, ABT-737, was used for the 
experiments in this thesis. Several next-generation Bcl-2 inhibtors based on the structure 
of ABT-737 are now in clinical trials (fig 1.9). 
 
 
 
 
 
1.5.1.5.1 ABT-737 
ABT-737 is a small molecule inhibitor of certain pro-life proteins, used for experiments in 
this thesis. Oltersdorf et al., (2005) discovered ABT-737, a small molecule BH3 mimetic that 
binds Bcl-2, Bcl-XL and Bcl-w (fig 1.9a). ABT-737 does not directly activate pro-death 
proteins BAX or BAK. Instead, it mimics a BH3-domain and binds to the hydrophobic groove 
of its target pro-life proteins. This prevents their interaction with pro-death proteins. It is 
highly effective in perturbing Bim-Bcl-2 interactions, more so than Bim-Bcl-XL. Therefore 
Fig 1.9. Chemical structures of Bcl-2 family protein inhibitors. (a) ABT-737. Structure 
taken from the Sussex Drug Discovery Centre. (b) ABT-263. Structure taken from the 
Sussex Drug Discovery Centre. (c) ABT-199. Structure taken from the Sussex Drug 
Discovery Centre. (d) GX-015-070 (Obatocloax). Image taken from Apexbio. 
39 
 
cells with high levels of Bcl-2 are especially susceptible to ABT-737 (Merino et al., 2012). 
ABT-737 is currently in phase II clinical trials.  
 
1.5.1.5.2 ABT-263 (Navitoclax) 
Three key sites on the backbone of ABT-737 were identified, which affect its oral absorption, 
metabolism and charge. These sites were altered producing ABT-363, a second generation 
BH3 mimetic, structurally similar to ABT-737 but with the addition of being orally available 
(Fig 197b). It is selective against Bcl-2 and Bcl-XL and Bcl-w in vitro (Tse et al., 2008). ABT-
263 is currently in phase II clinical trials.  
 
1.5.1.5.3 ABT-199 
One side-effect from ABT-263 treatment was a reduction in platelets, specifically caused 
by Bcl-XL inhibition (which controls platelet lifespan) and ultimately meant that the drug is 
dose-limiting. The first small molecule inhibitor selective for Bcl-2 (alone) is ABT-199 
(Souers et al., 2013). Structurally similar to ABT-263 (fig 1.9c), it does not have an effect 
on platelets (Souers et al., 2013; Vaillant et al., 2013). The compound is currently in phase 
I clinical trials. 
 
1.5.1.5.4 GX-015-070 (Obatoclax) 
This compound (fig 1.9 d) works in two ways. It prevents Mcl-1 binding to Bak and it 
upregulates the BH3 only protein Bim (Trudel et al., 2007). Konopleva et al., (2008) showed 
that this compound synergized with ABT-737 to induce apoptosis. Phosphorylated Bcl-2 
was resistant to GX-015-070, but again compounding the treatment with ERK inhibitors 
sensitized cells with phosphor-Bcl-2 to apoptosis (Perez-Galan et al., 2008). Therefore, GX-
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O15-070 is emerging as a potent inducer of apoptosis when used in combination with 
another molecule to target Bcl-2 family proteins. 
 
1.6 Cellular stress responses 
This thesis examined the role of APC with two separate stress responses, which will now 
be introduced. 
 
1.6.1 DNA damage response 
There has long been a link between APC and DNA damage. This thesis aimed to discover 
a more robust link between the two. DNA damage is a normal consequence of DNA 
synthesis that needs to be corrected. DNA damage can also occur as the result of 
extracellular compounds and environmental agents such as chemical damage and UV-
radiation. The DNA damage response (DDR) is the cooperation of cell cycle checkpoints, 
DDR signalling pathways and DNA damage repair in sensing, signalling and repairing DNA 
damage (see reviews by Rouse and Jackson, 2002; Ciccia and Elledge, 2009). DNA 
damage sensors ATM and ATR are recruited to damaged DNA where they act on cyclin-
dependent kinases to arrest the cell cycle, allowing DNA repair to occur (Kastan et al., 
1992). There are multiple methods a cell can use to repair different types of damage, such 
as non-homologous end-joining (Thode, Schafer, Pfeiffer and Vielmetter, 1990), 
homologous recombination (Gerstel and Phillips, 1958; Stephens, 1961), single strand 
break (SSB) repair (Walker and Sridhar, 1976; Sheridan, R.B. and Huang, P.C. 1977), 
base-excision repair (BER) (Lindahl, 1974), nucleotide-excision repair (NER) (Grossman, 
Riazzudin, Haseltine and Lindan (1979) and mismatch repair (MMR) (Wildenberg and 
Meselson, 1975). This thesis will briefly introduce BER.  
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The base excision repair (BER) pathway typically removes incorrect or damaged bases that 
do not distort the helix structure, such as deamination, oxidation or alkylation. DNA 
glycosylases recognise and remove these bases from DNA by hydrolysing the glycosylic 
bond between the target base and deoxyribose sugar (Lindahl, 1974), creating AP site(s) 
(apurinic/apyrimidinic). An AP endonuclease then cleaves and removes the remaining DNA 
backbone at the 5’ end. The endonuclease then recruits DNA polymerase β, which 
synthesises the correct base(s) and a ligase seals the single strand break (Bennett et al., 
1997). Short-patch BER is the correction of one base (Kubota et al., 1996), whereas long-
patch BER involves the processing of two or more bases (Klungland and Lindahl, 1997). 
Note that DNA damage resulting in helix distortion is often repaired by the related pathway, 
nucleotide excision repair.  
 
1.6.2 The unfolded protein response  
Over the course of this thesis a link was made between cell treatments ABT-737, Taxol® 
and siRNAs with ER stress, specifically, the unfolded protein response (UPR) (fig 1.7). The 
endoplasmic reticulum (ER) is a large tubular network that is a site of metabolic processes, 
the main store of intracellular calcium and the site of protein folding in the cell (Rao et al., 
2001). ER stress occurs when there is an accumulation of unfolded or misfolded proteins 
in the ER. To resolve the ER stress the cell activates the evolutionally conserved, pro-
survival, unfolded protein response (UPR) (Hollien, 2013). This mechanism aims to resolve 
ER homeostasis by reducing the ER burden through signalling to both the nucleus and the 
cytosol (fig 1.7). This signalling acts to control gene transcription, protein translation and 
expansion of the ER to increase its protein folding capacity (Hetz, 2012). However, if the 
ER stress is irremediable then the UPR can initiate apoptosis (Nagawa et al., 2000; Rao et 
al., 2001; Marciniak et al., 2004). If the ER stress continues without UPR activation, the 
toxic aggregation of unfolded proteins can lead to disorders such as Parkinson’s disease, 
ischaemia and diabetes (Kaufman, 2002). 
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The UPR signals are transduced by three main stress sensors embedded in the ER (see 
an excellent review by Hetz, 2012). During unstressed conditions the ER chaperone BiP 
(also known as GRP78) binds to the luminal surface of the stress sensors. However, during 
ER stress (fig 1.7), BiP dissociation triggers sensor activation and the UPR (Bertolotti et al., 
2000). 
 
The transmembrane kinase inositol requiring enzyme alpha (IREα) (Nikawa and Yawashita, 
1992; Cox et al., 1993) dimerises upon ER stress and autotransphosphorylates to activate 
its cytosolic RNase domain (Shamu and Walter, 1996; Liu, Schroder and Kaufman, 2000). 
The now active P-IRE (phosphorylated-IRE) has three main functions (fig 1.7). It recruits 
the adaptor protein TRAF2, which signals through JNK and interacts with NF-kB subunit 
IKK to alert the cell to ER stress (Hu et al., 2006). P-IRE also degrades certain mRNAs 
through the RIDD protein, preventing de novo protein synthesis (Hollien et al., 2009). P-
IRE also induces gene-transcription of ER stress genes by inducing the mRNA processing 
of X-BP1. X-BP1 is a transcription factor of genes involved in protein folding, protein quality 
control and ER-associated degradation (ERAD) genes (Cox and Walter, 1996).  
 
Another ER transmembrane stress sensor, protein kinase-like ER kinase (PERK) dimerises 
and autotransphosphorylates upon ER stress (Harding, Zhang and Ron, 1999; Liu, 
Schroder and Kaufman, 2000) (fig 1.7). Phosphorylated PERK (P-PERK) phosphorylates 
eukaryotic translation initiation factor two alpha (eIF2α) on serine 51 of the alpha subunit 
(Sudhakar et al., 2000). Phosphorylated eIF2α halts most de novo protein synthesis by 
interfering with the translation-initiation complex (Srivastava, Davies and Kaufman, 1995). 
Lastly, peIF2α allows the translation of ATF4 mRNA (fig 1.7), a transcription factor for genes 
involved in autophagy, apoptosis, amino acid metabolism and antioxidant responses 
(Harding et al., 2000). 
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Thirdly, activating transcription factor 6 (ATF6) is another transmembrane stress sensor, 
which has a cytosolic basic leucine zipper (bZIP) transcription factor (Haze et al., 1999) (fig 
1.7). In stressed cells ATF6 is transported to the Golgi apparatus through interaction with 
the vesicular traffic protein COPII (Schindler and Schekman, 2009). At the Golgi, ATF6 is 
processed by proteases S1P and S2P to release the cytosolic bZIP fragment, ATF6f. ATF6f 
then translocates into the nucleus (Ye et al., 2000). Here, it controls the transcription of 
ERAD genes and X-BP1, which is subsequently spliced by P-IRE (Yoshida et al., 2001; Lee 
et al., 2002; Yamamoto et al., 2007). 
 
1.7 Overall aims of the thesis  
This thesis aims to examine the non-Wnt functions of APC. In order to achieve this I aimed 
to use a reverse-genetics approach to create a conditionally, degradable APC in DT40 cells 
using the auxin-inducible degron (AID) system. This meant that immediate consequences 
of APC depletion could then be studied. Once the cell-line had been produced I aimed to 
use it to deplete APC and then introduce fragments of Apc to determine if APC loss-induced 
phenotypes could be rescued. This would then link certain areas within APC with a specific 
cellular function. When the AID-system cell line produced off-target effects, a new approach 
of studying the non-Wnt functions of APC was required. My project moved on to examine 
the link between APC and (the non-Wnt function) apoptosis, previously eluded to in the 
literature, but which lacked molecular explanation. A previous student in the lab had 
discovered that the use of the Bcl-2 inhibitor ABT-737 overcame the resistance of Apc 
deficient cells to Taxol®. This then prompted a study into a link between APC and Bcl-2 
family proteins (which govern the intrinsic apoptotic pathway). Once identified, I wanted to 
establish the link between APC and Bcl-2 and the effect(s) that Apc loss/mutant APC had 
on these proteins and their known functions. Furthermore, I wanted to be able to explain 
why Bcl-2 inhibitors sensitised Apc deficient cells to the microtubule poison Taxol®.
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Fig 1.8. The unfolded protein response. In unstressed cells the ER chaperone BiP is bound to the luminal surface of all three ER 
transmembrane stress sensors, IRE, PERK and ATF6. (a) BiP dissociation upon ER stress leads to IRE dimerization and 
autotransphosphorylation. Phospho-IRE recruits the adaptor TRAF2 that signals to JNK and binds the NF-kB subunit IKK to alarm the cell 
to ER stress. P-IRE also causes mRNA degradation through the RIDD protein and induces XBP1 mRNA processing. The XBP1 protein is a 
transcription factor and activates transcription of UPR target genes. (b)  After BiP dissociation, PERK dimerises and 
autotransphosphorylates. PERK then phosphorylates eIF2α which can inhibit de novo protein synthesis and activate ATF4, a transcription 
factor of UPR genes. (c) BiP dissociation leads to the binding of the vesicular transport protein COPII. ATF6 is transported to the Golgi 
where its cytosolic domain is cleaved by proteases S1P and S2P. The cleaved ATF6f is a transcription factor that activates transcription 
of UPR target genes. Figure adapted from Hetz (2012). 
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Chapter 2 - Materials and Methods 
 
2.1 Materials 
 
2.1.1 Antibiotics 
2.1.1.1 Ampicillin 
Ampicillin (Melford, 69-52-3) was stored at a stock concentration at 100µg/ml. 
Stored at -20C. 
 
2.1.1.2 Blasticidin 
Blasticidin (Invivogen, ant-bl-5) was stored at a stock concentration at 10mg/ml. 
Stored at -20C. 
 
2.1.1.3 Kanamycin 
Kanamycin (SIGMA, K1377-5G) was stored at a stock concentration at 50µg/ml. 
Stored at -20C. 
 
2.1.2 Drugs 
2.1.2.1 ABT-737 
A 1mM stock of ABT-737 (Selleck Chemicals, LLC S1002) was diluted in media and 
added to cells at a final concentration of 7μM for 24 hours before harvesting (unless 
otherwise stated). 
 
2.1.2.2 Cisplatin 
A 1mM stock of Cisplatin (Calbiochem, D00155099) was added to cells at a final 
concentration as indicated in the text, for 2 hours.  
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2.1.2.3 Hydroxyurea 
A 100mM stock of Hydroxyurea (SIGMA, H8627-5G) was added to cells at a final 
concentration as indicated in the text, for 16 hours.  
 
2.1.2.4 PARPi 
A 10mM stock of PARPi (Olaparib, Axon Medchem, Axon 1463) was added to 
cells to a final concentration as indicated in the text, for 24hours 
 
2.1.2.5 Taxol® 
Taxol® (SIGMA T1912) was stored as a stock solution of 5.9mM. A dilution in media 
was made to create a working solution of 5.9µM and this was added to cells at a 
final concentration as stated in the text. 
 
2.1.3 Buffers and Stains 
2.1.3.1 Agarose-gel electrophoresis 
2.1.3.1.1 50 X TAE  
2M Tris Acetate, 50mM EDTA and 0.05% glacial acetic acid. A 1X solution 
was then used for agarose gel electrophoresis. Stored at RT. 
 
2.1.3.2 Western blot 
2.1.3.2.1 MEBC lysis buffer 
50mM Tris-HCl pH 7.5, 100mM NaCl, 5mM EDTA-Na, 5mM EGTA-Na, 
40mM β-glycerophosphate, 0.5% NP40. Inhibitors (10µg/ml) added right 
before use: LPC (leupeptin, pepstatin A and chemystatin), 1M NaF and 0.1M 
NaVO4. Solution filter sterilised. Stored at 4C.  
 
2.1.3.2.2 RIPA lysis buffer  
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150mM sodium chloride, 1% NP-40/Triton-X-100, 0.5% sodium 
deoxycholate, 0.1% SDS and 50mM Tris, pH 8.0. Solution filter sterilised. 
Stored at 4C. 
 
2.1.3.2.3 PBS 
80g NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4 and H20 up to 1L. Store at 
RT. 
 
2.1.3.2.4.TBS 
121.4g Tris, 81.9g NaCl and add H20 up to 1L. Use HCl to pH to 7.4. Store 
at RT. 
 
2.1.3.2.5 1X TBS-T/Wash buffer 
1X TBS and 0.1% Triton-X. Stored at RT. 
 
2.1.3.2.6 1X TBS-T Milk/blocking agent  
10% 1X TBS, 5% non-fat milk, 1% donkey serum, 0.02% Triton X, 0.02% 
NaN3. Stored at 4C. 
 
2.1.3.2.7 1XTBS-T – BSA 
1X TBS, 0.02% Tween-20 and 5% BSA. Stored at 4C. 
 
2.1.3.2.8 Ponceau S  
0.1% ponceau in 1% acetic acid. Stored at RT. 
 
2.1.3.2.9 Nitrocellulose stripping buffer 
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NewBlot™ Nitrocellulose 5X stripping buffer (Li-cor® Biosciences 928-
4030). Used neat for 15 mins. 
 
2.1.3.2.10 Coomassie 
 2.1.3.2.10.1 Stain 
0.1% Coomassie Brilliant blue, 50% EtOH and 10% acetic acid. 
Coomassie powder mixed in EtOH o/n and then other constituents 
were added. Solution filter sterilized. Stored at RT. 
 
 2.1.3.2.10.2 Destain 1 
40% EtOH and 10% acetic acid. Stored at RT. 
 
 2.1.3.2.10.3 Destain 2 
15% EtOH and 10% acetic acid. Stored at RT. 
 
2.1.3.2.11 20x MOPS SDS-running buffer 
MOPS 50mM, TRIS Base 50mM, SDS 3.47mM, EDTA 1mM. Sourced from 
FORMEDIUM™ (MOPS-SDS1000). Stored at RT. 
 
2.1.3.2.12 Running buffer 
1X MOPS and H20 up to 500ml. To the central chamber of the gel tank, 
0.25% NuPage antioxidant (Invitrogen NP0005) was added. Stored at RT. 
 
2.1.3.2.13 Transfer buffer 
2X Laemmli, 7.5% methanol and 0.02% of 20% SDS. Stored at 4C. 
 
2.1.3.2.14 10X Laemmli buffer (1L) 
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30g Tris Base, 144g glycine, 10g SDS and H20 up to 1L. Store at RT. 
 
2.1.3.2 Immunoprecipitation 
2.1.3.2.1 IP wash buffer  
20mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA 0,05% Triton-X-100, 5% 
glycerol and protease inhibitor cocktail (1 per 50ml/1:1000). Solution filter 
sterilized. Stored at 4C. 
 
2.1.3.3 Immunofluorescence in 2D (cell culture) 
2.1.3.3.1 Permeabilisation buffer  
1% NP40 in 1X PBS. Stored at RT. 
 
2.1.3.3.2 Blocking Buffer 
5% goat serum diluted in 1X PBS, 2% BSA, 0.02% NaN3 and 0.1% TX-
100. Stored at 4C. 
 
2.1.3.3.3 Incubation buffer  
1X PBS, 2% BSA, 0.02% NaN3 and 0.1% TX-100. Stored at 4C. 
 
2.1.3.3.4 Wash buffer  
1X PBS, 0.02% NaN3 and 0.2% BSA. Stored at 4C. 
 
2.1.3.3.5 Mounting medium  
90% glycerol, 20mM Tris pH 8.8 and 0.5% p-phenylenediamine. Stored at 
RT. 
 
2.1.3.4 FACs 
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  2.1.3.4.1 Blocking buffer (100ml) 
1X  PBS, 0.1%  Tween-20 and 1% Bovine Serum Albumin (Sigma-Aldrich). 
Stored at 4C. 
 
2.1.4 Antibodies  
2.1.4.1 Primary antibodies 
TABLE 2.1 
Primary Antibodies and  IF Counterstains/Dyes 
Name Spec. Application Source Antigen 
(aa) WB IP IF FACS 
Ali (APC) M mc 1/1000 1mg/
ml 
ND ND CRUK - 
Bcl-2 (E17)                                        R mc 1/1000 1/50 1/75 ND Abcam 
ab32124 
50-150 
BrdU M mc ND ND ND 1/500 BD 
Pharmag
en 
555627 
- 
C-APC R pc 1/1000 ND ND ND Hybridom
a 
2815-
2829 
Calnexin 
(C5C9)* 
R mc 1/1000 ND ND ND CST 
2679S 
Full 
Length 
CAIX R pc 1/2000 ND 1/500 ND Novus 
Biological
s NB100-
417 
400-500 
DAPI - ND ND 1/500
0 
ND SIGMA 
D-9542 
- 
GAPDH M mc 1/2000 ND ND ND Millipore 
MAB374 
Full 
GFP M mc 1/1000 ND ND ND Roche 
11814460
001 
- 
HIF1-α M mc 1/1000 ND ND ND BD 
Bioscienc
e 610958 
610-727 
Histone H3 
(Phospho 
S10) 
R pc 1/1000 ND ND 1/300 Abcam  
ab5176 
S10 
Hoechst 
33342 
- - - 1/500 ND Invitrogen 
Molecular 
Probes 
H1399 
- 
HSP60 
(D85)* 
R pc 1/500 ND ND ND CST 
4869S 
D85 
residue 
IgG M mc ND 1mg/
ml 
ND ND SIGMA I-
5381 
- 
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IgG R pc ND 1mg/
ml 
ND ND SIGMA I-
5006 
- 
IRE1 
(14C10)* 
R mc 1/1000 ND ND ND CST3294 His963 
IRE1 
(Phospho 
S724) 
[EPR5253] 
R mc 1/1000 ND ND ND Abcam 
ab124945 
S724 
Keratin 18 
(RCK 106) 
M  mc Neat 
Hybrid
oma 
ND ND ND Ramaeke
rs et al., 
(1987) 
- 
MitoTracker® 
Deep Red FM 
- ND ND 500n
M 
ND Gibco™ 
51985_02
6 
- 
Myc M mc 1/1000 ND ND ND Santa 
Cruz SC-
9E10 
408-439 
Na/K 
ATPase* 
R pc 1/1000 ND ND ND CST 3010 Amino 
terminus 
N-APC R pc 1/1000 1mg/
ml 
ND ND Hybridom
a 
8-347 
Par4* R pc 1/500 ND ND ND Abcam 
ab5787 
324-342 
PDI (C81H6)* R mc 1/1000 ND 1/100 ND CST 3501 Synthetic 
peptide 
Phalloidin 
DyLight™ 
550 
- - - 1/500 ND ThermoFi
sher 
21835 
F-actin 
binding 
Topoisomera
se II α 
(D10G9) 
XP®* 
R mc 1/1000 ND ND ND CST 
12286 
C-
terminus 
YL1/2 
(tubulin) 
Ra pc 1/25 ND 1/25 ND Abcam 
ab6160 
Full 
β-catenin M mc 1/1000 ND 1/500 ND BD 
Bioscienc
es 
610154 
571-781 
β-catenin 74 R pc 1/1000 1mg/
ml 
ND ND Hinck, 
Nelson & 
Papkoff 
(1994) 
- 
 
 
 
 
 
Table 2.1.  R=rabbit, Ra=rat, M=mouse, Mc=monoclonal, Nd=not determined, 
Pc=polyclonal, Spec=species. 
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2.1.4.2 Secondary antibodies 
 
 
2.1.5 Bacterial strains 
Subcloning Efficiency™ DH5™ competent cells (Invitrogen, 18265-017). 
 
2.1.6 Plasmids  
For available plasmid maps see supplementary figures 1 and 2. 
 
2.1.6.1 pc.DNA3.1HisOsTIR9xMyc 
TABLE 2.2 
Secondary Antibodies 
Use Species Excitation  Dilution Incubation Source 
WB Rabbit Alexa-
Flour®680 
800nm 
DyLight™ 
1/5000 1 hr RT 800nm – 
Rockland 
680nm – 
Molecular 
Probes WB Mouse Alexa-
Flour®680 
800nm 
DyLight™ 
1/5000 1 hr RT 
WB Rat Alexa-
Flour®680 
800nm 
DyLight™ 
1/5000 1 hr RT 
WB Mouse anti-rabbit 
IgG Conformation 
Specific (no 
detection of 
denatured & 
reduced rabbit HC 
or LC) 
- 1/2000 1hr RT Cell 
Signalling 
3678 
WB Goat anti-mouse 
IgG1 (LC specific) 
800nm 
IRdye 
1/15000 1hr RT Li-cor 
Biosciences 
926-32350 
FACS Goat anti-mouse FITC 1/100 30min RT BD 
Pharmagen 
554001 
FACS Goat anti-rabbit FITC 1/100 30min RT BD 
Pharmagen 
554020 
IF Rabbit Alexa-
Flour® 488 
1/500 1 hr RT Invitrogen 
Molecular 
Probes 
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A kind gift from Noel Lowndes (NUI, Galway), courtesy of Prof. Kanemaki of the 
Department of Biological Sciences, Graduate School of Science, Osaka 
University, Osaka, Japan. 
 
2.1.6.2 pGK-Cre 
See Lallemand et al., (1998). 
 
2.1.6.3 pGFP  
A kind gift from MacKintosh lab, Cellular and Developmental Biology, University of 
Dundee (generated from pcDNA5.FRT). 
 
2.1.6.4 pGFP-Bcl-2  
Addgene plasmid #17999. 
 
2.1.6.5 pEGFP-C1 
Discontinued Clontech plasmid. See Addgene plasmid information 2487. 
 
2.1.6.6 pCMV-NEO-BAM-APC 
Generated in the lab. Apc cDNA with BamHI restriction sites. 
 
2.1.6.7 pJET1.2/blunt 
Obtained as part of the CloneJET PCR Cloning Kit, Thermo Scientific™, K1231. 
 
2.1.6.8 pFLAG  
A kind gift from MacKintosh lab, Cellular and Developmental Biology, University of 
Dundee (generated from pcDNA5.FRT). 
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2.1.6.9 pFLAG-Bcl-2 
Addgene plasmid #18003. 
 
2.1.6.10 pAID1.2N 
A kind gift from Prof. Kanemaki of the Department of Biological Sciences, Graduate 
School of Science, Osaka University, Osaka, Japan. 
 
2.1.6.11 Targeting vectors 
Generated by CJ Baird, Hiom lab, Jacqui Wood Cancer Centre, University of 
Dundee. 
 2.1.6.11.1 pGFP-IAA17-APC-Bsd [+]  
A GFP-degron (IAA17) tag targeted 5’ of chicken Apc exon 1 using 2 arms 
of homology. A floxed Bsr cassette is included in the same transcriptional 
orientation as the tags and Apc, driven by the β-actin promoter. 13,829bp. 
 
2.1.6.11.2 pIAA17-APC-Bsd [+]  
A degron (IAA17) tag targeted 5’ of chicken Apc exon 1 using 3 arms of 
homology. A floxed Bsr cassette is included in the same transcriptional 
orientation as the tags and Apc, driven by the β-actin promoter. 13,245bp. 
 
2.1.7 Oligonucleotides  
2.1.7.1 Oligonucleotides for gPCR 
TABLE 2.3 
gPCR Primers 
EUROFINS MWG Operon 100M Stock 
Name Sequence Tm (°C) 
GFP F CACATGAAGCAGCACGACTTCT 60.3 
GFP R AACTCCAGCAGGACCATGTGAT 60.3 
Bsd F ATGAAAACATTTAACATTTCTC 49.1 
Bsd R TAATTTCGGGTATATTTGAGVTGG 55.3 
5’Arm-2R GTGTGTTGGTGCAAGTTCAGG 59.3 
5’Arm-3R ACTGGTGATGTGGAATTTGC 59.3 
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5’Arm-4R CAAGTGACAAGGTTTCAGA 59.3 
5’Arm-5R ACATTACTTCATCTCACCC 59.3 
5’Arm-2 1F CCTCTTAACTACCAACTCTACCA 58.9 
IAA17 1R AGCTCTGCTCTTGCACTTCTCC 58.9 
 
2.1.7.2 siRNAs 
TABLE 2.4 
siRNAs 
Name Source Final 
Concentration 
Control siRNA QIAGEN 1027281 10nM 
CTNNB1  QIAGEN Flexitube 1027418; S102662478 10nM 
APC  EUROFINS siAPC 5,6 & 7 10nM 
Bcl-2_0 QIAGEN Flexitube SI00299397 20nM 
Hif1α 5’-CUGAUGACCAGCAACUU-3’ (Eurofins) 20nM 
 
2.1.7.3 qRT-PCR primers 
TABLE 2.5 
qRT-PCR Primers  
EUROFINS MWG Operon 100M Stock 
Name Sequence Tm (°C) 
Actin F CTGGGAGTGGGTGGAGGC 62.8 
Actin R TCAACTGGTCTCAAGTCAGTG 57.9 
APC-1 F GGAAGCATTATGGGACATGG 57.3 
APC-1 R TACTTCGCAGGCCTATTTGC 57.3 
β-catenin-2 For ATGGCTTGGAATGAGACTGC 57.3 
β-catenin-2 Rev TTCCATCATGGGGTCCATAC 57.3 
Cyclin D F GGCGGATTGGAAATGAACTT 55.3 
Cyclin D R TCCTCTCCAAAATGCCAGAG 57.3 
 
 
2.1.8 Matrigel 
Matrigel (basement membrane growth factor reduced), phenol red free (BD Bioscience 
356231, batch 503306 11mg/ml).  
 
2.2 Cell Culture Methods 
 
2.2.1 Cell lines 
See table 2.6. 
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TABLE 2.6 
Cell lines and organoids 
Name Type Sp Mutation(s)/Viruses
/ 
Morphology 
Culture Media Supplements Culture 
Ad/S 
Source 
341  MEFs M APC+/+ DMEM [+]4.5g/L D-
Glucose, L-Glutamine 
and Pyruvate (Gibco™ 
Life Technologies) 
10% FBS, 1% NEAA, 
1% P/S 
Ad Gift from R.A. 
Weinberg, 
Whitehead 
Institute, MA 
335  MEFs M Unstable Apc mRNA DMEM [+]4.5g/L D-
Glucose, L-Glutamine 
and Pyruvate (Gibco™ 
Life Technologies) 
10% FBS, 1% NEAA, 
1% P/S 
Ad Gift from R.A. 
Weinberg, 
Whitehead 
Institute, MA 
CaCo2 Colorectal 
adenocarcin
oma 
H Apc 1367 C>T 
(nonsense mutation) 
DMEM [+]4.5g/L D-
Glucose, L-Glutamine 
and Pyruvate (Gibco™ 
Life Technologies) 
10% FBS, 1% NEAA, 
1% P/S 
Ad American Type 
Culture 
Collection® 
DLD1 Colorectal 
adenocarcin
oma 
H Apc nonsense 
mutation 
DMEM [+]4.5g/L D-
Glucose, L-Glutamine 
and Pyruvate (Gibco™ 
Life Technologies) 
10% FBS, 1% NEAA, 
1% P/S 
Ad American Type 
Culture 
Collection® 
DT40 B cell 
lymphoma 
Ck 1. C-myc activation 
(due to ALV 
integration) 
immortalizes cells 
RPMI 1640 (1x) [+]L-
glutamine (Gibco™, Life 
Technologies) 
10% FBS, 3%CS, 1% 
P/S, 0.05% β-ME 
S American Type 
Culture 
Collection® 
 
DT40TIR 
B cell 
lymphoma 
Ck 1. C-myc activation 
(due to ALV 
integration) 
immortalizes cells 
2. OsTIR1 random 
integration 
RPMI 1640 (1x) [+]L-
glutamine (Gibco™, Life 
Technologies) 
10% FBS, 3%CS, 1% 
P/S, 0.05% β-ME 
S Created in lab 
 
DT40TIR-
EGFP-
B cell 
lymphoma 
Ck 1. C-myc activation 
(due to ALV 
integration) 
RPMI 1640 (1x) [+]L-
glutamine (Gibco™, Life 
Technologies) 
10% FBS, 3%CS, 1% 
P/S, 0.05% β-ME 
S Created in lab 
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IAA17-
APC-KI 
2. GFP-IAA17 KI 5’ 
to Apc exon 1 
 
DT40TIR-
IAA17-
APC-KI 
B cell 
lymphoma 
Ck 1. C-myc activation 
(due to ALV 
integration)  
2. IAA17 KI 5’ to 
Apc exon 1 
RPMI 1640 (1x) [+]L-
glutamine (Gibco™, Life 
Technologies) 
10% FBS, 3%CS, 1% 
P/S, 0.05% β-ME, 
30ug/ml Blasticidin S 
S Created in lab 
HCT116  
(HD PAR 
007) 
Colorectal 
adenocarcin
oma 
H 1. β-cateninSer45 del/+ 
2. KRASG13D/+ 
RPMI 1640 L-Glutamine 
(Lonza, Biowhittaker® 
BE12-702F) 
10% FBS, 1% P/S Ad Horizon 
Discovery 
HeLa Cervical 
adenocarcin
oma 
H HPV insertion; 
degrades 
p53 
DMEM [+]4.5g/L D-
Glucose, L-Glutamine 
and Pyruvate (Gibco™ 
Life Technologies) 
10% FBS, 1% NEAA, 
1% P/S 
Ad American Type 
Culture 
Collection® 
SW480 Colorectal 
adenocarcin
oma 
H Apc 1330 C>T 
(nonsense mutation) 
DMEM [+]4.5g/L D-
Glucose, L-Glutamine 
and Pyruvate (Gibco™ 
Life Technologies) 
10% FBS, 1% NEAA, 
1% P/S 
Ad American Type 
Culture 
Collection® 
U2OS Osteosarco
ma 
H (APC and β-catenin 
WT) 
DMEM [+]4.5g/L D-
Glucose, L-Glutamine 
and Pyruvate (Gibco™ 
Life Technologies) 
10% FBS, 1% NEAA, 
1% P/S 
Ad CRUK 
WT 
Organoids 
C57BL/6J Apc 
WT 
mouse 
Branched Crypt Media:  500ml 
Advanced DMEM/F12 
supplemented with 1% 
P/S, 1% HEPES, 1% 
200mM Glutamax, 0.2% 
500mM N-
acetylcysteine, 1% 
100X N2 and 2% 50X 
B27 
Growth Factors, ENR 
diluted in crypt media:  
5% 500ug/ml EGF, 2% 
100ug/ml Noggin, 25% 
R-spondin conditioned 
media  
- Jackson 
Laboratory, CA 
USA 
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Min 
Organoids 
C57BL/6J Apc 
Min 
Mouse 
1. ApcMin/+ 
Codon 850 
(nonsense) 
2. ApcMin/Min 
3. Branched until 
~P5 - Then cysts 
Crypt Media 1. ENR 
2. None once cyst 
morphology 
- Jackson 
Laboratory, CA 
USA 
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2.2.1.1 Suspension cells (DT40) 
2.2.1.1.1 Passaging cells 
DT40-KI transfected cells were grown with 30g/ml Blasticidin S (selectable 
marker). The cells were incubated at 37C/5% CO2, grown to confluency 
(~1x106/ml), counted using the CASYcounter (Innovatis) and split every other day. 
Optimal cell culture was considered to have >90% viable cells. Cells were taken up 
from liquid nitrogen storage, cultured in a T-25 flask with 7ml pre-warmed media o/n 
at 37C/5% CO2 and split the next day (when confluent). 
 
2.2.1.1.2 Freezing cells for long-term storage 
3x106 cells were pelleted (~passage III-V) and resuspended in 500l of freezing 
media (90% FBS: 10% DMSO). 500l aliquots were frozen at -80C for 24 hours 
and subsequently moved to liquid nitrogen for long-term storage. 
 
2.2.1.2 Adherent cells 
2.2.1.2.1 Passaging cells 
To split the cells the media was aspirated, the cells washed in Dulbecco’s PBS 
(DPBS), washed in trypsin (SIGMA T4174, diluted 1:100 in Dulbecco’s PBS) and 
then incubated in trypsin at 37C/5% CO2 until the cells detached from the surface 
of the dish. Trypsin was then inactivated by adding fresh pre-warmed media to the 
dish (media was added at double the volume of trypsin). Depending on the desired 
dilution, a certain volume of the cell suspension was transferred into a new flask/dish 
(TPP) and the appropriate volume of media added. Cells were then incubated at 
37C/5% CO2.  
 
Table 2.6.  Ad=adherent, Ck=chicken, H=human, M=mouse, S=suspension, Sp=species 
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2.2.1.2.2 Freezing cells for long-term storage 
Cells were washed in Dulbecco’s PBS, trypsinized and resuspended in 50l freezing 
media (90% FBS + 10% DMSO). Aliquots were then frozen at -80C for 24 hours 
and subsequently moved to liquid nitrogen tanks for long-term storage. 
 
2.2.2 Organoid culture 
 2.2.2.1 Intestinal crypt isolation 
Crypt isolation was performed by Dr. Alistair Langlands (Näthke lab, University of 
Dundee) as per Sato.T et al., (2009). Organoids were derived from Apc WT and 
ApcMin/+ mice, see table 2.6. 
  
2.2.2.2 Culturing and passaging 
The protocol was adapted from Sato.T et al., (2009) and carried out as follows. 
Media was aspirated from the wells of a 24 well plate without interfering with the 
Matrigel dot in the centre of the wells. 1ml of cold ADF added to each well. A pipette 
tip was used to scrape the bottom of the well to disrupt the Matrigel and resuspend 
the organoids. Then the solution was pipetted into a fresh falcon tube and mixed by 
pipetting. The tube was spun for 3mins at 600rpm to collect an organoid pellet. To 
wash the pellet it was resuspended in 3ml ADF and spun again for 3mins at 600rpm. 
The media was aspirated, but this time some media was left to leave a total volume 
of approximately twice the size of the pellet. The pellet was resuspended in the 
residual media. 100l Matrigel was added and one drop of the 
Matrigel/media/organoid mixture was added to the centre of 6 wells in a 24-well 
plate. The plate was kept at 37C/5% CO2 incubator for >5mins to allow the Matrigel 
to set. Finally 500L of pre-warmed crypt media (plus growth factors) (see table 2.6) 
was pipetted down the side of each well so as not to disturb the Matrigel dot. Plates 
were then put back into the incubator at 37C/5% CO2. 
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2.2.3 Transfection procedures 
2.2.3.1 Transient transfection in suspension cells by electroporation 
DT40 cells were set up one day prior to transfection at 2x105/ml. On the day of 
transection, using the Amaxa Cell Line Nucleofector Kit T (Lonzabio): 82L of 
room temperature Nucleofector Solution added to 18l of supplement, per 
transfection. 3x106 cells were pelleted per transfection, the supernatant removed 
and the pellet resuspended in the 100l Nucleofector solution. 7-10g of pDNA 
was typically added to the cell suspension, transferred to an Amaxa certified 
cuvette, inserted into the Nucleofector cuvette holder and run under the 
appropriate program (B-0023). To electroporate the cells the cuvettes were 
incubated for 10mins at RT. Then 500l of pre-warmed, pre-equilibrated RPMI 1640 
+ L-glutamine was added to the cuvette and gently transferred to a 6cm culture dish 
containing 5ml of pre-warmed media. Dishes were then incubated at 37C/5% CO2 
for 48 hours. 
 
2.2.3.2 Stable transfection for targeted insertion in DT40 Cells 
Cells were set up one day prior to transfection at 2x105/ml. On the day of 
transfection, 6x106 cells were pelleted per transfection and 30g of EtOH–purified, 
linearized targeting vector added. Cells/DNA/PBS mixture was electroporated using 
the Biorad Gene Pulser at 550V, 25F and  resistance. The time constant was 
usually in the region of 0.8ms. Cells were incubated on ice for 10 minutes, added to 
20ml pre-warmed media and then left to recover o/n in 37C/5% CO2 incubator. 
Subsequently, the volume of the media was brought up to 60ml, 30g/ml of the 
selective drug (Blasticidin S) added and the cells seeded onto 96 well plates using 
a multi-channel pipette. Colonies were expanded after 7-10 days into 24 well plates 
with 1ml of pre-warmed media and subsequently into 6 well plates with 4ml pre-
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warmed media. Scaled up clones were cultured in T-75s and screened for targeted 
insertion of the targeting vector by genomic PCR (gPCR). 
 
2.2.3.3 Transient transfection in adherent cells by chemical methods 
Cells were set up one day prior to transfection at 25-30% confluency in a T25 flask 
(TPP). Fugene 6® transfection reagent (Promega E2691) was allowed to warm to 
room temperature and then 8L was added to 50l pre-warmed media, mixed and 
incubated at room temperature for 5 mins. 2g of pDNA was then added to the 
Fugene/media and allowed to incubate at room temperature for >15mins (<45mins). 
The solution was added drop-wise onto the cells. The transfection procedure was 
repeated again after 24 hours and left for a further 24 hours (unless indicated) before 
the cells were harvested. 
 
2.2.3.4 Excision of Floxed Sequences by Transient Expression of Cre 
DT40TIR-(GFP) IAA17-APC cells were set up one day prior to transfection at 2x105/ml. On 
the day of transfection the bacteriophage P1 site-specific recombinase Cre was 
transiently transfected into 3x106 cells by adding 4µg of pPGK-Cre (Lallemand et 
al., 1998). To transfect the cells they were electroporated with the Amaxa 
Nucleofector System (Lonzabio). The transfected cells were then grown in 6cm 
dishes with 5ml of RPMI and left to recover o/n in 37C/5% CO2 incubator. 
Subsequently subcloning by limiting dilutions was set up (see 2.2.4). 
 
2.2.4 Subcloning by limiting dilution to derive clonally related cells from a 
heterogeneous population (DT40) 
To generate a 96-well plate containing single cells per well, 3x50ml falcon tubes were 
prepared with 30, 100 and 300 cells in 20ml media respectively. 200l of each dilution was 
plated out onto 96 well plates. Plates were then incubated for 7 days at 37C/5% CO2 
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without a change of medium. 24 subclones from each plate were then picked, replica-plated 
and grown both in the presence and absence of Blasticidin S. Clones that did not grow in 
the presence of the selective antibiotic were chosen indicating successful Cre 
recombination and Bsr excision. Loss of the Bsr cassette was then confirmed by PCR. 
 
2.2.5 MTS cell proliferation assay 
The MTS assay is a colorimetric viability assay. A tetrazolium compound is added to cells, 
and in viable, metabolically active cells the compound is bioreduced by NADPH/NADH into 
a soluble, formazan product. The absorbance (nm) of the formazan product is then 
measured to produce a measure of viability. The PROMEGA CellTiter 96® Aqueous One 
Solution Cell Proliferation Assay (G3580) was used as per the manufacturer’s instructions. 
DT40 cells were cells cultured in T-25 flasks (15,000cells/100l in a total volume of 5ml) 
with varying concentrations of: PARPi for 24 hours; Cisplatin for 2 hours; or Hydroxyurea 
for 16 hours. Cells were then pelleted, media aspirated off and the cells resuspended in the 
same volume of fresh media (no drug). 100l of the cell suspension was pipetted into each 
well of a 96 well plate and left to equilibrate for 1hr at 37C/5% CO2. 24/48/72h after the 
drug was washed-off, 20l of CellTiter 96® Aqueous One Solution Reagent added to each 
well and pipetted up and down to mix. Plates were incubated for 4 hours at 37C/5% CO2 
and then the absorbance measured at 490nm using a plate reader (Biotek ELx808 
Absorbance Microplate Reader). 
 
2.2.6 Organoid cell viability assay  
Organoids grown in Matrigel (see 217 and 2.2.2.2) were passaged and left for 2 days to 
allow adequate growth (cysts) and branching time (WT) before the assay. Organoids were 
then treated with varying concentrations of Taxol® for 24 hours and subsequently their 
viability was measured using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega 
G7570). First, 250l of media was removed from the wells, replaced with 250L of CellTiter-
 64 
 
Glo® Reagent. Plates were then left at RT on an orbital shaker for 2 mins before sitting on 
the bench at RT for 10mins. Then the organoids were transferred into a luminometer-
compatable 5ml tube (Sarstedt 55.476.005). The luminescence was then recorded using a 
luminometer (Lumat LB 9507, Berthold Technologies). A media only sample was used as 
a control for background luminescence, which was subtracted from the values of the sample 
readings. 
 
2.2.7 Hypoxia treatment 
HCT116 cells were set up 2 days prior to treatment at 10% confluency, in 15cm dishes 
(TPP). The dishes were put into a hypoxia chamber (1% O2) for 24 hours. Subsequently, 
cells were lysed in MEBC lysis buffer (see Western blot) in the chamber to prevent 
reoxygenation. 
 
2.2.8 Mitochondrial staining  
Cells were set up in 3cm dishes (TPP) and treated as required. Media was aspirated and 
500nM of MitoTracker® Deep Red FM (Invitrogen™ Molecular Probes™, M22426) diluted 
in Opti-MEM® reduced-serum medium (Gibco™, 51985_026)  was added  to the cells and 
incubated at 37C/5% CO2 for 45 mins.  The media was aspirated, the cells washed once 
in Dulbecco’s PBS (DPBS) and 2ml of fresh media was added. Cells were fixed and stained 
as detailed in 2.6.2 or they were imaged live. MitoTracker® has an emission wavelength of 
665nm and was detected with a fluorescence microscope. 
 
2.2.9 JC-1 Mitochondrial potential sensor 
Cells were set up in 3cm dishes (TPP® cell culture plastics) and treated as required. Then 
JC-1 mitochondrial membrane potential probe (Invitrogen™ Molecular Probes™, T-3168) 
was added to the cells at a final concentration of 250nM, diluted in Opti-MEM® reduced-
serum medium (Gibco™, 51985_026). Cells were incubated with JC-1 for 30mins at 
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37C/5% CO2. Then the media was aspirated off, the cells washed once in DPBS and 2ml 
fresh media was added. Cells were imaged live to detect JC-1 with a fluorescence 
microscope. JC-1 monomers emit at 520nm, whereas aggregates alone emit at 590nm.  
 
2.3 Methods for Protein analysis  
 
2.3.1 Cell lysis 
Flasks/dishes of cells were cooled for 5 mins on ice and then washed twice in cold-PBS. 
Cells were lysed in 1X MEBC and incubated on ice for a further 5mins. The cells were then 
harvested using a cell scraper, transferred to Eppendorf tubes and centrifuged at 18,213xg 
for 20mins at 4C. The protein concentration of the lysate was measured using the Bradford 
Assay (Bio-Rad Protein Assay Dye Reagent Concentrate 500-0006), according to the 
manufacturer’s instructions, to ensure equal loading on an SDS-PAGE gel. Lysates were 
snap-frozen and stored long term at -80C. 
 
2.3.2 Bradford assay  
2l of lysate + 798l H20 + 200l Coomassie Protein Assay solution (Thermo Scientific) 
was added to a 1ml protein UV-cuvette (VWR). The protein concentration was read at a 
wavelength of OD595nm using a spectrophotometer (Pharmacia Biotech Ultraspec 2000 
UV/Visible spectrophotometer). Controls were measured using BSA standards (0, 0.25, 0.5, 
1.0, 1.5 and 2.0mg/ml) to generate a standard curve. Then, samples were measured in 
triplicate, an average taken and the concentration in mg/ml calculated from the average. 
50g of protein lysate was used for a Western blot unless otherwise stated. 
 
2.3.3 Western blot 
 2.3.3.1 SDS-Polyacrylamide electrophoresis (SDS-PAGE) 
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SDS-PAGE was carried out to separate proteins by size and for further analysis by 
Western blot. The sample lysates were prepared for loading onto a Novex 4-12% 
Bis-Tris gel by combining: 50g of protein, 4x loading dye (NuPage) + Χl H20. 
Lysates were then boiled for 10mins and 1/20th 1M DTT added. A Novex tank was 
then prepared for SDS-PAGE by adding 200ml running buffer containing 1:400 
NuPage Antioxidant (Invitrogen NP0005) into the central chamber, with a further 
300ml running buffer added to the outer chamber of the tank. The samples were 
then loaded into the wells of the gel using gel loading tips (STARLAB, I1022-0600). 
The tank was connected to a power pack and run at 90V for roughly 3 1/2 hours at 
RT, until the sample buffer dye had just run off the bottom of the gel.   
 
2.3.3.2 Wet-transfer method 
To transfer the gel onto a 0.1µm pore nitrocellulose membrane a transfer cassette 
was stacked from bottom to top in reagents pre-soaked in transfer buffer, as follows: 
sponge, 2x3mm filter paper, gel, membrane, 2x3mm filter paper, sponge. The 
transfer cassette was then put in a Bio-Rad transfer tank with an ice block placed at 
the back and the transfer chamber filled with the remaining transfer buffer. The tank 
was transferred o/n (≥16hrs) at 4C. 
 
2.3.3.3 Ponceau S stain for transferred proteins 
The nitrocellulose membrane was stained with Ponceau S to confirm adequate 
transfer of proteins from the gel onto the membrane. The membrane was placed 
into a small container and covered with Ponceau. The container was put on a RT 
shaking plate for 10 mins. The Ponceau was then poured off and the membrane 
rinsed gently in cold water so the proteins were visible. 
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2.3.3.4 Blocking, antibody incubations and protein detection 
Once transferred, the nitrocellulose membrane was blocked by adding TBS-T Milk 
and shaking at RT for 1 hour. Primary antibodies were then added, dilutions and 
incubations can be found in table 2.1. The membrane was then incubated with wash 
buffer for 3x10minute washes. Li-Cor specific secondary antibodies were then 
added and incubated at RT with shaking for 1 hour (for dilutions see table 2.2).  The 
wash step was then repeated. Blots were imaged using the Li-Cor Odyssey 
chemiluminescent system. 
 
2.3.3.5 Quantification of bands 
Using the Li-Cor Odyssey software; boxes were drawn around the bands of interest 
to generate a numerical value based on the intensity of the band. The value for the 
untransfected sample/untreated control equals 100% band intensity. Subsequently, 
the value for each band was normalised by dividing it by the value of the equivalent 
loading control to generate a correction factor. Each band was then multiplied by 
the correction factor to compensate for loading. This number is then divided by the 
value for the untransfected sample/control and multiplied by 100 to report an 
increase or decrease relative to the untransfected/untreated control. 
 
2.3.4 Co-immunoprecipitation (CoIP) 
1.5ml screw-cap Eppendorf tubes were prepared on ice with 100L protein A/G beads 
(SIGMA-ALRDRICH), washed twice in 750l 1X MEBC and resuspended in 200l 1X 
MEBC plus 5g antibody (see table 2.1). IPs were carried out with specific antibodies in 
parallel to an IgG control. Tubes were then placed on a rotator at 4C o/n to conjugate the 
antibody to the beads. The next day, cells lysed in 1X MEBC (as for WB), the protein 
concentration was measured by Bradford Assay and 50g of the lysate kept for pre/input-
controls. Xmg lysate (see figure legends) added to the washed and conjugated beads.  
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Tubes were then placed on rotator at 4C for >2 hours. Tubes then centrifuged and the 
supernatant removed (saving 50g for post-IP controls). The beads were then washed 5x 
in 750l cold IP wash-buffer + protease inhibitors (same as WB) at 1:1000 - each wash 
requiring a 5 second pulse-spin to pellet the cells. To elute and run samples on Western 
blot, 20l of 1.3x loading buffer (NuPage) was added, samples boiled, 1/20th 1M DTT added 
and then samples were loaded on a 4-12% Bis-Tris gel as for WB. 
 
2.3.5 Proteasome inhibition 
10M MG132 (Sigma-Aldrich) was added to media. Cells were harvested after 2 hours at 
37⁰C/5%CO2. 
 
2.3.6 The auxin-inducible degron (AID) system 
2.3.6.1 Inducing APC degradation 
Cells were set up one day prior to AID test at 2x105/ml. To trigger degradation of 
degron-fused proteins 50mM auxin/indole-3-acetic-acid (IAA) (SIGMA) was added 
to the cultures (diluted in RPMI) to a final concentration of 500M (unless otherwise 
stated). Cells were then harvested at certain time points after IAA addition and then 
pelleted for Western blot analysis. 
 
2.3.7 Mass spectrometry 
 2.3.7.1 Sample preparation 
U2OS cells were grown in T75 flasks (TPP) +/- 7µM ABT-737 for 24 hours. Cells 
were then harvested, lysed and a Bradford assay performed to determine the 
protein concentration of the lysate (as in 2.3.1 and 2.3.2). 100µg of each sample 
lysate was run on a 4-12% Bis-Tris gel (Novex). Once run, the gel was put into a 
15cm dish (TPP) and stained with Coomassie (2.1.1.2.8) for 30-60mins. The gel 
was then destained for at least 1 hour in destain 1 and destain 2 until the background 
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was removed sufficiently to reveal protein bands. Finally, the gel was rinsed with 
dH20. Bands of interest were excised from the gel using a scalpel and placed into 
an autoclaved 1.5ml Eppendorf tube. The mass-spectrometry facility at the 
University of Dundee performed in-gel digestion (de-staining, reductive alkylation 
and tryptic digestion) before running the samples on an ESI-Trap mass-
spectrometer (Pharmacia Biotech Ultraspec 2000 UV/Visible spectrophotometer). 
 
2.3.7.2 Data analysis 
ESI-Trap tandem mass-spectrometry (MS) results were entered into MASCOT™ 
(Matrix Science) - a search engine that identifies proteins from MS data by matching 
identified peptides against the human NCBI protein database.  Each peptide from 
the MS data was matched to a protein and given an ion score that represented the 
probability of the peptide match occurring at random. The sum of ion scores for each 
peptide comprising a given protein made up the protein score, which was arranged 
to provide a logical list of results. To examine whether a protein was enriched in 
ABT-737 treated U2OS cells versus untreated U2OS cells, an EMPAI analysis was 
done. This provided label-free quantitation of peptides within the given mixture from 
the data already generated. MASCOT™ calculated the EMPAI using the algorithm 
(10PAI-1) on the top 20 proteins as given by the protein scores. This generated a list 
of proteins arranged by the most abundant. 
 
2.3.8 Subcellular fractionation 
Cells were set up, treated in T25 flasks and subsequently fractionated using the 
ProteoExtract® Subcellular Proteome Extraction Kit (Calbiochem 539790). Every step was 
performed on ice. To harvest cells they were washed 2x in cold PBS, 1ml of Wash Buffer 
added, and cells scraped and collected into a 1.5ml Eppendorf tube. The cells were 
centrifuged at 300xg for 10 minutes at 4C, the supernatant aspirated and the wash step 
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repeated. To obtain fraction 1 (cytosol), 500l Extraction Buffer I + 5l inhibitor cocktail was 
used to resuspend the pellet. The cell solution was then incubated for 10 mins at 4C with 
gentle agitation followed by centrifuging for 10mins at 1000xg. The supernatant collected 
was fraction 1. Next, 500l of Extraction Buffer II + 5l inhibitor cocktail was added to the 
pellet, incubated for 30 mins at 4C with gentle agitation and centrifuged for 10 mins at 
6000xg. The supernatant collected was fraction 2 (membrane). The residual material was 
gently resuspended in 250l Extraction Buffer III + 5l inhibitor cocktail + 1.5l Benzonase® 
and incubated for 10 mins at 4C with gentle agitation, then centrifuged for 10mins at 
10,000xg. The supernatant collected was fraction 3 (nucleus). The pellet was then 
resuspended in 250l Extraction Buffer IV +5l inhibitor cocktail to provide fraction 4 
(cytoskeleton). Fractions were snap-frozen and stored long term at -80 C. Fractions were 
then prepared for SDS-PAGE as explained in 2.3.3. The following proteins were used as 
fraction markers: GAPDH for cytosol, Hsp60 or Na/K ATPase for membrane, 
topoisomerase IIα for nucleus and keratin 18 for cytoskeleton (see table 2.1). 
 
2.3.9 Mitochondrial fractionation 
Cells were set up and/or treated one day prior to fractionation in T25 flasks and 
subsequently fractionated using the Mitochondrial/Cytosol Fractionation Kit (Abcam® 
ab65320). Every step was performed on ice. Cells were washed 2x in cold PBS and 500l 
1x Cytosol Extraction Buffer Mix (+1/500 protease inhibitors plus 1/1000 DTT) added and 
incubated on ice for 10 mins. Using a cell scraper the cells were then scraped from the 
plastic ware and transferred into a 1.5ml Eppendorf tube. To homogenise the cells, the 
lysate was passed 60 times with a Dounce tissue grinder (pre-chilled on ice) and the 
homogenate then transferred into a fresh 1.5ml Eppendorf tube and centrifuged at 700xg 
for 10mins at 4C. The supernatant was then transferred into a new Eppendorf tube and 
centrifuged at 10000xg for 30mins at 4C, the supernatant was the cytosolic fraction. The 
pellet left was the intact mitochondria, which was resuspended in 60l cold PBS to form the 
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mitochondrial fraction. Fractions were snap-frozen and stored long term at -80°C. 
Hsp60/Na+&K+ ATP-ase was used as a mitochondrial fraction marker and GAPDH as the 
cytosolic marker (see table 2.1). 
 
2.3.10 Endoplasmic reticulum isolation 
Cells were set up at 15% confluency, two days prior to ER isolation, in T75 flasks. 7M 
ABT-737 was added 24 hours prior to isolation (plus an untreated control). Every step was 
carried out on ice. The total ER (rough and smooth) was subsequently isolated using an 
edited protocol from the Endoplasmic Reticulum Enrichment Kit (Novus Biologicals NBP2-
29482). Flasks were put on ice for 5 mins before the isolation started; cells were washed 
2x in 1X PBS, then 1ml 1X Isosmotic Homogenization Buffer added plus 20l 100X PIC. 
The cells were harvested using a cell scraper and the solution then transferred into a pre-
chilled Dounce tissue grinder. The solution was homogenized by 60 passes with the tissue 
grinder and the homogenate transferred into a 1.5ml Eppendorf tube. The tube was 
centrifuged at 1,000xg for 10mins at 4C. Then the floating lipid layer (if present) was 
removed and the supernatant transferred into a Beckman Polyallomer 3.5ml 13x51mm 
ultracentrifuge tube (Beckman 349623). The tubes were centrifuged at 12,000xg for 15mins 
at 4C using a swinging bucket rotor (Beckman Coulter® SW 55 Ti) in an ultracentrifuge 
(Beckman Optima™ L-90K). The floating lipid layer (if present) was then removed and the 
remaining supernatant was centrifuged at 90,000xg for 60mins at 4C in the same swinging 
bucket rotor in the ultracentrifuge. The supernatant was discarded and the pellet 
resuspended in 100l 1X suspension buffer and 10L 100X PIC. Samples were then 
subject to a Bradford assay to determine the protein concentration, snap frozen and stored 
at -80C. 
 
2.3.11 Bcl-2 chemical inhibition using ABT-737 
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ABT-737 (Selleck Chemicals LLC S1002) a BH3 mimetic, was diluted in media to create a 
working solution of 1mM. It was then added to the cells media at a final concentration of 
7μM. Untreated cells were grown in parallel as controls. Cells were incubated at 37C/5% 
CO2 for 24 hours before harvesting. 
 
2.4 DNA/RNA Methods 
 
2.4.1 Genomic DNA extraction from DT40 cells 
The E.Z.N.A. SQ Blood Kit (OMEGA Bio-tek) DNA purification protocol (edited) for cultured 
cells 0.5-1x106 was used. Cells were pelleted, resuspended in 25l PBS and vortexed. 
150l WTL buffer was added and mixed resulting in a viscous solution. 1l RNase A was 
added to the lysate, incubated at 37C for 10mins and cooled to RT. 50l of PCP Buffer 
was added, vortexed for 30secs and incubated on ice for 5mins. The lysate was centrifuged 
at max speed for 3mins at RT to pellet cells. The supernatant was transferred to a fresh 
2ml Eppendorf tube containing 150l 100% isopropanol, inverted 30-40x and centrifuged 
at ≥13,000xg for 1min at RT to pellet the DNA. Supernatant was decanted, the pellet blotted 
briefly on a paper towel, 150l ice-cold 70% EtOH was added, inverted and centrifuged at 
≥13,000xg for 2mins at RT. Then the EtOH was poured out carefully, excess blotted off and 
the pellet air-dried for 10mins. The DNA was rehydrated in 40-200l 8mM NaOH 
(depending on the size of the pellet), incubated at 65C for 1hr and the NaOH was 
neutralised with 1:100 1M Tris, pH 7. 5. The DNA was left at RT o/n with occasional mixing. 
A spectrophotometer was then used to measure the concentration and purity of the DNA, 
which was diluted 1µl in 70µl H20. The DNA was stored long-term at -20C. 
 
2.4.2 Screening for targeted insertion by gPCR 
10ng/l of genomic DNA was used per PCR reaction in conjunction with the Takara LA 
Taq (TAKARA BIO INC) ‘cool start method’. Samples were run on a 0.7% agarose gel 
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and agarose-gel electrophoresis used to size-separate amplified fragments. The gel was 
run at 90V for >45mins and images taken using a UV transilluminator. PCR reactions and 
associated programs used for PCR screening with two targeting vectors are shown below. 
 
 
 
 
2.4.3 PCR product Blunt-end ligation and subsequent PCR product sequencing 
Following gPCR, the PCR product was ligated into a T4 cloning vector (RBC RC001 
RC013) using the reaction mixture shown below. Both a dilute and a concentrated reaction 
for each sample plus a positive and negative control were made. Reactions were incubated 
o/n at 4C. Reactions (4 per sample) were then plated out onto ampicillin containing agar 
plates and put into a 37C incubator o/n. Isolated colonies from sample plates were then 
used to inoculate a starter culture of 3ml LB + ampicillin (1/1000). Starter cultures were 
grown at 37C with shaking for 8-10 hours. 400µl was then used to make a mini-prep culture 
with 40ml LB + ampicillin (1/1000), cultured with shaking o/n at 37C. The following day a 
pEGFP-IAA17-APC KI 
PCR Reaction Cycles 
dH20 12.6l Initial Denaturation 94C 1m 
PI (20M) 5’Arm-2R 0.5l Denaturation 98C 10s 
 
 
X34 
P2 (20M) GFP R 0.5l Annealing 66C 30s 
Template gDNA (10ng/L) 1l Extension 72C 6m 
dNTPs (2.5mM) 3.2l Final Extension  72C 10m 
10x LA Buffer II (Mg2+plus) 2l Hold 4C  
LA-Taq polymerase 0.2l    
Total Volume 20l    
pIAA17-APC KI 
PCR Reaction Cycles 
dH20 12.6l Initial Denaturation 94C 1m 
PI (20M) 5’Arm-2R 0.5l Denaturation 98C 10s 
 
 
X34 
P2 (20M) IAA17 R 0.5l Annealing 63.5C 30s 
Template gDNA (10ng/L) 1l Extension 72C 6m 
dNTPs (2.5mM) 3.2l Final Extension  72C 10m 
10x LA Buffer II (Mg2+plus) 2l Hold 4C  
LA-Taq polymerase 0.2l    
Total Volume 20l    
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Mini-prep of each culture was carried out and the concentration of the resulting plasmid 
DNA was measured with a spectrophotometer. 500ng of the pDNA was then digested using 
ECORI to establish plasmids containing PCR inserts; correctly sized inserts were then sent 
for Sanger sequencing using M13F and M13 R primers. 
 
Blunt-end ligation using the T&A cloning vector 
 Sample Positive 
Control 
Negative 
Control 
Ligation buffer A 1l 1l 1l 
Ligation buffer B 1l 1l 1l 
T&A cloning 
vector 
2l 2l 2l 
PCR product 2/5l - - 
T4 DNA ligase 1l 1l 1l 
Control DNA - 3l - 
dH20 3/0l 2l 5l 
Total Volume 10 l 10l 10l 
 
2.4.4 Restriction digest to linearize targeting vectors 
Per digestion, 50g of pDNA was set up in a 300l digest with 10x fast digest buffer 
(Fermentas), SalI (Invitrogen) at 1:60 and l d H20 and incubated o/n at 37C. Agarose 
gel electrophoresis at 90V was subsequently carried out with 500ng of the digest alongside 
undigested targeting vector (control) to establish if digestion had occurred. 
 
2.4.5 Ethanol precipitation of targeting vectors 
30l of 3M NaAc pH 5.2 was added to a 300l restriction digest (after o/n digestion) in a 
1.5ml Eppendorf tube. 660l ice-cold EtOH was added to the tube, inverted to form a white 
precipitate and incubated at 4C >30mins or -20C o/n. The tube was then centrifuged at 
4C for 30mins at maximum speed and supernatant decanted to leave a DNA pellet. 1.5ml 
ice-cold 70% EtOH added, the tube was inverted several times, centrifuged at RT for 5 mins 
at max speed and the wash step repeated. The supernatant was decanted, the excess 
blotted, the pellet air-dried for ~10mins and resuspended in 30l PBS. Samples were stored 
at -20C. 
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2.4.6 DNA gel electrophoresis 
0.7% agarose was dissolved in 50ml 1x TAE together in a conical flask by heating in a 
microwave. One drop of Ethidium bromide using a dropper (Invitrogen, 15585-011) was 
then added to the cooled agarose solution before it was poured into a gel tank containing 
a comb and left to set. (Note that for cloning purposes, GelRed (Biotium, 41005) was added 
to the cooled agarose rather than the mutagen Ethidium bromide). The tank was then filled 
with 1x TAE. Samples were prepared by adding DNA (50ng per band is sufficient to detect 
on a gel) to 6X loading dye (Thermo Fisher, R0611) and water to make up a volume of 
approximately 10l per sample. Samples were then loaded into the wells of the gel and run 
alongside 5l of a 1kb DNA ladder (New England Biolabs N3232L). The gel was then run 
at 110V/400mA until the ladder had sufficiently migrated through the gel (30-90 minutes). 
The gel was then imaged using a UV transilluminator. 
 
2.4.7 Reverse-Transcription PCR (RT-PCR) in DT40 cells  
 2.4.7.1 RNA isolation 
Cells were pelleted, lysed in 0.2ml of RNA-Bee RNA isolation agent (Amsbio, CS-
501B) per 6x106 cells and mixed by repeated pipetting. 0.2ml of chloroform was 
added per 1ml of RNA-Bee, the tube shaken vigorously for 15-30 secs and 
incubated on ice for 5mins. The homogenate was then centrifuged at 4C, 12,000xg 
for 5mins. The aqueous phase was transferred into a fresh tube, 500l of 100% 
isopropanol added and incubated for 5-10mins at RT. The solution was centrifuged 
at 12,000xg for a further 5mins at 4C to form an RNA precipitate at the bottom of 
the tube. The supernatant was removed and the pellet washed in 75% EtOH (at 
least 1ml per 1ml of RNA-Bee), shaking the tube to dislodge the pellet from the side 
of the tube. Centrifuged for 5mins at 7500g and 4C and the wash repeated. The 
pellet was air-dried for up to 10mins and dissolved in 100l DEPC H2O. 
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2.4.7.2 cDNA synthesis 
cDNA synthesis was done using the Thermo Scientific Maxima First Strand cDNA 
Synthesis kit utilising both random hexamers and oligo (dTs) as shown below. 
 
 
2.4.7.3 RT-PCR 
PCR with the generated cDNA was carried out using GFP F and GFP R primers 
(table 2.3) with DreamTaq™ polymerase (ThermoFisher, EPO711). Reaction 
components and cycle programs are outlined below. 
 
2.4.8 Quantitative Reverse-Transcription PCR (qPCR) 
 
 
 
 
 
 
 
2.4.8.1 RNA extraction from cultured adherent cells 
RNA was extracted using the NucleoSpin RNA kit according to manufacturer’s 
instructions (Macherey-Nagel 740955.250). Cells were set up prior to harvest in a 
T75 flask so as to be confluent on the day of harvesting. The media was aspirated 
First Strand cDNA synthesis Cycles 
Template RNA 10ng/l Hexamer Primer 
Incubation 
25C 10m 
Oligo (d)Ts (100pmol) 1l Oligo dT Incubation 50C 30m 
Random Hexamers 
(100pmol) 
1l Termination 85C 5m 
10mM dNTPs 1l Hold 4C  
Nuclease-free H20 (DEPC) l   
5x RT buffer 4l   
Maxima H Minus Enzyme Mix 1l   
Total Volume 20l   
DreamTaq™ PCR Cycles 
dH20 12.5l Initial Denaturation 95C       5s 
PI (20M) 0.5l Denaturation 95C        
40s 
 
 
 
x35 
P2 (20M) 0.5l Annealing 60C 
40s        
Template cDNA 2l Extension 72C 
6m        
dNTPs 2l Final Extension  72C      5m   
Buffer 2l Hold 4C         
DreamTaq™ polymerase 0.5l   
Total Volume 20l   
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and the cells washed 1x in cold PBS, then 700l of Buffer RA1 and 7l β-
mercaptoethanol were added in drops around the flask. The cell solution was then 
collected with a cell scraper, transferred into a violet NucleoSpin filter within a 2ml 
collection tube and centrifuged for 1min at 11,000xg. The filter was then discarded 
and 350l of cold EtOH added to the lysate and pipetted up and down 5 times to 
mix. Then the solution was transferred into a NucleoSpin RNA column within a new 
2ml collection tube, centrifuged for 30s at 11,000xg and the column was placed in 
a fresh 2ml collection tube. Next, 350l of MDB was added to the column to de-salt 
the membrane, centrifuged again for 1min at 11,000 and 95l DNase reaction 
mixture was added onto the centre of the column and incubated for 15mins at RT. 
(DNase reaction mixture: 10l reconstituted rDNase + 90l reaction buffer for 
rDNase, per RNA isolation, made in a 1.5ml Eppendorf tube.) 200l Buffer RAW2 
was added to wash the column and centrifuged for 30s at 11,000xg. The column 
was added to a new 2ml collection tube, 600l Buffer RA3 added to the column and 
centrifuged at 11,000xg for 30s. The flow-through was discarded and 250l Buffer 
RA3 was added and centrifuged at 11,000xg for 2mins to dry the membrane in the 
column. To elute the RNA, the column was placed into a 1.5ml nuclease-free 
collection tube, 60l RNase-free H20 added and then centrifuged for 1min at 
11,000xg. The RNA concentration was then measured using a spectrophotometer 
and subsequently diluted to a concentration of 200ng/l. RNA was kept on ice at all 
times and stored at -20C. 
 
 
2.4.8.2 cDNA synthesis 
cDNA was synthesized using the qSCRIPT™ cDNA synthesis kit (Quanta 
Biosciences 95047-500). Multiple reactions were set up each containing 1g RNA 
(5µl of RNA at 200µng/µl). A 15l master-mix was made (minus the RNA) and 
 78 
 
reactions were added to 0.2ml thin-walled clear PCR tubes (AXYGEN 321-10-05). 
The RNA was added (1g) and the tubes put into a PCR machine (Eppendorf 
Mastercycler Gradient) and the program set as below. A no-reverse transcriptase 
(NRT) control sample was also made. 
 
 
 
 
 
 
2.4.8.3 Primer optimization: melt curve and melt peak setup and analysis 
The annealing temperature and efficiency for each primer needed to be optimised 
before use. Both of these were simultaneously tested by preparing a 96 well plate 
with 2 replicates of each condition as follows: 
 
 
 
 
 
 
 
 
A temperature was chosen with the lowest Ct value (best amplification) and the 
lowest amount of unspecific product, which is the best compromise between target 
gene primers and the reference gene primers. The cDNA concentration was chosen 
based on the primer efficiency generated by the software, with the best giving 
between 90-110% efficiency. 
First strand cDNA Synthesis 
Components 1 Rxn Programme 
Template RNA 5l (1g) 22C      5m 
Nuclease-free H20 5l 42C      30m 
qSCRIPT reaction mix (5X) 4l 85C       5m 
qSCRIPT RT 1l 4C           
Total Volume 20l  
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2.4.8.4 qRT-PCR sample preparation 
Samples were prepared using the Perfecta® SYBR® Green FastMix® (Quanta 
Biosciences 95072-012) as outlined below. Target genes were examined as well as 
a comparison to the reference gene actin. 
 
 
 
 
 
 
2.4.8.5 Cycle programming  
cDNA samples were run on the Bio-Rad CFX Connect™ Real-Time PCR Detection 
System using a 3-step cycle program as shown below. 
 
 
 
 
 
 
 
 
2.4.8.6 Analysis 
qRT-PCR analysis was done using CFX Manager™ Software.  
 
2.4.9 RNAi 
Cells were plated out one day prior to transfections in T-25s (TPP) so that cells were are 
40% confluent on the day of siRNA transfection. For each knock-down, 10l of siRNA 
qRT-PCR Sample Preparation 
Components 1 Rxn 
SYBR 2X 10l 
Primers F+R (10M) 0.6l 
Nuclease-free H20 4.4l 
Template (100pg/l) 5l 
Total Volume 20l 
qRT-PCR 3-Step Cycle Program Conditions 
Cycle Program 95C 30s   
 95C 5s  
x39 
 
 XC 15s  
 72C 10s PLATE READ 
Melt Curve 
Analysis 
95C 1m   
 55C 1m   
 55C -> 95C 
(0.5C increments) 
5s  PLATE READ 
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duplex was incubated with 400l of pre-warmed Opti-MEM® reduced-serum medium 
(Gibco™, 51985_026) in a 1.5ml Eppendorf tube and flicked to mix. 14l of INTERFERin® 
(PolyPlus Transfection™ 409-50) transfection reagent was added and the tube vortexed 
for 10 seconds to homogenise the solution. Tubes were then incubated at RT for 10 
minutes. Meanwhile, the media was aspirated off the cells and replaced with 6ml of pre-
warmed media. Then 400l of the transfection mix was dropped onto the cells and the flask 
was swirled to mix. Flasks were then put in a 37C/5% CO2 incubator and left for 48 hours. 
If a second siRNA transfection was required to increase the efficiency of the knock-down, 
the same procedure was repeated 24 hours after the initial transfection. 
 
For Apc mutant cells (CACO2 and SW480), knockdowns were performed using 
Lipofectamine® 3000 transfection reagent (Life Technologies, L3000001). 14l of 
Lipofectamine® 3000 was added to 400l of Opti-MEM® (reduced-serum medium 
(Gibco™, 51985_026) and mixed well by vortexing. 10l of siRNA was then added, mixed 
by pipetting and incubated at RT for 5 mins. The siRNA-lipid complexes were then added 
to the cells drop-wise and incubated at 37C/5% CO2. A further transfection was carried out 
24 hours later, with cells harvested a further 24 hours after, totalling 48 hours post first 
transfection. 
 
2.5 Bacterial Handling Techniques 
 
2.5.1 Transformation 
50l of Subcloning Efficiency™ DH5™ (Invitrogen, 18265-017) competent cells (per 
transformation) were thawed on ice in a 14ml round-bottomed tube. 3ng of pDNA/targeting 
vector or 5l of a ligation was added to the cells, incubated on ice for 30mins, heat shocked 
at 42C for 45 seconds and returned to the ice for 2 minutes. 250l of pre-warmed SOC 
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medium was added and incubated with shaking at 37C for 1 hour at 225rpm. 75l of each 
transformation was spread onto pre-warmed antibiotic plates and incubated at 37C o/n. 
 
2.5.2 Plating out bacteria 
Transformed bacteria were pipetted drop-wise onto the 
applicable antibiotic agar plate and the solution was spread 
around the plate using a sterile plastic spreader. Colonies 
from pre-existing plates could also be transferred to a fresh 
plate in order to maintain the stock. A sterile loop was used 
to pick a single colony from a plate and then streaked onto the appropriate plate to form 
streak 1. A new loop was and passed through streak 1 to create streak 2 and so on until 
there are 4 streaks. The fourth was streaked into the centre of the plate and contained 
single colonies. 
 
2.5.3 Bacterial Cultures 
For a starter culture/miniprep culture; 5ml LB + 1:1000 antibiotic was inoculated with a 
single isolated colony and incubated all day (>8hrs) at 37C with shaking. For a midi-prep, 
40ml LB + 1:100 starter culture + 1:1000 antibiotic was cultured in a 250-500ml conical flask 
o/n with shaking at 37C. 
 
2.5.4 Minipreps 
To isolate DNA, the E.Z.N.A. Fastfilter Plasmid Mini Kit (OMEGA Bio-tek D6905-03), and 
the vacuum protocol was used. A miniprep culture was pelleted by centrifugation, the 
supernatant decanted, the pellet resuspended in 250l Solution I and then transferred into 
a fresh 1.5ml Eppendorf tube. 250l Solution II was added, incubated at RT for 2mins and 
the tube inverted gently several times to obtain a clear lysate. 350l Solution III was then 
added and the tube immediately inverted several times to form a white precipitate. Tubes 
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were then centrifuged at max speed for 10mins. The vacuum manifold was then prepared 
and 100l of Equilibration Buffer was added to the columns first, followed by the cell lysate. 
When all the lysate had passed through the column 500l HB buffer was added and then 2 
washes of 700l DNA Wash Buffer. The columns were then air-dried; put into collection 
tubes and centrifuged at 13,000 rpm for 2 mins. 30l of pre-warmed (55C) Elution Buffer 
was added to the centre of the column, incubated at RT for 1min, then spun at 10,000 rpm 
for 1 min. The eluted material was passed over the column again and spun for a further 
1min to elute any residual DNA. The DNA content of the sample was then measured. 
Similar protocols were followed for Midi/Maxipreps. 
 
2.5.5 Long-term storage of transformants  
To store transformed bacteria long-term; 700l of a starter culture was added to 300l 
glycerol, snap-frozen on dry ice and stored at -80C. When needed, the stock was taken 
up on dry ice (so as not to thaw) and a small amount was scraped from the vial and spread 
onto the applicable antibiotic plate, which was then put into a 37C incubator o/n. The 
glycerol stock was returned to -80C. 
 
2.6 Microscopy 
 
2.6.1 Preparing collagen coated coverslips 
In the tissue-culture fume hood: 22x22mm, 1.5 thickness coverslips (VWR 631-0125) were 
put into a 15cm sterile dish with enough 70% EtOH to cover the slides. Then using sterile 
forceps the coverslips were taken out of the 70% EtOH, put into individual wells of a 6 well 
dish (TPP) and washed 2x in DPBS. Collagen VII (SIGMA C8897, from rats’ tails) was 
added, enough to cover the slide and the bottom of the dish/well. Slides were then left in 
the tissue culture hood all day to allow the collagen to coat the coverslip. The collagen was 
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then aspirated off, the lids were removed and the uncovered dishes/plates left in the fume 
hood o/n in UV light to sterilise.  
 
2.6.2 Preparing cells for immunofluorescent staining  
Cells were seeded onto collagen-covered coverslips and left to recover o/n at 37C/5% 
CO2. Cells were fixed by aspirating the media and gently pipetting 200l of pre-warmed 4% 
PFA onto the edge of the plate/dish and left at RT for 10 mins. The PFA was aspirated off, 
the coverslips were transferred into a dark and humid box and 200l of IF wash buffer was 
added to the corner of the coverslip. The cells were left for 10 mins at RT, then 200l 
permeabilisation buffer was added to the coverslip and left for 10 mins. The wash step was 
repeated and then 200l of blocking buffer was added and the cells left at RT for 30 mins. 
Primary antibody(s) (table 2.1) was added (diluted in incubation buffer) and incubated for 
1hr at RT. Then the cells were washed 3x5mins in wash buffer, which was then aspirated 
off. Secondary antibody(s) (table 2.2) was then added (dilution in incubation buffer) for 1 hr 
at RT and washed 3x5mins in wash buffer. Cells were then counterstained with 1/5000 
DAPI (SIGMA D-9542) in 200l PBS, and phalloidin at 1/500 for 1 hr at RT (table 2.1). 
PBS/counterstain(s) was then aspirated and the slides washed 1x in cold PBS. Coverslips 
were then mounted onto slides. 
 
2.6.3 Mounting the coverslips 
To mount the slides, 10L of mounting medium was added to the centre of a microscope 
slide, the PBS (from 2.6.2) was aspirated from the slide and using sterile forceps, the 
coverslip was carefully placed face-down onto the drop of mounting medium. Once the 
mounting medium had spread across the slide it was sealed with nail-polish. When dry 
(>15mins in the dark) the back of the coverslip was washed in MilliQ water to remove salt 
crystals before viewing under a microscope. Slides were stored at -20C. 
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2.6.4 Microscopes  
IF imaging of fixed/live cells was performed with a Zeiss 700 microscope using Zen 2011 
software. Time-lapse brightfield videos of organoids were recorded using a Leica DMIRB 
inverted microscope and OpenLab software. Images were taken every 30 mins for 48 hours. 
Tisse culture fluorescence microscopy was carried out using the Invitrogen™ EVOS Floid™ 
cell imaging system. 
 
2.6.5 Image analysis 
Images from the Zeiss 700 were saved as LSM files and opened in Volocity 6.4 (Perkin 
Elmer). MitoTracker® images were analysed using Imaris (Bit Plane). Organoid movies 
were assembled using FIJI by Image J (Schindelin et al., 2012). 
 
2.7 Fluorescence activated cell sorting (FACS) 
 
2.7.1 Preparing suspension cells for FACS (with fixation) 
DT40 cells were pelleted in a 15ml falcon tube and washed 2x in 1ml cold PBS. The cells 
were resuspended in 250l cold PBS and then 2ml cold-70% EtOH was added while 
vortexing to fix the cells. The cells were then kept at -20C for ≥5hrs. Once the cells were 
treated with antibodies (see below and table 2.1), they were pelleted and resuspended in 
PBS 500l/RNase A 1:1,000/PI 20g/l in 5ml round-bottomed FACS tubes. FACS was 
done using the Becton Dickinson LSRFortessa™ flow-cytometer and 10,000 events were 
measured per sample. 
 
2.7.2 Measuring the quantity of cells in G2/M by treatment with BrdU 
DT40TIR and DT40TIR;(GFP)IAA17-APC cells were incubated at 37C/5% CO2 with 20M BrdU for 
20mins, then fixed and kept at -20C for ≥5hrs as in 2.7.1. The fixed cells were then pelleted 
and washed once in 2ml cold-PBS. The cells were pelleted again and resuspended in 1ml 
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2M HCl/0.5% Triton-X-100 (to relax the DNA for BrdU antibody access) while vortexing and 
incubated at RT for 30mins. The cells were pelleted and washed in 1ml PBS and then 
pelleted and resuspended in 1ml PBS/0.1% Tween 20/1% BSA (blocking agent). Again the 
cells were pelleted (centrifuged at 300rcf for 5mins at RT), resuspended in 100l blocking 
agent + Anti-BrdU antibody (1:500) and incubated at RT for 1 hour. The cells were washed 
again in blocking agent, then resuspended in blocking agent + secondary antibody (1:100) 
and incubated at RT for >30mins. Cells were then prepared for FACS as outlined in 2.7.1. 
 
2.7.3 Measuring the quantity of cells in mitosis by treatment with anti-PH3 
DT40TIR and DT40TIR; (GFP)IAA17-APC cells were fixed and kept at -20C for ≥5hrs as detailed in 
2.7.1. The fixed cells were pelleted and washed once in 2ml cold-PBS. The cells were 
pelleted and resuspended in 1ml 2M HCl/0.5% Triton-X-100 while vortexing and incubated 
at RT for 30mins. The cells were pelleted and washed in 1ml PBS, pelleted and 
resuspended in 1ml PBS/0.1% Tween 20/1% BSA (blocking agent). Again the cells were 
pelleted (centrifuged at 300rcf for 5mins at RT), resuspended in 100l blocking agent + 
Phospho-Histone H3 antibody (1:300) and incubated at RT for 1-2hrs. The cells were 
washed again in blocking agent, resuspended in blocking agent plus secondary antibody 
(1:100) and incubated at RT for >30mins. The cells were then prepared for FACS as 
outlined in 2.7.1. 
 
2.7.4 Preparing adherent cells for FACS (live cells) to measure mitochondrial 
membrane potential (MMP) 
U2OS cells were grown in T25s (TPP) and treated as required. Then, the media was 
aspirated and the cells were washed once in DPBS. 2ml of pre-warmed Opti-MEM® 
reduced serum media (Gibco™, 51985_026) was added to the flask containing 500nM 
MitoTracker® Green (Invitrogen Molecular Probes M-7514), which is MMP independent 
and 250nM MitoTracker Red CMXRos (CST 9082), which is MMP dependent. The cells 
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were put back into the incubator at 37C/5% CO2 for 45 minutes. The cells were then 
harvested for FACS (see 2.7.1).  
2.7.4.1 Measuring MMP and quantifying mitochondria 
To measure the MMP cells were prepared for FACS without fixation. The 
media was aspirated from the flasks, washed 1x in DPBS, 1.5ml trypsin 
added and the flasks were put back into the incubator at 37C/5% CO2. Once 
the cells had detached from the flask, 3ml of pre-warmed media (DMEM) 
was added to inactivate the trypsin. The cell solution was transferred into a 
50ml falcon tube and the cells were spun down. Then, the falcon tubes were 
put on ice to prevent changes in MMP, the media was poured off the pellet 
and the tube was flicked to redistribute the cells into a single cell suspension 
within the small volume of residual liquid remaining. 500µl PBS-BSA (2%) 
containing 5µg/ml DAPI was added to the single cell suspension and the 
solution was transferred into a FACS tube and kept on ice. FACS was 
performed after gating of cells (selected by DAPI) to exclude the G0-subG1 
population. Cells were then examined by size (FSC and SSC) and their 
MitoTracker® Green and CMXRos content. 
 
2.7.5 Statistical Analysis 
The gating of cells was achieved with BD FACSDiva™ software while carrying out the 
experiment. Further analysis was performed using FlowJo single cell analysis software for 
FACS data. 
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Chapter 3 
Generating cells expressing APC that can be conditionally and reversibly degraded. 
 
Background 
Adenomatous polyposis coli (APC) is a multi-functional tumour suppressor protein. It is key 
in governing several cellular processes in epithelial cells. Its best defined role is in canonical 
Wnt signalling as part of the β-catenin destruction complex. APC is also involved in 
regulating the cytoskeleton as it binds microtubules and actin (Mogensen et al., 2002; Kita 
et al., 2006; Kroboth et al., 2007; Moseley et al., 2007). This binding action stabilises 
microtubules (Zumbrunn et al., 2001). Consequently, APC has an indirect but important role 
in microtubule dynamics, mitotic spindle assembly, cell division and cell migration. In 
addition to these roles there are links between APC and cellular metabolism, apoptosis, 
cellular proliferation, trafficking, cell polarity, cell adhesion and DNA damage. Moreover, 
human APC has been found to interact with more than 100 other proteins that contribute to 
at least 24 different cellular functions (Nelson and Näthke, 2013). How APC contributes to 
or regulates the functions of the proteins it binds, or how they are coordinated, is not known.  
 
Aim 
The aim of this PhD was to use a reverse genetics approach to study the non-Wnt-related 
functions of APC. To this end I needed to generate a cell line expressing APC that could 
be rapidly and conditionally degraded (fig 3.1). This would permit the study of APC loss 
prior to its impact on the transcriptional repertoire of the cell. Such a cell line would also 
enable rescue of observed phenotypes by re-introducing full length APC (by relieving the 
inhibition) or fragments of Apc.  
 
Model System 
The model system used to carry out genetic manipulation in order to create a degradable 
APC, was DT40. These white-leghorn chicken (Gallus gallus) cells are ALV (Avian-leukosis  
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virus) induced B-cell lymphoma cells. The ALV virus integrated upstream of c-myc and this 
lead to their immortalisation. These chicken B cells were chosen for several reasons. Firstly, 
they are very efficient at homologous recombination, making them genetically tractable and 
a good model to study cell autonomous functions. Secondly, Apc is conserved in DT40 and 
has 84% protein homology with human APC (see appendix B). In addition, these cells have 
a fast doubling time of 11-12 hours when cultured at 37C. Lastly, Apc is on the Z 
chromosome in chicken and therefore present in only one copy.  
 
The reasoning for creating an EGFP-(degron)-tagged APC was because there is currently 
no cell line containing robust GFP-APC, available as a reagent. Possessing EGFP-APC 
would allow for GFP-pull down experiments to examine APC-interacting proteins. In 
addition, the EGFP-tag would allow for the visualisation of the APC fusion protein using IF, 
and the production of quantitative APC experiments using such methods as FACS analysis. 
 
Generation of Constructs 
To degrade endogenous APC, the Auxin-Inducible Degron (AID) system was used 
(Nishimura et al., 2009). In cells expressing a TIR protein, which forms a specific SCFTIR 
E3 ubiquitin ligase, the AID system depletes endogenous proteins tagged with a short 
degron motif, in the presence of auxin. Auxin binds the degron-fusion protein and the SCFTIR 
ubiquitin ligase, bringing them closer together. This results in the ubiquitination and 
subsequent degradation of the protein (fig 3.2). This protein degradation is conditional, only  
Figure 3.1. Workflow to create a degron knock-in at the Apc N-terminus. (1) Ethanol 
precipitated and linearized targeting vector was stably transfected into DT40 cells harbouring 
a transgene expressing the TIR protein (DT40TIR). (2) Transfected clones were selected in 
media containing Blasticidin and expanded. Clones were frozen (3) and expanded (4) prior 
to extraction of genomic DNA (5). Successful targeting of the degron was determined by PCR 
(6). PCR products were then sequenced (7). Western blot screening of targeted clones 
determined auxin (IAA) sensitivity (8). Where indicated, the Blasticidin resistance cassette 
contained within intron 1 was removed after transient expression of Cre recombinase (9) and 
screened by Western blot (10).    
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happening in the presence of auxin and the protein depletion is reversible upon auxin 
withdrawal.  
 
As the C terminus of Apc contains important PDZ and microtubule binding domains, the 
degron motif was fused to the N terminus of Apc. A knock-in of (EGFP)-degron protein-
coding cDNA was targeted 5’ of Apc by homologous recombination (fig 3.3). In order to 
produce a contiguous mRNA the (EGFP)-degron coding sequence was inserted upstream 
of Apc exon 1.  The ATG start codon of Apc was deleted and reintroduced at the start of 
both the EGFP and degron cDNA sequences. Both additionally contained Kozak 
sequences to enhance translational initiation by the ribosome. Expression of heterologous 
reporter proteins such as EGFP can sometimes alter protein expression, often due to codon 
bias in the host cell/organism (Baca and Hol, 2000; Yilmaz and Arslanyolu, 2015).  
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Figure 3.2. The AID system. (a) When the exogenous F-box protein TIR protein is 
expressed, it joins up with Cul1 and Skp1 to form the SCFTIR E3 ubiquitin ligase. The 
ligase degrades proteins containing a degron motif (represented by the black area 
within the substrate) in the presence of auxin. (b)   Once auxin is added it binds to both 
the degron and the F-box TIR protein, bringing the substrate into contact with the 
SCFTIR. This allows the poly-ubiquitination of the substrate, targeting it for proteasomal 
degradation. 
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Therefore, the degron cDNA also contained a kozak sequence in case the EGFP was not 
expressed. Note that the (EGFP)-degron-Apc allele remained under the control of the 
endogenous Apc promoter. To target the (EGFP)-degron cDNA 5’ of the Apc start codon, 
Figure 3.3.  Targeting strategy to create a degron-Apc knock-in by homologous 
recombination. The targeting vectors were designed to introduce a short (EGFP)-degron 
sequence immediately 5’ of the endogenous Apc start codon to produce a contiguous mRNA. 
Regions of homology within the targeting vector are shown in grey. Recombinant exon 1 (with 
a deleted start codon) is shown in blue. The start codon was reintroduced at the start of both 
the EGFP and degron sequences. A floxed Blasticidin selectable marker was introduced in 
intron 1 under control of a β–actin promoter. Lox P sites are represented by black triangles. 
Position of PCR primers are shown on the recombined allele. (a) Targeting strategy to knock-
in EGFP-degron cDNA using pEGFP-IAA17-APC. (b) The same strategy was employed as in 
(a) to knock-in degron cDNA (without GFP) 5’ of Apc. In this case, a degron motif was targeted 
5’ to exon 1 using the targeting vector pIAA17-APC. 
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a targeting vector was produced by amplifying 3 specific genomic regions at the Apc locus, 
by PCR. These regions were termed ‘arms of homology’. The homologous regions were 
designed to flank exon 1; a 5’ region upstream of exon 1 and a 3’ region in intron 1. A floxed 
Blasticidin S (Bsr) resistance cassette, driven by the β-actin promoter, was also inserted 
into intron 1 in the same transcriptional orientation as Apc. A map of the targeting vector(s) 
is shown in supplementary figure 1. 
 
Results Summary 
 Generation of a conditionally, degradable APC in DT40TIR cells using the Auxin-
Inducible Degron system (AID).  
 The degron-Apc allele was hypomorphic. 
 Off-target effects associated with the use of auxin reduced the usefulness of these 
cells to study the non-Wnt functions of APC. 
 
Results 
3.1 Establishing a control cell population; DT40TIR 
In order to make degradable APC, the AID system and its three main components were 
used (fig 3.2). Firstly, a thermostable F-box TIR protein isolated from the rice plant Oryza 
sativa was needed to form SCFTIR complexes in DT40 cells. Secondly, a degron motif 
(IAA17) taken from Arabidopsis thaliana was tagged onto the N-terminus of Apc in cells 
stably expressing the TIR protein. Lastly, indole-3-acetic acid (auxin) was used to bind both 
the degron motif within the substrate and the SCFTIR complex, bringing them together to 
allow APC ubiquitination and degradation (fig 3.2). 
 
First, varying concentrations of auxin (from 0-2µM) were added for 24 hours to ensure the 
viability of DT40 cells was not altered, which it was not, at any auxin concentration used 
(supplementary figure 3). In order to use this system to degrade endogenous APC, the AID  
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system required DT40 cells that stably expressed the TIR protein. This allows the SCFTIR 
E3 ubiquitin ligase complex to spontaneously form. A DT40 cell line stably expressing 
OsTIR9xMyc, had been generated previously. Several different clones were examined for 
TIR expression (using the Myc tag for detection) and APC and β-catenin levels (fig 3.4). 
Clone 4 was chosen as it had levels of APC and β-catenin most similar to WT cells. This 
clone then formed the control cell population DT40TIR. 
Figure 3.4.  Creation and selection of a control cell population. (a) DT40TIR cells were 
created by stable transfection of WT DT40 cells with a mammalian expression vector 
containing the TIR protein with a 9xMyc tag (pcDNA3.1HIS OsTIR9xMyc). Cells were 
cultured under G418 selection. (Carried out by C.J Baird). Clones were analysed by 
Western blot to confirm expression of the TIR protein using an anti-Myc antibody. (b) 
Individual clones were cultured +/- 10μM MG132 for 2 hours (to determine if APC is still 
poroteasomally degraded in DT40TIR cells) and subject to Western blot with antibodies 
against APC, β-catenin, Myc and loading control GAPDH. Protein expression in the 
clones was compared to untransfected WT DT40 cells. Data is representative of 3 
technical replicates. 
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3.2 Creating EGFP-IAA17-APC in DT40TIR cells 
A targeting vector, pEGFP-IAA17-APC (see supplementary figure 1) was stably transfected 
into DT40TIR cells by electroporation. Transfectants were selected using Blasticidin and 
Figure 3.5.  Screening EGFP-IAA17-APC clones for the presence of targeted 
insertions and auxin sensitivity. (a) Genomic PCR was carried out using one primer 
within the targeting vector (GFP R) and one upstream (5’Arm-2R), as shown in figure 3.2. 
DNA from DT40TIR cells and the targeting vector (T.V) were used as negative controls. 
The PCR product of ~4,000bp is indicated by the arrow. (b) 10 clones picked from (a) (9 
contained targeted insertions and 1 (10F) was negative) were cultured in 500μM IAA for 
1 hour and subject to Western blot analysis to measure levels of APC. HeLa cell lysate 
was used as a positive control for APC protein expression. {+} represents 500µM IAA 
(auxin) and {++} reprents 1mM IAA. Data is representative of 3 technical replicates. 
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Blasticidin resistant clones identified and expanded. Cells harbouring insertions of pEGFP-
IAA17-APC were identified by PCR using one primer within the targeting vector (GFP R) 
and one primer upstream of the insertion (5’arm-2R) (fig 3.5). The optimisation of the PCR 
screen is shown in supplementary figure 4. Nine positive clones and one negative clone 
(10F) were chosen to test for auxin-induced degradation of APC. Each clone was cultured 
with 500µM auxin for one hour, harvested and analysed by Western blot for the presence 
of APC. None of the clones exhibited decreased APC protein after auxin treatment. One 
clone, (12A) had little detectable APC, one clone (12E) had near WT levels of APC and the 
other 8 clones had markedly decreased APC protein (APClow). This indicated that the 
EGFP-degron-Apc was hypomorphic.  Unexpectedly, no expression of GFP was detectable 
(fig 3.5 and data not shown). It has previously been shown that gene expression can be 
affected by the close proximity of a cassette expressing antibiotic resistance, to gene 
regulatory elements (Chen et al., 1993). Therefore, in an attempt to rescue APC expression 
in APClow clones, the floxed Blasticidin resistance (Bsr) cassette in intron one was removed 
by transient expression of a plasmid encoding the bacteriophage P1 Cre recombinase (fig 
3.6a). Successful Cre recombination resulted in Bsr excision as confirmed by PCR (data 
not shown). Excision of the Bsr partly rescued APC expression and additionally, induced 
auxin sensitivity (auxin-induced APC degradation) in 2of 5 Bsr- clones (fig 3.6b, c). Note 
that the Western blot (fig3.6b) result is different in the Western blot quantitation in fig 3.6c, 
after protein bands were normalised to the loading control (tubulin) in TIR cells. This then 
provised a true, quantitative result. 
 
3.3 Creating IAA17-APC in DT40TIR cells 
A knock-in of the Apc allele in DT40TIR cells had been achieved that directed EGFP-degron 
cDNA upstream of Apc. However, the GFP was not translated: the GFP was not detectable 
by Western blot using an anti-GFP antibody (chicken or mouse species), nor did the anti-
APC antibody(s) detect a larger protein attributable to the EGFP tag; no EGFP was detected 
using a tissue culture fluorescence microscope; no EGFP was picked up using FACS  
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Figure 3.6.  Removal of the resistance cassette induces auxin sensitivity. (a) 
Schematic detailing the structure of the N-terminal degron-Apc allele before and after 
transient expression of Cre, which removes the resistance cassette. Lox P sites are 
represented by black triangles. (b) Western blot of proteins in 5 clones after Cre 
expression and subsequently cultured +/- 500μM IAA for 1 hour. (c) Quantification of 
APC expression in each clone (b) compared to DT40TIR cells. Data is representative of 
3 technical replicates. 
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analysis; nor was APC picked up following a GFP-trap pull-down experiment (lall 
experiments were compared to EGFP positive controls – data not shown). Therefore, 
production of a degron-Apc was required, i.e. an Apc locus containing no EGFP cDNA. 
DT40TIR cells were transfected with pIAA17-APC (see supplementary figure 1), transfected 
cells selected with Blasticidin and positive clones expanded. As before, targeted insertions 
were selected using a PCR screen with primers - IAA17 R and 5’Arm-2R (fig 3.7a). PCR 
optimisation is shown in supplementary figure 5. Three PCR positive clones and one PCR 
negative clone were selected and the Bsr cassette in intron 1 removed after expression of 
Cre. Bsr excision was again verified by PCR (data not shown). AuXin mediated APC 
depletion was then measured (fig 3.7b) in four original (O1, X4, O2, V5) and five daughter 
(O1E, X4A, X4H, O2E, V5G) clones (Bsr-).  
 
APC expression was partly rescued in all five Bsr- daughter clones and auxin sensitivity was 
also detected in all five, i.e. APC was depleted upon auxin treatment (fig 3.7b). Two clones 
were then chosen representing varying APC levels in comparison to DT40TIR: V5 
(APCminimal) had very little APC concomitant with high levels of β-catenin, as expected based 
on the role of APC in the β-catenin DC. X4A (APClow) expressed an intermediate level of 
APC between that of DT40TIR (APChigh) and clone V5 (APCminimal). These clones were 
subject to a timecourse of 500µM auxin treatment to determine if APC levels fluctuated at 
different rates in cells with more/or less APC. However, increasing the incubation time did 
not affect APC depletion as protein levels remained largely consistent throughout the 
timecourse (fig 3.7c). Therefore, the amount of APC present in a cell did not appear to affect 
the rate of APC depletion. Three of five degron-APC clones (fig 3.7b) with the Bsr removed 
(X4A, X4H and V5G) showed APC depletion after a one hour incubation with 500µM auxin. 
However, APC expression was decreased in all clones, even before the addition of auxin. 
This again suggested that knocking-in the degron motif produced a hypomorphic allele with 
reduced APC expression. While the addition of auxin to these hypomorphic cell lines did 
reduce the APC protein (in clone X4A), degradation of APC was not complete.  
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3.4 Attempting to further deplete APC by increasing the auxin incubation time 
Next, a more complete reduction of APC was attempted. Nishimura et al., (2009) added 
500µM auxin for 15 minutes to degrade GFP in S. cerevisiae expressing a degon-GFP 
protein and a TIR protein. In the experiments above a one hour auxin (500 µM) incubation 
was used. To determine whether APC depletion might require a longer exposure to auxin 
three clones with different levels of APC expression (DT40TIR, X4A and V5) were incubated 
in 500µM auxin for 24 hours. However, increased degradation of APC was not detected 
even after this prolonged treatment. Moreover, an off-target effect of auxin addition was 
detected. Specifically, APC depletion with a concomitant increase in β-catenin was 
observed in DT40TIR cells when exposed to auxin (fig 3.8a). This suggested that the AID 
system may be malfunctioning in DT40TIR cells. This means that SCFTIR complexes in these 
cells were able to degrade APC without a degron, in the presence of auxin – in opposition 
to the theory (fig 3.2). Thus, the control cell population was not reliable. 
 
3.5 Attempting to increase APC depletion by increasing the amount of SCFTIR E3 ubiquitin 
ligases 
Even though auxin caused degradation of APC in control cells (DT40TIR) it was important to 
try to increase APC depletion in targeted clones. The rate limiting step in APC degradation 
may be the availability of the TIR protein to form the SCFTIR complex. APC might only be 
fully degraded if there is sufficient specific E3 ubiquitin ligases available to ubiquitylate the  
Figure 3.7.  Screening of IAA17-APC clones for targeted insertion and auxin sensitivity. (a) 
Genomic DNA PCR was performed using one primer within the targeting vector and one 
upstream, as in figure 3.2. DNA from DT40TIR cells and the targeting vector were used as negative 
controls.  Clone 1A from the previous transfection (EGFP-IAA17 positive) was used as a positive 
control. The PCR product of 3358bp is indicated by the arrow. (b) Clones containing the targeted 
insertion (a) were subject to transient expression of Cre to recombine out the resistance cassette. 
Parental clones (Bsd+) and daughter clones (Bsd-) were cultured +/- 500μM IAA for 1 hour. 
Western blots show APC and β-catenin levels in each clone. (c) 2 clones were chosen from (b) 
representing different APC expression levels and subjected to a time course of 500μM IAA 
treatment. Graph shows quantification of APC and β-catenin protein expression levels. Data is 
representative of 3 technical replicates, except (b), which is representative of 3 biologial 
replicates. 
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Figure 3.8.  Variable response of degron-APC to auxin. (a) Clones were cultured in 500μM 
IAA for 24hours. Western blot shows APC and β-catenin levels, with quantitations in the right-
hand panels. (b) Clones were transiently transfected with pcDNA3.1HisC-TIR9Myc and 24 
hours later were cultured in 500μM IAA for a further 24 hours. Protein levels were quantified, 
shown in the right-hand panels. (c) Clones were treated with 1mM IAA for 24 hours. Upper 
panels show Western blot and quantifications are in the lower panels. Data is representative 
of 3 technical replicates. 
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degron motif. Hence a plasmid carrying TIR cDNA was transiently transfected into DT40TIR, 
X4A and V5 cells to increase the available ligase. Cells were then incubated with 500µM 
auxin for 24 hours. This resulted in no detectable APC in clone V5 and a corresponding, 
large increase in the amount of β-catenin (~4x). There was no effect on the degradation of 
APC in clone X4A, but again there was an effect in DT40TIR cells (fig 3.8b); TIR transient 
transfection plus auxin in DT40TIR cells led to a 2 fold increase in APC. This showed that 
unmodified APC in the control cells was also affected by auxin. This further confirms the 
unreliability of these cells for my studies. 
 
3.6 Attempting to increase APC depletion by increasing the auxin concentration 
Finally, I determined whether a more specific decrease in degron-APC could be achieved 
using a different concentration of auxin. Nishimura et al., (2009) used up to 500µM to 
degrade their proteins of interest, the largest of which was 100kDa (MCM4).  I hypothesised 
that as APC is more than three times larger than MCM4, it may require a higher 
concentration of auxin to target APC effectively and rapidly. DT40TIR, X4A and V5 cells were 
cultured in 1mM auxin over 24 hours to determine whether a higher auxin concentration 
could more efficiently deplete APC. This proved successful in the APClow clone X4A, which 
had no detectable APC after treatment with 1mM auxin for 24 hours (fig 3.8c), concomitant 
for an increase in β-catenin. Increasing the auxin concentration had no visible effect on the 
APC in V5, although the β-catenin levels did increase with time. This suggested that there 
was some reduction of APC that could not be detected by Western blot. (Note the APC 
quantification of V5 is somewhat unreliable because there is so little APC to begin with). 
Unsurprisingly, once again there was an off-target effect; a decrease in APC and associated 
increase in β-catenin after 24 hours 1mM auxin in control DT40TIR cells. 
 
 
 
 
 102 
 
3.7 An Alternative approach to the AID system 
Due to the problems resulting from targeting the degron motif 5’ of Apc in DT40TIR cells, I 
attempted to degrade APC using the original AID system method (Nishimura et al., 2009). 
This involved expressing both the TIR and EGFP-degron-Apc cDNAs in one plasmid. Once 
transfected into cells this would produce the TIR protein and separate EGFP-degron-APC 
fusion protein, with the aim of degrading APC upon the addition of auxin. I.e. exogenous 
APC would be targeted for degradation. 
 
Firstly, EGFP (from pEGFP-C1) was cloned into a plasmid containing both TIR and degron 
cDNA (pAID1.2N, see supplemental figure 2) using the restriction site BstXI. This targeted 
EGFP to the N-terminus of the degron motif (for EGFP-degron expression). This then 
enabled Apc cDNA to be cloned (from pCMV-Neo-Bam-APC) into the plasmid’s multiple 
cloning site (PvuI and MluI restriction sites) to produce a GFP-degron-APC fusion protein. 
Transformation of competent bacteria with pAID1.2N-EGFP-APC resulted in no colonies 
(data not shown). Therefore, the whole process was repeated, but the EGFP and Apc 
cDNAs were firstly inserted into separate pJET1.2 cloning vectors. This ensured that 
cloning produced complete cDNA sequences when the cDNAs were further cloned from 
pJET1.2 into pAID1.2N using BstX1 (EGFP) or PvuI and MluI (Apc). Cloning of Apc cDNA 
(into pAID1.2-EGFP) and subsequent transformation of bacteria with pAID1.2-EGFP-APC 
resulted in one bacterial colony. Mini-preps were then carried out using the transformed 
bacteria. To check if ligation of the vector (pAID1.2-EGFP) and insert (Apc cDNA) was 
successful, a restriction digest was carried out using PvuI and MluI restriction enzymes, 
followed by agarose-gel electrophoresis. This showed that the insert was present, but it ran 
at the wrong molecular weight (data not shown). This suggested that the Apc cDNA had 
undergone some sort of structural rearrangement, possibly forming a quadraplex. This 
meant that the pAID1.2-EGFP-APC plasmid I had generated could not be used for AID 
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system experiments. Due to time pressure at this stage in my PhD, I had to move on with 
the project and so moved away from the generation of AID system cell lines.  
 
3.8 Conclusions 
To conclude, a conditionally, degradable, endogenous APC was created in DT40TIR cells. 
APC was depleted after a one hour incubation with 500µM auxin. Nonetheless, we 
concluded that this system was not the best option for studying the non-Wnt functions of 
APC for a number of reasons. The degron-Apc is a hypomorphic allele and results in cells 
with 50-100% less APC than control DT40TIR cells. Whereas, a one hour incubation with 
500µM auxin had minimal affect in DT40TIR cells, increased concentrations of auxin or 
longer incubation times caused an off-target effect. Specifically, it led to decreased WT APC 
(and produced a concomitant increase in β-catenin) when cells were treated with 500µM 
auxin for 24 hours.  The cumulative effect of increased TIR expression plus 500µM auxin 
resulted in the opposite effect – an increase in APC. For these reasons the degron-Apc 
generated in the lab was not used to examine non-Wnt functions of APC. 
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Chapter 4  
Response of degron-APC cells to Taxol® and DNA damaging agents. 
 
Background 
Most Apc mutant cells, found in the majority of CRCs, possess truncated Apc expressing 
the N-terminal third of the gene. This usually includes the oligomerisation and armadillo 
domains and some/no β-catenin binding domains. These cells do not arrest as well as WT 
APC cells at the spindle assembly checkpoint (SAC) during mitosis, in response to arresting 
agents such as Taxol®. Taxol® suppresses microtubule dynamics by binding to tubulin. 
Cells with different expression levels of full-length APC provided an opportunity to study the 
involvement of APC in mitotic arrest, i.e. it whether there is a threshold concentration of 
APC required for cells to adequately arrest in response to Taxol®. 
 
Evidence in the literature linking APC and DNA damage further suggests examining a 
functional link between APC and cell cycle progression, which can be affected by DNA 
damage (Narayan and Jaiswal, 1997; Steffensen et al., 1997; Jaiswal et al., 2006; Balusu 
et al., 2007). There are several ways a cell can respond to DNA damage, employing various 
repair pathways to fix the damage. For example: single strand break repair (SSB), 
nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR), non-
homologous end joining (NHEJ) and homologous recombination (HR). These can all be 
executed in response to upstream signals that recognise DNA damage. The degron-APC 
cells provided an opportunity to study the relationship between APC levels and DNA 
damage response in DT40 cells, a standard system for studying DNA damage. 
 
Aim 
I aimed to determine if decreased APC protein caused changes in cell cycle or DNA 
damage response using cells with varying levels of APC. 
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Model System 
The overall aim of my PhD was to study the non-Wnt functions of APC using a reverse 
genetics approach. I generated a degron-Apc cell line DT40TIR; (GFP) IAA17-APC that allowed for 
the controlled degradation of endogenous APC upon addition of auxin. The degron-Apc 
allele was hypomorphic and it generated clones with varying full-length APC expression. 
Certain clones were chosen to study cell cycle and DNA damage response; X4A (APClow) 
and V5 (APCminimal) in comparison to the control cell population DT40TIR (APChigh). 
 
Method 
To study changes in the cell cycle in DT40TIR, X4A and V5 cells, FACS analysis was used 
to separate cells into G1, S and G2/M phases. Cells were incubated for 20 minutes with 
20µM of the synthetic nucleoside Bromodeoxyuridine (BrdU), which is taken up by cycling 
cells. The cells were then washed, harvested, fixed and stained with an anti-BrdU antibody 
to asses cells’ proliferation, and PI to demonstrate the cells’ DNA content. To examine cells 
in mitosis, cells were harvested, fixed and stained with an anti-PH3 antibody and PI. Cells 
were treated with varying concentrations and time periods of Taxol® and then stained with 
anti-BrdU or PH3 antibodies. The selection of live, single cells used for this FACS analysis 
and subsequent experiments is shown in supplementary figure 6. 
 
To examine how cells with diminished APC responded to DNA damage, the colorimetric 
MTS cell viability assay was used to measure the percentage of viable cells in a sample. 
After incubating cells in different concentrations of PARPi, Cisplatin or HU the drugs were 
washed off and cells resuspended in drug-free media. After 24, 48 or 72 hours the MTS 
assay was used to measure the viability of the cells.  
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Results Summary 
Cells with reduced APC levels: 
 Arrested in mitosis less well in response to low doses of Taxol®. 
 Exhibited no changes in DNA damage response after treatment with PARPi. 
 Recovered better from Cisplatin-induced DNA damage.  
 Recovered less well from HU-induced DNA damage. 
 
Results 
4.1 Establishing the cell cycle profile of WT APC cells 
In order to determine if a decrease in APC resulted in cell cycle changes, the cell cycle 
profile of APC WT cells was established. DT40TIR cells were incubated with BrdU and 
washed, harvested, fixed and stained with an anti-BrdU antibody (fig 4.1 top panel) and PI 
(fig. 4.1 bottom panel). The cells were gated using FACS to exclude G0 and sub-G1 cells 
(using PI-supplementary figure 6) and the remaining cells were analysed for cell cycle 
distribution. Next, DT40TIR cells were treated with varying concentrations of Taxol® for 24 
hours, then fixed and stained with PI. FACs analysis then determined the percentage of 
cells at each phase of the cell cycle (fig 4.1b). The untreated (control) DT40TIR cells had 
almost 60% of cells in S phase, with 20% in S and G2/M phases. This distribution changed 
dramatically upon the addition of 10nM Taxol®. The proportion of G2/M cells increased to 
70% after treatment with at least 10nM Taxol®. The number of cells in S phase decreased 
to as low as 0% (1µM). This shows that the Taxol® was effective in arresting the cells. 
 
4.2 Comparing G2/M arrest using BrdU 
In order to examine how lowered APC expression may affect the cell cycle, the 3 varying 
APC expressers (APChigh, APClow and APC minimal) were treated with 100nM Taxol® for 6 
hours, as well as growing untreated cells as control samples. 
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A concentration of 100nM Taxol® was chosen for further experiments, as this concentration 
achieved 0% of cells in S phase (fig 4.1b). The incubation period was decreased from 24 
to 6 hours-due to the higher concentration. Subsequently, the cells were incubated with 
BrdU before harvesting, fixing and staining with an anti-BrdU antibody and PI (fig 4.1c). 
Both the BrdU plot (left panel) and the PI plot (right panel) show the distribution of cells 
within the cell cycle and reveal the effect of the arresting agent Taxol®. In all 3 cell lines the 
proportion of cells in G2/M versus S or G1 phase was unchanged in the presence of Taxol® 
Figure 4.1. Lowering APC expression has no effect on G2/M arrest induced by 
Taxol®.  (a) DT40TIR cells were incubated with 20 μM BrdU for 20 mins, fixed and stained 
with an anti-BrdU antibody (top panel) and PI to look at the distribution of cells within the 
cell cycle (bottom panel). (b) DT40TIR cells treated with varying concentrations of Taxol® 
for 24 hours. (c) Clones (IAA17-APC cells) and control DT40TIR cells were treated with 
500μM Taxol® for 6 hours and subsequently incubated with 20 μM BrdU for 20 mins. Cells 
were then fixed and stained with anti-BrdU and PI and analysed by FACS. The left hand 
panel for each cell line represents the BrdU plot, with gating to show how cells were 
selected for each cell cycle stage. The right hand panel represents the PI plot, showing 
the number of cells in G1 versus G2/M. (d) Quantification of the percentage of cells in 
G2/M, S and G1 based on the BrdU and PI FACS analysis in Taxol® treated cells (c). 
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(fig 4.1d) – 76.6% of APChigh, 78% of APClow and 75.6% of APCminimal cells were in G2/M 
phase. This suggested that Taxol® (100nM) had the same effect in all 3 cell lines. 
 
4.3 Evaluating mitotic arrest using Phospho-Histone H3 
BrdU treatment did not reveal if cells were arrested at the G2/M checkpoint, or whether they 
had progressed into mitosis and subsequently arrested. Cells in mitosis contain 
phosphorylated N-terminal histone tails on histone H3 (PH3) to allow for chromatin 
relaxation around the nucleosome. Aurora B phosphorylates serine 10 of histone H3 to 
produce phosphohistone 3, during mitosis (Hsu et al., 2000). This enables chromosome 
pairing and assembly in mitosis (Hans and Dimitrov, 2001).The proportion of cells in mitosis 
was not significantly different in Taxol® treated cells with less APC (fig 4.2b). However, it 
was possible that the concentration of Taxol® was too high to detect subtle changes in 
mitotic arrest. Therefore, a Taxol® titration was performed (6 hour incubation) and the cells 
stained with anti-PH3 for FACS analysis (fig 4.3a). The titration showed that at low doses 
of Taxol®, there were more mitotically arrested cells in cells containing less APC. These 
cells were more sensitive to Taxol® than cells with WT APC levels. However, this could 
also mean that cells with less APC proliferated faster and thus more cells arrested in 
mitosis. (Due to a faster cell cycle, more cells were generated, so there were more cells 
available to go through mitosis - higher PH3). 
 
 4.4 Cells with reduced APC arrest less well in mitosis in response to low doses of Taxol® 
To determine if there was a temporal response to Taxol®, a time-course of low-dose Taxol® 
treatment at 5nM (fig 4.3b), 10nM (fig 4.3c) and 20nM (fig 4.3d) was performed. The number 
of cells in mitosis was determined by FACS using PH3. No difference can be seen in the 
distribution of APC-varying cells when treated with 5nm or 10nM Taxol®. Although changes 
seem to occur at 9+ hours Taxol® treatment, there were more dying cells at these time-
points and so these are not accurate reflections of cell cycle distribution.   
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Figure 4.2. Lowering APC expression has no effect on mitotic arrest in response to 
100nM Taxol®.  (a) APChigh (DT40TIR), APClow (X4A) and APCminimal (V5) cells were treated 
with 100nM Taxol® for 6 hours or left untreated (ctrl). Cells were fixed and stained with 
an anti-PH3 antibody and PI and analysed by FACS. The black box represents the mitotic 
cells. (b) Quantification of the varying APC cells in mitosis when untreated (ctrl) or Taxol® 
treated, taken from (a).   
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Figure 4.3. Cells with lowered APC expression arrest less well in mitosis in response 
to low doses of Taxol®.  (a) Cells with varying APC expression; APChigh (DT40TIR), APClow 
(X4A) and APCminimal (V5) were treated with 100nM Taxol® for 6 hours. Cells were then fixed, 
stained with an anti-PH3 antibody and PI and analysed by FACS. (b) Cells were treated with 
5nM Taxol®, harvested every hour for 10 hours, stained with an anti-PH3 antibody and PI 
and analysed by FACS (c) as in (b) treated with 10nM Taxol® (d) as in (b) treated with 20nM 
Taxol®.   
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However, slight changes seemed to occur when cells with varying APC levels were treated 
with 20nM Taxol®; APClow and APCminimal cells (with <50% less APC than APChigh cells) 
arrested less well than APC WT cells (DT40TIR).  APCminimal cells arrested the least and 
APClow cells arrested less than APChigh and more than APCminimal. Hence the cells with an 
intermediary amount of APC arrested at an intermediate level. This result is in opposition 
to what was observed at low doses of Taxol® in fig 4.3a, where there were more reduced-
APC cells arrested in mitosis after 6 hours 20nM Taxol® treatment. However, the data in 
fig 4.3d is consistent over several hours (hours 3, 4, 6 and 7). Due to these experiments 
only being carried out once, it is therefore difficult to make any robust conclusions from the 
data. The experiments need to be repeated to determine whether the data in fig 4.3a or 
4.3d is correct. 
 
4.5 Cells with less APC respond differently to DNA cross-linkers and stalled replication forks  
Next, to examine the DNA damage response (DDR), DT40TIR, X4A and V5 cells were 
treated with three different DNA damaging agents. The response of APChigh, APClow and 
APCminimal cells were measured to drugs that affect DNA in three different ways: PARPi 
inhibits the PARP protein required to repair SSBs in DNA; Cisplatin cross-links DNA and 
cells require mechanisms to excise the lesion(s) from one or both DNA strands, such as 
topoisomerase proteins; and Hydroxyurea (HU) is thought to deplete the nucleotide pool, 
causing replication fork crashes that must be resolved. I hypothesized either: an initial 
decrease in cell viability after drug treatment (due to cell death induced by the DNA 
damage); or stasis in cell numbers - as the cell cycle was paused in order for the DNA 
damage to be repaired. Subsequent survival rates then depended on how effectively cells 
repaired the DNA damage. 
 
DT40TIR, V5 and X4A cells were incubated with PARPi, Cisplatin or HU. The drug was then 
washed off and cells were resuspended in drug-free media. 24, 48 and 72 hours later, cell 
viability was measured using an MTS assay (fig 4.4).  Different incubations of each drug 
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were used so that the MTS assay measured the viability after DNA damage was incurred 
as a result from each DNA damaging agent – the same incubation of each drug may have 
resulted in measuring cell death rather than DNA damage, due to the different potencies of 
each drug used. The most potent agent (Cisplatin) had a direct affect on DNA, whereas HU 
and PARPi affect DNA damage response pathways and (as they are less potent) require a 
longer incubation time.   
 
There was no difference between the responses of the different cells to PARPi (fig 4.4a). 
However, at 72 hours post-Cisplatin (fig 4.4b), there were more APClow and APCminimal cells, 
with APCminimal cells showing the highest survival. Perhaps cells with less APC can repair 
DNA cross links faster and consequently proceed through the cell cycle sooner. Whereas, 
APChigh cells (DT40TIR) may still be repairing DNA and cannot continue through the cell 
cycle. Conversely, cells with less APC may not notice and/or repair cross-links. Instead 
these cells may continue through the cell cycle without repairing the damage. 
 
After HU treatment, cells with less APC recovered less well. APCminimal cells recovered the 
least and APClow cells demonstrated that an intermediate level of APC produced an 
intermediary response to HU between APChigh and APCminimal. This is the opposite response 
to Cisplatin. 
 
4.6 Conclusions 
With regards to the cell cycle, APC depleted cells seemed to arrest less well to low doses 
of Taxol®, although the difference is slight. There appears to be a positive correlation 
between the level of APC and mitotic arrest; the more APC available to the cell, the more 
cells arrest in mitosis in response to Taxol®. This is evident as cells with the least amount 
of APC (APCminimal) arrested the least in response to Taxol® and cells with an intermediary 
level of APC (APClow) arrested less than APChigh, but more than APClow. However, this was 
not measured statistically due to the changes being small. Thus, only a trend can be 
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reported at this time. Results from the viability assay suggested that APC-reduced cells 
coped with SSB as readily as APC WT cells. They coped with replication fork crashes less 
well, and either repaired cross-links more efficiently than APC WT cells (DT40TIR), or did 
not respond to them. Why this is the case is unclear. However, as each repair pathway 
comprises many different proteins and upstream signals, it is possible that APClow and 
APCminimal cells have different proportions of these repair proteins and thus cope differently 
when various DNA damage occurs. It is also plausible that APC may bind to certain DNA 
damage proteins, either acting to activate or inactivate them (Narayan et al., 2005; Balusu 
et al., 2007; Jaiswal et al., 2013), or causing steric hindrance. Nevertheless, it is important 
to remember that changes observed in APC viability were small. Importantly, it is possible 
that APC deficient cells may not die very well, regardless of drug treatment. Therefore, 
looking at apoptosis in these cells is important to determine how to kill them specifically. 
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Figure 4.4.  Having less APC may alter cells’ response to some DNA damaging 
agents.  MTS assays were performed on DT40TIR cells and IAA17-APC clones after 
exposure to DNA damaging agents, which affect different DNA repair pathways. After 
PARPi, Cisplatin or HU drug treatments, cells were washed and re-suspended with drug-
free media. Cells were seeded into 96 well plates, 12,000 per well and cell survival was 
measured 24, 48 and 72 hours post drug treatment. (a) PARPi treatment for 24 hours. (b) 
Cisplatin treatment for 2 hours. (c) Hydroxyurea treatment for 16 hours. 
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Chapter 5 
Increased Bcl-2 and altered mitochondria may be responsible for the reduced 
sensitivity of Apc deficient cells to cytotoxic agents. 
 
Background 
Apc mutant cells like those found in more than 90% of sporadic CRCs have a compromised 
spindle assembly checkpoint. This is partly due to the loss of C-terminal microtubule binding 
domains of Apc (Munemitsu et al., 1994; Smith et al., 1994; Muhua et al., 1998; Kaplan et 
al., 2001; Dikovskaya et al., 2007). This means that Apc mutant cells treated with 
microtubule poisons such as Taxol®, do not arrest in G2/M as readily as Apc WT cells. 
Consequently, these mutant cells also do not undergo apoptosis induced by a prolonged 
mitotic arrest (Radulescu et al., 2010). However, exactly how a mitotic arrest induces 
apoptosis or how APC is linked with apoptosis in unknown. Understanding the latter 
connection is important to identify a means to selectively kill Apc mutant cells.  
 
For over twenty years a link between APC and apoptosis has been investigated (Browne 
et al., 1994; Dikovskaya et al., 2007; Cristofaro et al., 2015). Previous observations in the 
Näthke lab showed that Apc deficient cells were less sensitive to low doses of Taxol®, but 
were more readily killed by the combination of Taxol® and the Bcl-2 inhibitor ABT-737 
(unpublished data). This functional link between APC and apoptosis still lacked a molecular 
explanation. The aim of this thesis was to investigate the link between APC and apoptosis 
and establish how it was related to functions of APC in Wnt signalling. 
 
Aim 
The aim of this study was to investigate why Apc deficient cells are less sensitive to low 
doses of Taxol® and how the Bcl-2 inhibitor ABT-737 induces Taxol® sensitivity. Then to 
determine a mechanism for this resistance that might be clinically exploitable to specifically 
kill these cells. 
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Model System 
2D cell culture models of human epithelial cancer cell lines were used: Apc+/+ U2OS and 
HeLa cells, APC+/+; β-cateninΔSer45/+ HCT116 CRC cells, Apc1367/1367 CaCo2 CRC cells and 
Apc1308/1308 SW480 CRC cells. Some findings were then validated in a 3D model system; 
Apc+/+ and ApcMin/Min intestinal organoids derived from Apc WT and ApcMin mice, on a 
C57BL/6J background (see table 2.6). ApcMin/+ was the first mouse model for polyposis and 
is the most frequently used model of Apc mutation-induced CRC. It has a nonsense 
mutation in Apc at codon 850 that produces a short, truncated Apc (N-Apc). This N-Apc 
fragment lacks the β–catenin and microtubule binding domains (Su et al., 1992). These 
heterozygous mice develop numerous intestinal polyps analogous to the human condition 
Familial Adenomatous Polyposis (FAP).  Patients with FAP develop numerous (10’s to 
1,000’s) benign colonic polyps. This is a fully penetrant condition due to an inherited 
autosomal dominant, nonsense mutation in Apc. When left untreated, these polyps can 
accrue further mutations and develop into adenocarcinomas (CRC). 
 
Method 
To identify changes in the apoptotic machinery in Apc mutant cells, I focused on Bcl-2 (B 
cell lymphoma-2) family proteins as they are a key component of the intrinsic apoptosis 
machinery. RNAi was used to knock-down Apc, CTNNB1 (β-catenin) and a candidate gene 
Par-4 (prostate apoptosis response gene-4) in human epithelial cancer cell lines. The 
effects on the pro-life protein Bcl-2 were then examined. Different fractionation techniques 
were used to establish changes in protein levels in various cellular compartments. Most 
procedures were carried out in the presence and absence of the Bcl-2 inhibitor (a BH3 
mimetic) ABT-737 (Oltersdorf et al., 2005). Changes in the unfolded protein response 
(UPR) were studied by examining phospho-IRE protein levels and changes in mitochondria 
were investigated using the mitochondria-selective probes MitoTracker® (Calarco, 1995) 
and JC-1 (Smiley et al., 1991). Once changes in these proteins in cell culture experiments 
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were identified, the effects of Taxol® and ABT-737 on intestinal organoids, a 3D tissue-
mimetic model, were investigated. 
 
Results Summary 
 Apc depletion caused a β-catenin-independent increase in Bcl-2. 
 ABT-737 treatment caused an increase in Bcl-2 in the membrane fraction, but not 
mitochondrial or ER membranes. 
 Taxol®, ABT-737 and Apc depletion activated the unfolded protein response, and 
caused a change in the localisation and/or structure of mitochondria – a read out for 
cellular stress. 
 Apc depleted cells are smaller (µm2 and FSC). 
 
Results 
5.1 Apc depletion causes an increase in Bcl-2 in certain cell-lines 
To establish whether there is a link between APC and apoptotic proteins, RNAi was used 
to knock-down Apc and Apc/β-catenin in U2OS and HeLa cells. Then, levels of the pro-life 
protein Bcl-2, which is involved in protecting cells from apoptosis, were examined. A 
Western blot showed that upon Apc depletion there was a variable increase in Bcl-2 in 
U2OS cells that was not affected by β-catenin depletion (fig 5.1a).  This suggested that the 
increase in Bcl-2 caused by Apc knock-down may be β-catenin (Wnt pathway) independent. 
This is consistent with the data that Bcl-2 also increased when the RNAi experiment was 
repeated in CRC cells expressing a truncated Apc (N-Apc), which is inactive in Wnt 
signalling (fig 5.1b). However, this increase was variable and less strong in HeLa cells and 
not robust. Knocking down β-catenin alone did not cause a change in Bcl-2 consistent with 
the conclusion that Bcl-2 changes are independent of β-catenin status (fig 5.1c). However, 
to fully exclude a relationship between β-catenin and Bcl-2 changes, experiments 
overexpressing β-catenin are required.  
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Figure 5.1. Apc depletion causes an increase in Bcl-2 in certain cell-lines. (a) U2OS and 
HeLa cells were treated with ctrl, Apc and β-catenin siRNAs. Western blot (left panel) and 
quantification (right panel) shows a variable increase in Bcl-2 in U2Os cells, but not HeLa cells. 
N=3, error bars represent the standard deviation. (b) Apc mutant CaCo2 and SW480 cells were 
treated as in (a). Western blot (left panel) and quantification (right panel) shows an increase in 
Bcl-2 in CaCo2 cells, but not SW480 cells. (c) HeLa cells were treated with β-catenin siRNA 
alone to determine if the Bcl-2 increase upon Apc knock-down was β-catenin dependent. 
Western blot (left panel) and quantification (right panel). 
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5.2 Par-4 protein levels cannot explain the increase in Bcl-2 upon Apc depletion 
Next, experiments were needed to establish if the effect of APC on Bcl-2 was direct or 
indirect.  Specifically, experiments aimed to determine if APC binds Bcl-2 directly or whether 
another protein is involved that links APC and Bcl-2.  A potential candidate for such an 
indirect link to Bcl-2 was revealed in mass-spectrometry datasets from the lab, which 
identified binding partners of endogenous APC.  Specifically, we found that APC co-
immunoprecipitated with Par-4 (unpublished data). Par-4 transcriptionally inhibits Bcl-2 
through a WT1 (Wilms’ tumour 1) binding site in the Bcl-2 promoter (Cheema et al., 2003). 
I hypothesized that APC could bind to Par-4, sequestering it and preventing its degradation. 
This in turn would maintain low/reduced levels of Bcl-2 by Par-4-mediated transcriptional 
inhibition (fig 5.2a). In this model, Apc depletion would lead to release and degradation of 
Par-4 causing an increase in Bcl-2, as observed upon Apc knock-down (fig 5.2b). A 
potential flaw with this theory is that sequestration by APC might also prevent Par-4 from 
reaching its target sites in the nucleus. However, APC is present in the nucleus (Henderson, 
2000; Neufeld et al., 2000) and thus could bind Par-4 where it is active, i.e. the nucleus.  To 
test this idea, Apc or β-catenin were knocked down using RNAi in U2OS and HeLa cells 
(data from fig 5.1) and levels of Par-4 were compared (fig 5.2d). In addition to the increase 
in Bcl-2 there was also an increase in Par-4, the opposite of the expected change. The 
same was observed when Apc and β-catenin were knocked-down in CRC cell lines with 
mutant, truncated Apc (fig 5.2e). Thus, the increase in Bcl-2 resulting from Apc depletion 
could not be explained by a reduction in Par-4 protein (fig 5.2c). An alternative possibility 
that could explain the observations is that when Par-4 is bound to APC it is active and 
represses Bcl-2; but when Apc is depleted and Par-4 is released it is inactive and can no 
longer inhibit Bcl-2. Based on the finding that, neither WT nor mutant (truncated) APC could 
be co-immunoprecipitated with Par-4 (data not shown), it is unlikely that Par-4 acts as a link 
between APC and Bcl-2. 
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To look for a direct link between APC and Bcl-2, Co-IPs were used. Bcl-2 did not co-
immunoprecipitate (IP) with APC (fig 5.2f and supplementary figure 7). Furthermore, IPs for 
Bcl-2 did not reveal APC (fig 5.2g). This was despite the fact that, full-length and mutant 
APC were previously shown to associate with Bcl-2 in HCT116, SW480 and HEK293APC1309 
cells when using Co-IP (Brocardo et al., 2007); However, in this case, Co-IPs were 
performed with ectopically expressed proteins. In the absence of further data, an interaction 
between APC and Bcl-2 could not be confirmed. More experiments are needed to unravel 
the relationship between APC and Bcl-2. 
 
5.3 ABT-737 causes a Bcl-2 increase in the membrane fraction  
The elevated Bcl-2 levels that occurred in response to Apc depletion (fig 5.1) may provide 
some explanation as to why Apc deficient cells do not die in response to Taxol® as readily 
as Apc WT cells. Previously, we found that a combination of the Bcl-2 inhibitor ABT-737 
with Taxol® killed Apc deficient cells more effectively than wild type cells, or than either 
drug individually (unpublished data). To establish if this increased sensitivity could be 
explained by changes in Bcl-2, HCT116 CRC cells (Apc+/+) and U2OS cells were treated 
with 7µM ABT-737 for 24 hours (fig 5.3a). This caused an increase in Bcl-2 in both cell 
lines. To determine where this Bcl-2 increase occurred, HCT116 cells were again treated 
with ABT-737 and fractionated to separate cytosol, membrane, nucleus and cytoskeletal 
compartments. Western blots showed an increase in Bcl-2 in the membrane fraction upon  
Figure 5.2. Par-4 protein levels cannot explain the increase in Bcl-2 upon Apc knock-down. 
Model showing how Par-4 and APC could be linked: (a) APC protects Par-4 from degradation, 
resulting in Par-4-mediated Bcl-2 inhibition; (b) APC loss leads to Par-4 degradation and 
subsequent Bcl-2 increase. (c) Experimental results show that APC loss leads to an increase in 
Par-4 as well as Bcl-2. (d) Apc and β-catenin were knocked down in U2OS and HeLa cells. 
Western blots show levels of Par-4 and Bcl-2. The right-hand panel shows the quantification of 
the Western blot, with relative amounts of Par-4 and Bcl-2 compared to control siRNA (100%). (e) 
Apc and β-catenin were knocked down in CaCo2 and SW480 cells. Western blots show levels of 
Par-4 and Bcl-2. The right-hand panel shows the quantification of the Western blot, with relative 
amounts of Par-4 and Bcl-2 compared to control siRNA (100% protein intensity). (f) APC IP (2mg 
lysate) in U2OS cells shows an inconclusive CoIP with Bcl-2. 336 is a negative control for the Ali 
APC antibody used (see table 2.1). For uncut blots, see supplementary figure 7. (g) Bcl-2 IP (2mg 
lysate) in U2OS cells is negative for a Bcl-2-APC CoIP.  
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Figure 5.3. ABT-737 causes a Bcl-2 increase in the membrane fraction. (a) Western blot 
of whole cell lysate showing an increase in Bcl-2 after 7µM ABT-737 treatment (24h) in 
HCT116 cells (top panel) and U2OS cells (bottom panel). (b) HCT116 cells were treated 
plus/or minus 7µM ABT-737 for 24 hours. The proteins were then separated into cytosol (C), 
membrane (M), nucleus (N) and cytoskeletal (S) fractions. Fractions were subject to Western 
blot alongside a whole cell lysate (WCL) control to look at Bcl-2 protein levels. TopoIIα is a 
nuclear marker, HSP60 is a membrane marker, Keratin 18 is a cytoskeletal marker and 
GAPDH is a cytosolic marker. Β-catenin demonstrates a good fractionation as it is present in 
every fraction. (c) CaCo2 cells were subject to Western blot after being treated and 
fractionated as in (b). For uncut membranes and molecular weights (a-b) see supplementary 
figure 8. (d) Quantification of Bcl-2 present in the membrane fraction of HCT116 (a) and CaCo2 
(b) cells, plus/or minus ABT-737. 
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ABT-737 treatment (fig 5.3a). The same was true in CaCo2 (Apc-/-) (fig 5.3b) and U2OS 
cells (supplementary figure 8). The quantification also showed that membrane-associated 
Bcl-2 (fig 5.3c) increased by more than 50% in CaCo2 cells and nearly doubled in HCT116 
cells, upon ABT-737 treatment versus no treatment. 
 
5.4 The ABT-737-induced Bcl-2 increase does not accumulate at mitochondria or the ER 
Knowing that ABT-737 caused an increase in membrane-associated Bcl-2 prompted an 
investigation as to which specific membrane compartment this protein accumulated.  One 
approach was to identify the relative abundance of Bcl-2 in the different compartments 
where Bcl-2 is found.  
 
Bcl-2 is a membrane protein and uses its C-terminal transmembrane domain to insert into 
cellular membranes (Hockenbery et al., 1990; Krajewski et al., 1993; Nguyen et al., 1993; 
Akao et al., 1994). Bcl-2 is best known for its association with the mitochondrial outer 
membrane (MOM) (Krajewski et al., 1993; Nguyen et al., 1993; de Jong et al., 1994). There, 
its function is to maintain mitochondrial membrane integrity (Vander Heiden et al., 2000) 
and help maintain the mitochondrial membrane potential (Δψm). Therefore, it was possible 
that the increase in membrane-associated Bcl-2 in response to ABT-737 occurred at the 
mitochondrial membrane. To test this idea, protein lysates of U2OS cells treated with ABT-
737 were separated into cytosolic and mitochondrial fractions. Western blots revealed that 
Bcl-2 in the mitochondrial fraction did not change in response to ABT-737 treatment (fig 
5.4a).  
 
Bcl-2 does not only bind to the MOM, but also to the endoplasmic reticulum (ER) at contact 
sites between the ER and mitochondria (Franke and Kartenbeck, 1971). These sites are 
now termed mitochondria associated membranes (MAM) and form bridges to join  
 125 
 
 
 
 
 
 
 
mitochondria and the ER (Lithgow et al., 1994). To test if the increase in membrane-
associated Bcl-2 upon ABT-737 treatment occurred at the ER, the ER was isolated from 
U2OS cells after treatment with ABT-737. Then, the ER associated proteins were examined 
by Western blot. However, there was no increase in Bcl-2 in the ER fraction after ABT-737 
treatment (fig 5.4b). Thus the membrane where Bcl-2 is enriched remained unidentified.  
 
5.5 ABT-737 causes a stress response that mimics the effect of hypoxia on APC 
One observation made throughout experiments using ABT-737 was that it caused a 
reduction in APC in APC+/+ U2OS cells (fig 5.5a) and HCT116 cells (fig 5.5b), by up to 50%  
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Figure 5.4. The ABT-737-induced Bcl-2 increase does not occur at mitochondrion or ER. 
(a) U2OS cells were treated plus/or minus 7µM ABT-737 for 24 hours and subsequently separated 
into cytosolic and mitochondrial fractions. Western blot shows Bcl-2 levels as well as the 
mitochondrial marker Na+/K+ ATPase and the cytosolic marker GAPDH. N=3, experiments are 
representative of biological replicates. (b) U2OS cells were treated as in (a). The endoplasmic 
reticulum was then isolated and subject to Western blot alongside a whole cell lysate (WCL) 
control.  ER markers are Calnexin and protein disulphide isomerase (PDI). N=3, experiments are 
representative of 3 technical replicates. 
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Figure 5.5. ABT-737 causes a stress response on APC similar to hypoxia. (a) U2OS cells 
were treated with ctrl or Apc siRNA, plus/or minus 7µM ABT-737 for 24 hours. Western blot 
shows a decrease in APC upon ABT-737 treatment. (b) HCT116 cells as treated in (a). (c) 
Quantification of APC from (a-b). (d) HCT116 cells were cultured in normoxia (N) or hypoxia 
at 1% O2 (H) for 24 hours. Cells were lysed and subject to a Western blot (left panel) to look 
for APC. The hypoxia marker Hif-1α and its target gene CAIX were used as markers of 
hypoxia. The right panel shows the quantification of APC. (e) HCT116 cells were cultured as 
in (d). 1mg of the lysate was used to IP β-catenin and look for a β-catenin-APC CoIP (left 
panel). The quantification of the amount of APC bound to β-catenin (CoIP) is shown in the 
right panel. 
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(fig 5.5c). This was similar to the effect of hypoxia (Newton et al., 2010). Exposing HCT116 
cells to hypoxia (1% O2) resulted in a decrease in APC (fig 5.5d left panel) by up to 50% 
(fig 5.5d right panel). This reduction in APC led to fewer APC-β-catenin complexes (fig 5.5e) 
relative to the amount of the APC (fig 5.5e right panel). This reduction in the amount of APC 
bound to β-catenin is predicted to result in an increase in β-catenin available for binding 
TCF/LEF and activation of Wnt target genes (see appendix A). Similarly, it is likely that an 
ABT-737-induced APC reduction could result in an increase in Wnt-target genes also. 
However, ABT-737 did not lead to an increase in one target gene (Cyclin D) looked at by 
qRT-PCR, in both U2OS and HCT116 cells (supplementary figure 9). More replicates and 
other target gene analysis is needed to conclude anything about the impact of ABT-737 on 
Wnt signalling. Nevertheless, treatment with ABT-737 (up to 10µM for 24 hours – analogous 
to my method) has been reported to alter the transcription of 430 genes by at least two-fold 
in PV-10 renal carcinoma cells (Song et al., 2011). Unfortunately, a list of these affected 
genes is not available so I could not determine whether Apc was affected by ABT-737 in 
PV-10 cells. 
 
5.6 ABT-737, Taxol® and siRNA treatment activate the unfolded protein response 
When using the anti-Bcl-2 antibody for Western blot, I noticed it recognised an extra band 
that correlated with APC status and ABT-737 treatment (increasing). Mass spectrometry 
(MS) showed that this band did not represent Bcl-2 family proteins. However, it revealed 
many stress response proteins in that area of the gel (supplementary figure 10).  
 
The idea that ABT-737 was a stressor because it decreased APC like hypoxia, was 
consistent with my finding that the ER chaperone Calnexin increased after ABT-737 
treatment (fig 5.4b). This indicates ER stress, specifically activation of the unfolded protein 
response (UPR), a mechanism conserved across eukaryotes (see a review by Hollien, 
2013). This data prompted an investigation into stress responses.  
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When cells experience stress, induced by extrinsic or intrinsic cues, this can lead to an 
accumulation of unfolded or misfolded proteins in the ER causing proteotoxicity (see a 
detailed review of UPR activation by Tameire et al., 2015).  In response to the increase in 
unfolded proteins cells activate the UPR to relieve the ER stress and restore proteostasis. 
Signal transduction during the UPR is facilitated by three main stress sensors IRE, PERK 
and ATF6 and leads to: pausing of the cell cycle, expansion of the ER and reduction in 
most de novo protein synthesis, except for some ER-resident proteins (e.g. Calnexin). This 
allows cells to cope with the ER burden (see a detailed review by Hetz, Chevet and Oakes, 
2015). If a cell can resolve the ER stress it resumes the cell cycle. If the stress is 
irremediable then the UPR will elicit apoptosis (Zinszner et al., 1998). 
 
To determine if ABT-737 caused ER stress and activation of the UPR, levels of phospho-
IRE (P-IRE), a marker of UPR activation, were measured in isolated ER fractions - taken 
from data in fig 5.4. In both WCL and ER samples there was a significant increase in P-IRE 
after ABT-737 treatment (fig 5.6a). This indicated activation of the UPR and confirmed 
previous data. Wroblewski et al., (2013) showed activation of the UPR by ABT-737 in 
human melanoma cells by examining p-eIF2α levels. Next, I wanted to determine if UPR 
activation in response to ABT-737 was robust in other cell types and whether other 
treatments elicited the same response. HeLa cells were treated with an Apc or control 
siRNA together with ABT-737 and Taxol® (fig 5.6b). Then P-IRE levels were measured by 
Western blot. Apc knock-down resulted in an almost 30% increase in P-IRE relative to total 
IRE. Both ABT-737 and Taxol® treatment (in conjunction with mutant APC) also caused an 
increase. ABT-737 caused the largest increase (72%, in conjunction with control siRNA). A 
similar pattern of UPR activation was observed in CaCo2 CRC cells (fig 5.6c).  
 
This data suggests that ABT-737, Apc loss and importantly control siRNA, all activate the 
UPR. Moreover, it suggests they are all stressors on the cell. However, as the control siRNA 
treatment elicited the same response as the Apc siRNA (UPR activation), 
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Figure 5.6. ABT-737, Taxol® and siRNA treatment activate the unfolded protein 
response. (a) The Western blot from the ER isolation (same as fig 5.4) was re-blotted with 
an anti-P-IRE antibody. (b) HeLa cells were treated with either ctrl or Apc siRNA in 
conjunction with 7µM ABT-737 or 250nM Taxol®. A Western blot then identified total and 
phospho-IRE levels and phospho-histone H3 (PH3) to determine if the Taxol® had efficiently 
arrested the cells. The bottom panel shows the quantification of P-IRE relative to total IRE 
levels. (c) CaCo2 cells treated as in (b). The bottom panel shows the P-IRE quantification 
relative to total IRE levels. 
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it is impossible to tell whether Apc loss activated the UPR or if it was the siRNA treatment 
itself. Therefore, no conclusions can be drawn about the Apc siRNA treatment. 
 
5.7 Apc loss may activate the UPR via Hif-1α 
APC has previously been linked to hypoxia, another stress-induced pathway (see 5.5 and 
Newton et al., 2010). Specifically, APC and the hypoxia-inducible transcription factor Hif-1α 
have an antagonistic connection. Hypoxia represses Apc via a Hif-responsive element 
(HRE) in the Apc promoter. Conversely, Hif-1α depletion leads to an increase in Apc mRNA 
and protein (Newton et al., 2010). The hypoxia-induced decrease in APC is likely a survival 
mechanism that cancer cells can exploit to promote proliferation. Important for the 
experiments in this thesis, Hif-1α also induces the UPR to facilitate the survival of hypoxic 
tumours (Bi et al., 2005; Rouschop et al., 2009). 
 
Based on these links between APC and HIF-1α, it was important to establish whether 
activation of the UPR upon Apc loss was Hif-1α dependent. Therefore, P-IRE levels were 
measured by Western blot (fig 5.7) in U2OS cells knocked down for Apc, Hif-1α or both 
using siRNA. The effect of the proteasome inhibitor MG132 was also investigated to permit 
sufficient accumulation of the highly labile Hif-1α protein (in normoxia). Strikingly, the control 
siRNA again caused upregulation of phospho-IRE by 71%. This is more evidence that 
suggested the transfection process itself caused the cells to become stressed and activate 
the UPR. Therefore, any UPR effect seen in Apc and Hif-1α depleted cells may be due to 
the siRNA transfection procedure. Thus, no robust conclusions can be drawn from the 
experiment. Moreover, every cell treatment used to far has stressed the cells, resulting in 
UPR activation.  
 
5.8 ABT-737, Taxol® and Apc loss cause no obvious change to Bcl-2 localisation  
Experiments in this thesis revealed that Apc depletion leads to an increase in Bcl-2 (fig 5.1) 
and that ABT-737 caused an increase in membrane-associated Bcl-2 (fig 5.3). To 
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characterise these changes in more detail and identify the membrane compartment where 
the Bcl-2 protein accumulated, immunofluorescence (IF) was used. I specifically focused 
on mitochondria using MitoTracker® because: Bcl-2 binds the MOM; and ABT-737 
activates the intrinsic/mitochondrial apoptotic pathway by inhibiting the formation of Bcl-2-
Bax dimers. Therefore, any morphological changes of mitochondria in response to Apc 
depletion or ABT-737 treatment was investigated.  
 
None of the anti-Bcl-2 antibodies allowed detection of endogenous Bcl-2 by IF, so cells 
were transfected with pGFP-Bcl-2 and its distribution examined by IF. Mitochondria were 
revealed well and GFP-Bcl-2 also appeared to localise to the ER (fig 5.8a). To confirm that 
GFP-Bcl-2 was indeed localised to the ER, cells were co-stained with an antibody against 
the ER marker Calnexin. The distribution of GFP-Bcl-2 and Calnexin overlapped (fig 5.8b), 
which suggested that Bcl-2 was mostly associated with the ER/mitochondria associated 
membranes/mitochondria. A vehicle control produced no obvious change to its localisation 
or mitochondria (fig 5.8b bottom panels).  Treatment with Apc siRNA, Taxol® or ABT-737 
resulted in no obvious change in the intensity or localisation of GFP-Bcl-2 (data not shown). 
However, these treatments produced a change in mitochondria.  
 
5.9 ABT-737, Taxol® and Apc loss cause a change in mitochondria indicative of cellular 
stress 
From the IF experiments in fig 5.8 and fig 5.9, changes in mitochondrial location were 
observed. ABT-737, Taxol® and both control and Apc siRNA treatments caused a 
pronounced retraction of mitochondria from the cell periphery. Instead mitochondria were 
concentrated around nuclei (fig 5.8c) and this peri-nuclear clustering was often asymmetric. 
The changes in mitochondria in control siRNA treated cells (fig 5.8) together with previous 
data (fig 5.6) provide further evidence to the idea that the transfection procedure itself  
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causes cellular stress. It is therefore difficult to deduce anything about specific effects on 
the localisation of mitochondria in response to siAPC, as the phenotype may be a result of 
stress from the transfection procedure. However, all cellular treatments used caused 
activation of the UPR (stressors) and subsequently all change the distribution of 
mitochondria. The stress could result in a change in the distribution of mitochondria, so 
mitochondrial location could be a read out for ER stress. In fact, two known stressors, 
oxidative stress and hypoxia, have previously been reported to cause peri-nuclear  
Figure 5.7. Apc loss may activate the UPR via stress-activated Hif-1α. (a) U2OS cells 
were treated with 10µM MG132 and either ctrl, Apc and/or Hif-1α siRNA. A Western blot then 
shows APC, Hif-1α and P-IRE protein levels. (b) Quantification of P-IRE from (a) relative to 
total-IRE. 
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clustering (Hallmann et al., 2004; Swiger et al., 2008; Al-Mehdi et al., 2012). Hence, drug-
induced and transfection-induced stress affecting mitochondria is plausible.  
 
Further experiments focused on mitochondrial morphology as this can indicate their state. 
There are three main observable mitochondrial shapes. Normally, mitochondria appear as 
either individual organelles or extended filamentous structures, closely associated with the 
ER and they extend outwards from a perinuclear region (Johnson et al., 1980). 
Mitochondria can also appear globular, when swollen. Interestingly, ABT-737 treated and 
Apc depleted cells, showed a lack of filamentous mitochondria. Importantly, only Apc 
depleted cells had mitochondria resembling large, globular structures akin to swollen 
mitochondria. This suggests that something in Apc depleted cells is different from other 
stressors (control siRNA, Taxol® and ABT-737), resulting in mitochondrial swelling - which 
warranted further investigation. 
 
To further explore the effect of Apc loss on mitochondria, live imaging was performed on 
U2OS cells treated with MitoTracker®. Cells with and without Apc were compared (fig 5.9). 
As before, in untreated (ctrl) cells, filamentous mitochondria are clearly visible (fig 5.9a). 
Again Apc depleted cells contained swollen mitochondria, concentrated in a peri-nuclear 
region.  
 
Figure 5.8. ABT-737, Taxol® and Apc loss cause no obvious changes to Bcl-2 localisation 
by IF. (a) U2OS cells were transfected with pGFP-Bcl-2. 48 hours post-transfected the cells were 
incubated with MitoTracker® for 45 minutes before being fixed and counterstained with Hoechst. 
GFP-Bcl-2 and MitoTracker® were detected using fluorescence microscopy. The scale bar 
represents 37µm. (b) Untreated (ctrl) and vehicle treated U2OS cells were transfected and treated 
as in (a). The cells were fixed and stained with an anti-Calnexin antibody and then counterstained 
with Hoechst. The scale bar represents 9 (ctrl) and 37µm (veh). (c) Untreated (ctrl) U2OS cells, 
or cells treated with 7µM ABT-737 (24 hours), 250nM Taxol® (6 hours) or Apc siRNA (48 hours) 
were cultured with MitoTracker® as in (a). Cells were then fixed and counterstained with Hoechst 
and phalloidin. The scale bar represents 37µm except siCTRL, which is 34µm. 
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Swollen mitochondria as a result of Apc loss may be a direct consequence of the Bcl-2 
increase seen upon Apc knock-down (fig 5.1). Bcl-2 binds the mitochondrial outer 
membrane (MOM), where it has been shown to have in vitro channel activity (Schendel et 
al., 1997). Bcl-2 may act specifically as a weak K+ ion channel (Schlesinger et al., 1997). 
Based on these findings, an increase in Bcl-2 could lead to an increase in mitochondrial ion 
channels on the MOM causing an influx of ions and water. This causes swelling of the inner 
mitochondrial matrix and distention of the inner and outer mitochondrial membranes. The 
result would be the swollen mitochondria seen by IF upon Apc knock-down. However, this 
theory is unlikely as ABT-737 treated cells also have increased Bcl-2 but show no swollen 
mitochondria. Alternatively, the swollen mitochondria may be unrelated to Bcl-2 levels and 
caused by some other consequence of Apc loss.  
 
To summarise the mitochondrial data so far, all cell treatments (control and Apc siRNA. 
Taxol® and ABT-737) caused peri-nuclear clustering of mitochondria, which was often 
asymmetric. Additionally, all cell treatments were stressors on the cell resulting in UPR 
activation. Therefore, mitochondrial translocation may be a read out for cellular stress. 
However, only Apc siRNA caused a morphological change from filamentous to swollen 
mitochondria, 
 
5.10 ABT-737, Taxol® and Apc loss do not affect mitochondrial functionality 
Next, to establish if mitochondria in ABT-737 treated cells (retracted to a perinuclear region) 
were still functional, the cationic dye JC-1 was used. The monomeric form is taken up by 
all mitochondria, but it aggregates only in mitochondria with an active membrane potential 
(Δψm). Therefore, mitochondria with depolarised membranes (i.e. compromised function) 
show fewer aggregates. As JC-1 cannot be visualised in fixed cells, cells were treated 
plus/or minus ABT-737 and live cell microscopy performed. As before (figs 5.8 and 5.9a) 
ABT-737 treatment resulted in mitochondria accumulating in a peri-nuclear region, usually  
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Figure 5.9. ABT-737, Taxol® and Apc loss cause a change in mitochondria indicative of 
cellular stress. (a) U2OS cells were treated with either control or Apc siRNAs for 48 hours, 
250nM Taxol® for 6 hours, 7µM ABT-737 for 24 hours or untreated. Cells were then incubated 
with MitoTracker® for 45 minutes before live imaging was performed to identify mitochondria. The 
white box in the left hand panel represents the area magnified in the right hand panel. The scale 
bar represents 27µm, except siAPC whose scale bar represents 22µm. (b) U2OS cells were 
treated plus/or minus 7µM ABT-737 for 24 hours and then incubated with JC-1. JC-1 monomers 
are shown in the green channel and aggregates in the red channel. The scale bar represents 
27µm. (c) Schematic representing the spread of mitochondria in untreated U2OS cells. (d) 
Schematic representing the altered distribution of mitochondria in ABT-737 treated U2OS cells. 
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asymmetric. This is shown schematically in fig 5.9c-d. Surprisingly, the JC-1 was still 
aggregating in mitochondria of ABT-737 treated cells. This suggested that they maintained 
a ‘normal’ membrane potential and were functioning normally. This suggested that ABT-
737 induced a change in the localisation of mitochondria, but not the functionality; 
mitochondria still had active membrane potentials. ABT-737 also affected mitochondrial 
morphology as there are far fewer filamentous mitochondria after treatment. Due to the non-
uniform uptake of JC-1, quantitative data could not be produced. This lead to the use of 
other experimental techniques to achieve quantitative results.  
 
5.11 Apc loss and ABT-737 treatment have opposing effects on mitochondria 
The IF data suggested a change in mitochondrial morphology from filamentous to globular 
structures in Apc depleted cells. It also showed less filamentous mitochondria in ABT-737 
treated cells. To establish whether these structural changes reflected mitochondrial fusion 
or lack of fission, Imaris (Bitplane) was used to measure the number of mitochondria 
present in cells. Cell size was also measured to establish whether it was affected by either 
treatment, to compare the number of mitochondria per cell. There was a positive correlation 
between cell size and mitochondrial number (fig 5.10a) as previously observed in budding 
yeast (Rafelski et al., 2012). Cells treated with either ABT-737 or Apc siRNA were smaller 
and had fewer mitochondria. The same was true for cells transfected with pGFP-Bcl-2 
(supplementary figure 11). These transfected cells were smaller in area (µm2) and had 
fewer mitochondria, in comparison to untreated cells. Therefore, all three treatments 
caused a decrease in cell size and a corresponding (proportional) reduction in 
mitochondria. This could be another function of stress in the cell; to reduce cell size.  
 
Calculating the ratio of mitochondria per unit space revealed that the number of 
mitochondria per µm2 was similar in all cases (fig 5.10b).  This is consistent with the idea 
that the concentration of mitochondria in cells is relatively constant but does not reveal any 
effect of APC or ABT-737 on this parameter. A reduction in mitochondria is often due to 
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mitophagy, the destruction of mitochondria by autophagy (Kim, Rodriguez-Enriquez and 
Lemasters, 2007). This usually happens when mitochondria are defective, damaged or 
stressed (Gilkerson et al., 2012). An increase in mitochondrial number can de due to 
increased mtDNA production in response to oxidative stress, but this is poorly understood 
(Lee et al., 2000). Therefore, the lack of a change in mitochondrial number indicates that 
the mitochondria themselves are not stressed or defective when treated with Apc siRNA, 
ABT-737 or pGFP-Bcl-2. Thus, although the position of mitochondria in the cell moved away 
from the cell periphery, the number remains largely unchanged. Together with the JC-1 
staining (fig 5.9) this suggests, that mitochondria are not stressed and functioned normally. 
 
To measure more subtle changes in mitochondrial function in Apc depleted, ABT-737 and 
Taxol® treated cells, flow activated cell sorting (FACS) was used. CMXRos was used to 
measure changes in mitochondrial membrane potential (MMP), which relates to the MMP-
independent dye MitoTracker® Green (to measure differences in the number of 
mitochondria). In cells lacking Apc, the mitochondria:MMP ratio shifted to the right (fig 
5.10c). This suggested that mitochondria have a decreased MMP. This was in opposition 
to what was expected based on biochemical data showing that siAPC cells have more Bcl-
2 - which maintains MMP (fig 5.1). Conversely, the mitochondria:MMP ratio decreased in 
ABT-737 treated cells and suggested a slight increase in MMP. This indicates that the 
mitochondria were ‘healthier’ than siAPC cells. However, these changes are minor and only 
trends can be reported at this time. 
 
To summarise the data, control siRNA, Taxol®, ABT-737 and Apc depletion all caused 
activation of the UPR, as measured by P-IRE (fig 5.6). Equally, all cell treatments caused 
a translocation of mitochondria to a peri-nuclear region, which did not affect mitochondrial 
function (figs 5.8 and 5.9). Together, this data suggested that stressed cells cluster their 
mitochondria around the nucleus. However, only Apc loss had a measurable effect on 
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mitochondria, causing mitochondrial swelling (fig 5.8 and 5.9) and decreased mitochondrial 
function (fig 5.10c).  
 
5.12 Combining Taxol® and ABT-737 treatment kills ApcMin/Min organoids more efficiently  
Next, I wanted to confirm previous data from 2D cell culture in intestinal organoids (a 3D 
system representative of Apc depleted CRC cells). Comparing the response of these 
organoids to Taxol® and ABT-737 treatment could show whether lack of full length APC 
rendered three dimensional epithelial structures (resembling intestinal) tissue, more 
sensitive to these agents. 
 
Intestinal organoids with wild-type Apc (Apc+/+, APC WT) or mutant Apc (ApcMin/Min cysts) 
mimicking Apc loss (see table 8) were used. Firstly, the viability of organoids was measured 
24 hours after treatment with increasing concentrations of Taxol® (fig 5.11a). Apc deficient 
cells do not arrest efficiently in response to Taxol® (Dikovskaya et al., 2007; Radulescu et 
al., 2010). Therefore, I expected cells in Apc WT organoids to arrest in mitosis and 
eventually apoptose. Whereas, I expected cells in the ApcMin/Min cysts not to arrest and to 
die less readily, similar to Apc deficient cells.  Indeed, Apc mutant cysts were largely 
unaffected by Taxol®, even at doses up to 1µM. Whereas, the viability of Apc WT organoids 
decreased to 63% upon treatment with 500nM Taxol®. Previous data in the lab had already 
shown that ABT-737 reduced the viability of Apc WT organoids at a dose of 1µM, but 10µM 
ABT-737 was required to affect ApcMin/Min cysts (data not shown). Therefore, the Apc–
deficient cysts required higher doses of ABT-737 to reduce viability, but were largely 
unaffected by high doses of Taxol®. Previous data in the lab also suggested that treating 
Apc depleted cultured cells with ABT-737 increased their sensitivity to Taxol®. Therefore, 
it was important to test whether the same is true for organoids, which represent a more 
physiological situation than cultured cells.  I also aimed to investigate the effects of these 
compounds on the morphology of these 3D structures. 
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Organoids were cultured in Taxol®, ABT-737 or both (ABTTAX) for 48 hours and images 
recorded every 30 minutes. As expected, Taxol® arrested cells in organoids with WT Apc, 
but not those with ApcMin. This arrest was established visually by a halt in organoid growth 
and the rounding-up of cells. ABT-737 had no visible effect on the growth of WT organoids, 
although it appeared to retard the growth of ApcMin cysts. Combining both drugs (ABTTAX) 
killed cysts, indicated by the appearance of many dead cells within one-two hours, no 
further growth, and partial shrinking of the organoid. The effect of ABTTAX on Apc WT 
organoids was less severe. The organoids appeared to be arrested as indicated by a halt 
in growth, with partial cell death. These observations suggest that although there was no 
visible effect of ABT-737 alone, it rendered ApcMin/Min cells more sensitive to Taxol®, just as 
it did in 2D cell culture models (data not shown). Note that in fig 5.11b the 0h time point 
should read 45mins – the time taken to treat all organoids and set up plate on the 
microscope. This accounts for the cell death at the first timepoint in ABTTAX treated 
organoids.            
 
Based on UPR data (fig 5.6), I hypothesised that ApcMin/Min intestinal organoids have 
increased P-IRE, similar to Apc mutant CaCo2 cells due to UPR activation. This could make 
ApcMin/Min organoids more sensitive to the combination of Taxol® and ABT-737, similar to 
Apc mutant CRC cells (fig 5.6 and unpublished data). Unfortunately, due to time constraints 
P-IRE in the organoids was not measured. 
Figure 5.10. Apc loss and ABT-737 treatment have opposing effects on mitochondria. (a) 
U2OS cells were treated with 7µM ABT-737 for 24 hours, Apc siRNA for 48 hours, or untreated 
(ctrl). The cells were then cultured with MitoTracker® for 45 minutes. Mitochondria were 
visualised using fluorescent microscopy. Images were then imported into the microscopy 
software Imaris. Using fluorescence detection the number of MitoTracker®-positive spots was 
counted and the area of the cells were measured. 5 cells were analysed per treatment. There is 
a positive correlation between cell size and mitochondrial number. (b) The number of 
mitochondria were divided by the area of the cell to give a ratio of MitoTracker® positive spots: 
area. The bar graph shows that there is no difference in number of mitochondria per area 
between treatments. Error bars represent the standard error, n=5 cells. (c) U2OS cells were 
treated as indicated, incubated with MitoTracker® Green and CMXRos, prepared for FACS and 
counterstained with DAPI. Apc–depleted cells have a higher ratio of mitochondria: MMP 
meaning that there are less mitochondria with active MMPs. (d) U2OS cells treated as in (c). 
Apc–depleted cells are smaller in size based on FSC.  
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Figure 5.11. ABT-737 and Taxol® affect Apc WT and ApcMin intestinal organoids differently. 
(a) Viability of Apc WT organoids and cysts (ApcMin/Min) after treatments with varying doses of 
Taxol® for 24 hours. N=3, experiments representative of biological replicates, error bars represent
the standard error. (b) Apc WT organoids and Apc mutant cysts were treated with 250nM Taxol®, 
7µM ABT-737 or both (ABTTAX) as indicated. Organoids were cultured for 48 hours. Images 
taken from 48 hour videos are shown before filming commenced, immediately after drug addition 
(0h) and after 48 hours. 
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5.13 Conclusions 
In summary, Apc deficient cells are not as readily killed by Taxol® as Apc WT cells, likely 
because their cell cycle arrest checkpoint is compromised (Dikovskaya et al., 2007). In 
addition, they may be protected from death by an increase in Bcl-2. This protection can be 
overcome by combined treatment with the Bcl-2 inhibitor ABT-737. A possible mechanism 
is the activation of the unfolded protein response by control and Apc siRNA, Taxol® and 
ABT-737. This stress is reflected by a change in mitochondrial distribution. However, only 
Apc deficient cells had swollen mitochondria. Based on these findings, in ApcMin/Min cysts 
the UPR is expected to be activated, the mitochondria distributed closer to the nucleus, with 
a swollen appearance.  In addition, cells in ApcMin/Min cysts are expected to contain higher 
amounts of Bcl-2 than those in wild type organoids.  These changes could explain the 
increased sensitivity of cysts to the combination of Taxol® and ABT-737. These results 
warrant further examination to find mechanisms behind mitochondrial changes as well as a 
link to the UPR. Moreover, further work would determine if this combined therapy of ABT-
737 and Taxol® is clinically useful in treating CRC. 
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Chapter 6 - Discussion  
 
6.1 Off-target effects associated with the AID system 
The AID system was able to partially degrade APC in 1 hour using 500µM auxin. However, 
when attempting to increase the effectiveness of the system (i.e. obtaining a greater/total 
APC depletion) off-target effects were observed in the control cell population DT40TIR. The 
control DT40TIR cells contain only the F-box protein TIR and do not have a degron motif. 
This suggests that the AID system has off-target effects in these cells.  There are a number 
of possible explanations for these observations.  
 
Ubiquitin-mediated protein degradation is irreversible and consequently is used in cellular 
processes that must proceed uni-directionally, such as the cell cycle and circadian rhythm. 
In fact, more than 80% of proteins are degraded by ubiquitin–mediated, 26S proteasomal 
degradation (Yen et al., 2008) making substrate specificity crucial. The purpose of F-box 
proteins is to provide substrate specificity to E3 ligases by recognising short degradation 
motifs in substrates, termed degrons. SCF complexes are assembled by Cullin scaffold 
proteins. The Cullin carboxy terminus binds to the RING protein RBX1 that recruits the E2 
ligase (fig 6.1). The amino terminal of the Cullin binds Skp1 and an F-box protein (see a 
detailed review by Skaar, Pagan and Pagano, 2013).  
 
It is possible that in the AID system, the TIR protein from Oryza sativa (OsTIR1) may 
recognise a sequence in APC that acts as a degron and thus targets APC to the SCFTIR, in 
the presence of auxin. Such a putative sequence would likely be hydrophobic, as the TIR 
binds IAA17 through hydrophobic interactions (Tan et al., 2007). There are 69 known F-box 
proteins in humans. Most of these can recognise multiple substrates, usually through 
canonical phosphodegrons. 
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For example, the F-box protein β-TrCP (encoded by both FBXW1 and FBWX11) recognises 
the phosphorylated consensus motif DSGXXS (Hart et al., 1999), with both Serine residues 
phosphorylated (i.e. a phosphodegron). However there are several post-translational 
modifications F-box proteins use to detect a degron, other than phosphorylation: 
glycosylation (Yoshida et al., 2002) and methylation (Lee at al., 2012). Even some 
unmodified degron motifs can act as substrates (D’Angiodella et al., 2010).  
 
These alternative degron motifs could explain why APC is degraded in cells containing 
SCFTIR E3 ubiquitin ligase complexes even when it does not have a degron (IAA17) motif. 
Fig 6.1. SCF complexes with and without the requirement of a cofactor. (a) Typical F-box-
substrate recognition by a canonical degron that has been post-translationally modified, i.e. a 
phosphodegron. The scaffold protein Cullin1 (CUL1) binds RBX1 at its carboxy terminus, which 
in turn binds an E2 ubiquitin ligase. The amino terminal of CUL1 binds to the adapter protein 
SKP1, linking the Cullin to the F-box protein. SKP1 binds the F-box protein, which also binds 
to a substrate that is specific to that F-box protein, typically by recognizing a phosphodegron 
motif within the substrate. The E2 ligase then polyubiquitinates the substrate, targeting it for 
proteasomal degradation. (b) Inducible degron recognition by an F-box protein. CUL1 binds 
the same set of proteins as in (a). The F-box protein, in this case TIR, can only bind the 
substrate in the presence of auxin. Auxin binds to both the TIR F-box protein and the 
substrates’ degron motif, bringing the substrate into the SCFTIR complex in order to be 
polyubiquitinated. 
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However, I could not find any canonical phosphodegron motifs in the Gallus gallus APC 
protein sequence.  Nonetheless, an exact match to a consensus degron motif is not always 
necessary for substrate recognition by an F-box protein (Nash et al., 2001). In summary, 
although only one degron motif (IAA17) has been identified thus far, it is possible that the 
TIR protein can recognise multiple degron motifs and that APC contains one of these, as 
yet unrecognised, motifs.  
 
The LRR (leucine-rich-repeat) domain of the TIR protein is responsible for auxin binding 
(Tan et al., 2007). It provides a structural framework for protein-protein interactions (Kobe 
and Kajave, 2001). APC contains many phosphorylation sites as well as sites for acetylation 
and methylation (fig 6.2). It is possible that certain post-translational modifications of APC 
act as non-canonical degron motifs and are recognised by auxin, bound to the TIR-LRR. 
This could lead to the degradation of APC in DT40TIR cells (treated with auxin). A 
bioinformatics approach could identify potential non-canonical degrons in APC. This would 
involve comparing the APC protein sequence (plus/minus post-translational modifications) 
against all known degron motifs and post-translational modifications. However, there are 
other possible explanations for the degradation of APC in DT40TIR cells in the presence of 
auxin, discussed below.
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Fig 6.2. Sites of APC post-translational modification. Image taken from a search in 
www.phosphositeplus.org and modified. The scale represents amino acids 1-2843 of APC. 
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The AID system utilises an inducible degron mechanism and relies on the phytohormone 
auxin to stabilise a link between the TIR F-box protein and IAA17 (Tan et al., 2007). TIR 
and IAA17 have low binding affinity in the absence of auxin, but nonetheless a low level of 
interaction can occur without auxin (Tan et al., 2007). This may explain a very slight 
reduction in APC in control cells treated with auxin. However, the AID system may also 
require a co-factor other than auxin to function fully; the TIR protein incorporates the small 
molecule inositol hexakisphosphate (InsP6, also known as phytate). Phytate acts as a 
structural cofactor supporting a key arginine residue (arg403) in the TIR, maintaining the 
integrity of the auxin-binding pocket (Tan et al., 2007). DT40 cells possess phytate and are 
in fact used as a model system for studying inositol trisphostate receptor (IP3R) signalling 
(Vazquez et al., 2002). Perhaps, DT40 cells possess a high level of phytate or a different 
structural isoform, which can enhance the SCFTIR-mediated degradation of proteins such 
as APC, in the absence of a degron (fig 6.3a-b). Additionally, Phytate has already been 
identified as an allosteric regulator of the Vibrio cholerae RTX toxin in eukaryotic cells 
(Lupardus et al., 2008). Therefore, it is possible that phytate acts as an allosteric regulator 
of other proteins, such as TIR. This would explain my data - the degradation of a substrate 
lacking a degron motif (fig 6.3c). Alternatively, phytate is highly charged and a high 
concentration of phytate may change the charge of the TIR binding pocket. This could bring 
it into closer proximity with certain residues within APC, enabling APC to be targeted for 
degradation by the SCFTIR - in the presence of auxin and without a degron motif. Structural 
modelling of the TIR binding pocket plus/minus phytate and plus/minus auxin could reveal 
such a possible conformational change/change in the charge of the binding pocket. This 
could show if the SCFTIR can degrade APC in the absence of an IAA17 degron motif. 
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6.2 Modifying 5’ regions of Apc affects APC protein expression 
After transfecting DT40TIR with both, pGFP-IAA17-APC or pIAA17-APC (for maps see 
supplementary figure 1), all resulting targeted clones (except clone 12E) produced 50-100% 
less APC than either WT DT40 or DT40TIR cells (figs 3.4 and 3.6). Thus, the degron-Apc 
allele was hypomorphic. There are a number of reasons for these effects that are discussed 
below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.3. TIR-substrate binding with auxin and co-factor InsP6. Alternative binding theories. 
(a) The TIR binding pocket (shown in grey) binds to IAA (auxin), which acts as a glue, binding 
to the degron motif found within the target substrate, in this case APC.  (b) Knowing that the 
molecule InsP6 (shown in red) binds to the auxin binding pocket within the TIR protein to maintain 
its structure, and knowing that in DT40TIR cells there is APC (substrate) degradation in the 
absence of a degron motif, it is possible that the cofactor InsP6 is able to link the substrate with 
the F-box protein TIR, without a degron. (c) InsP6 binding may cause a conformational change 
in the TIR protein binding pocket. This creates a much wider binding pocket and provides entry 
for the substrate, which when bound to the InsP6 molecule is joined to the TIR and so can be 
phosphorylated. Image modified from Tan et al., (2007). 
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The intron/exon structure of the regulatory region of Apc (upstream from exon 1) is complex. 
Published works aiming to elucidate the functional significance of this structure is limited. 
Apc contains three alternative promoters, PN, P1A and P1B (fig 6.4a). P1B has not been 
extensively studied. PN drives a unique Apc transcript found in totipotent ES cells and 
mouse colon tissue, detected by 5’ RACE (Karagianni et al., 2005). P1A is the major 
promoter of multiple Apc transcripts and is present in most tissues (Rohlin et al, 2011). 
There are also three non-coding exons (fig 6.4) upstream of canonical exon 1 (as well as 
three alternative exon ones). Exon 1 contains a transcriptional start site (TSS) and Kozak 
sequence as do two of the three non-translated exons (0.3 and 0.1). This means that when 
alternative splicing creates transcripts lacking exon 1, the TSS and Kozak sequences are 
retained in the transcript (Santoro et al., 1997). 5’ Apc transcripts created by alternative 
splicing can generate up to six different mRNAs, based on the first few exons alone 
(Thliveris et al., 1994) (fig 6.4b).  
 
Taken together, the complex nature of the regulatory regions and start sites of Apc mean 
that genetic manipulation in this area is challenging. The GFP-degron and degron (alone) 
cDNA sequences were targeted immediately 5’ of canonical exon 1. The multiple 
combinations of untranslated exons with both exons 1 and 2, make it likely that the presence 
of either GFP-degron or degron cDNA affected the alternative splicing of exons 0.3, 0.1 and 
0.2. This may have produced less stable transcripts (resulting in less APC protein). 
Alternatively, transcripts may have lacked regulatory elements of untranslated exons that 
are involved in the transcription or translation of Apc. 5’RACE followed by DNA sequencing 
in targeted clones would determine which alternative exons are retained in the transcript. It 
would also help to identify the splicing of the mature mRNA and whether key regulatory 
regions of 5’Apc remain in the mRNA. 
 
In summary, the degradation of APC in DT40TIR cells incubated with auxin could result from 
several different mechanisms (fig 6.2-6.5). APC may contain a previously unidentified F-
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box target sequence. The structure of the TIR-auxin complex may be altered due to post-
translational modification of the TIR or the presence of altered/increased concentration of 
the co-factor phytate. Alternatively, post-translational modifications of the APC amino 
terminal may be recognised by auxin to promote recognition of APC by the SCFTIR. 
Perhaps, several of these scenarios operate simultaneously resulting in APC degradation 
in DT40TIR cells. 
 
6.3 Potential effects of low APC levels on DNA damage repair 
In creating the degron-APC cell line (DT40TIR; IAA17-APC), clones with lowered APC expression 
were unintentionally created. These clones, specifically V5 (APCminimal) and X4A (APClow) 
were treated with three DNA damaging agents and subsequent cell viability was measured 
using the MTS viability assay (fig 4.4). Possible explanations for these results will now be 
discussed. However, given the relatively small difference in DNA damage response in the 
APC–lowered cells, this discussion is mostly speculation. More work is needed to determine 
whether there is a true and significant link between APC and DNA damage response.  
 
Both clones with lowered APC recovered better from the cross-linking agent Cisplatin. 
Cisplatin (cis-diammine-dichloro-platinumII/DDP) causes DNA adducts of both inter- and 
intrastrand crosslinks. It is a neutral complex that reacts with water molecules in vivo to 
form a reactive aquated complex that can interact with DNA (see a review by Siddik, 2003). 
Upon cisplatin-induced DNA damage, the damage sensor and kinase ATR is activated 
(Damia et al., 2001). ATR phosphorylates p53 (Tibbetts et al., 1999), resulting in its 
activation to transduce a program of DNA damage response. An increase in DNA damage 
repair is associated with inhibition of drug-induced cytotoxicity. The repair of DNA crosslinks 
caused by Cisplatin requires Topoisomerase II (Topo II), which is reported to be 
overexpressed in certain cancers. Consequently, this causes platinum drug resistance (Ali- 
Osman et al., 1993; Hengstler et al., 1999). Therefore, it is reasonable to assume that DT40 
cells (B-cell lymphoma cells) with low levels of APC overexpress Topoisomerase II to more 
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efficiently repair Cisplatin-induced damage. This theory would require an interaction 
between APC and Topoisomerase II, such as APC helping to degrade Topo II under normal 
conditions. This means that when APC levels are low/depleted, there is an increase in Topo 
II.  In fact, Topo IIα can bind to the 15R and 20R repeats in the middle of APC (M-APC). 
Therefore, a link between APC and DNA damage response through topoisomerase II is 
possible (Wang et al., 2008; Wang et al., 2010). This theory would explain why APClow and 
APCminimal cells recover quicker from Cisplatin than APChigh DT40TIR cells. Furthermore, loss 
of Apc causes an upregulation of p53 (Méniel et al., 2015). In the APClow and APCminimal 
cells, a predicted elevation in p53 levels could explain the increased survival of these cells 
compared to APC WT cells (with lower p53) exposed to Cisplatin – more p53 enables the 
faster/more efficient signalling in response to the presence of DNA adducts.  
 
Apc has previously been linked to base excision repair, a mechanism used to repair abasic 
sites in DNA. A PCNA-like box was found in APC (Narayan et al., 2005) that can bind DNA 
polymerase β. This prevents the polymerase from carrying out long-patch base excision 
repair (BER). Specifically, APC bound DNA polymerase β prevents polymerase β-directed 
strand displacement. Therefore, APC-bound polymerase β dictates the DNA repair pathway 
a cell can use, i.e. short nucleotide BER over long-patch BER (Narayan et al., 2005; Balusu 
et al., 2007). The main repair pathway for DNA adduct removal (such as those caused by 
Cisplatin) is a BER-related mechanism called nucleotide excision repair (NER). 
Upregulation of only several of the 17 proteins required for NER results in an increased 
excision repair capacity in platinum-resistant cells (see a review by Reed, 1998). Again 
using the idea that APC could form complexes that regulated destruction of proteins other 
than -catenin, APC may act to degrade one, or several of the NER proteins. Consequently 
upon APC loss, these NER
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Fig 6.4. Schematic representation of 5’ Apc 
gene structure. (a) The top panel represents the 
exon structure of Apc found on chromosome 
5q21-22. The black boxes represent canonical 
exons and the white boxes indicate alternative 
exons. The arrow represents the direction of 
transcription. The bottom panel shows a zoomed 
in representation of 5’Apc including its regulatory 
region, covering the area in the red box from the 
top panel. Alternative promoters are shown in 
grey, alternative exons are shown in white and 
canonical translated exons are black boxes. 
Exons 0.3, 0.1 and 0.3 are untranslated exons 
(identified by the asterisk). 0.3 and 0.1 contain 
transcriptional start sites and kozak sequences. 
(b) Alternative splicing of 5’Apc including exons 
upstream of canonical exon 1 to include a 
transcriptional start site and kozak sequence. 
There are 7 known splice variants (i-vii). Image 
adapted from Thliveris et al., (1994). 
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proteins are no longer degraded. APClow and APCminimal cells would then contain more NER 
proteins than APC WT cells such as DT40TIR. This would lead to more efficient NER in 
response to Cisplatin treatment, and increased viability in the MTS assay as seen in fig 4.4.  
To test this idea, using RNAi, Apc knock-down experiments could be performed on Apc+/+ 
CRC cells such as HCT116. Subsequent Western blots would identify if certain NER 
proteins are increased in Apc depleted cells. Then, Co-IP experiments on any ‘hits’ from 
the Western blots would determine if APC and the NER proteins interacted directly. 
Proteasomal inhibitors such as MG132 would demonstrate whether any of the NER proteins 
investigated were in fact proteasomally regulated; as is expected for alternative APC 
destruction complexes. An alternative approach would be to over-express Apc and 
determine if NER proteins were depleted. However, this would be difficult in practice 
because over-expressing Apc leads to apoptosis-induced cell death in human CRC cells 
(Morin, Vogelstein and Kinzler, 1996). Apc overexpression also prevents cell cycle 
progression from G0/G1-S phase (Baeg et al., 1995), which can lead to cell death. 
Additionally, over-expressing the C-terminal two thirds of Apc in Xenopus by only four fold 
compromises the mitotic spindle (Dikovskaya et al., 2007). Therefore, Apc overexpression 
experiments may not provide useful experimental data. 
 
However, It is important to consider that cells with reduced APC may not repair Cisplatin-
induced DNA adducts better than cells with WT APC. In fact, these cells may simply not 
respond to this DNA damage because they do not recognize the damage, or simply fail to 
respond to it. In this case, these cells would not arrest in order to repair the DNA damage. 
Instead, they would continue through the cell cycle and as a result would exhibit 
chromosome instability and/ or genomic instability due to unrepaired DNA damage. This 
scenario provides another potential explanation for the increased survival of APC depleted 
cells in response to Cisplatin. To test this idea, the amount of the DNA damage sensors 
ATR and ATM and their phosphorylation should be measured in Apc depleted cells to 
determine if these proteins are activated in response to Cisplatin. If Apc depleted cells either 
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cannot sense DNA damage, or relay the damage signal through ATM/ATR, then the cells 
would not arrest in order to repair the damage. 
 
Conversely, cells with reduced APC (APClow and APCminimal) recovered less well from HU-
induced DNA damage than DT40TIR cells with WT APC (APChigh). There are currently no 
documented links between Apc and either replication forks or hydroxyurea. However, HU 
has a more potent effect in APClow and APCminimal cells (fig 4.4), suggesting that they are 
less able to repair paused replication forks. Hydroxyurea (HU) stalls replication forks by 
depleting the nucleotide pool through ribonucleotide reductase inhibition (Elford, 1968). The 
mechanisms involved in rescuing these stalled forks are not clear. Sirbu et al., (2013) found 
139 proteins enriched at stalled replication forks in comparison to collapsed and active 
forks, using iPOND-mass-spectrometry. One group of proteins enriched at the site of the 
stalled forks are polymerases, required to synthesise DNA. APC has previously been 
shown to reside in the nucleus (Neufeld and White, 1997; Henderson, 2000; Sena et al., 
2006). Existing data in our lab (unpublished data) and data in the literature suggests that 
APC can bind to polymerases, specifically: polymerase β/beta (Narayan, Jaiswal and 
Balusu, 2005), which is required for BER (Bennett et al., 1997); and polymerase σ/sigma 
(unpublished data), which is involved in mis-match repair (MMR) (Longely, Pierce and 
Modrich, 1997). Sirbu et al., (2013) found Polymerase-δ/delta enriched at stalled replication 
forks. Together this suggests that loss of APC could cause a reduction in this polymerase, 
so that the replication fork cannot restart after damage/stalling. However at this time, these 
ideas are speculative. They imply that APC either: acts in a protective/stabilising role over 
polymerase δ under normal cellular conditions; or APC somehow modifies the function of 
the polymerase so it is unable to synthesize DNA at stalled replication forks. To determine 
if Apc depleted cells cannot restart stalled replication forks through a lack of certain 
polymerases, RNAi experiments followed by Western blots would determine if polymerase 
levels decreased after Apc knock-down. Additionally, immunoprecipitating APC and 
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determining if polymerases were bound to APC would show whether APC binds 
polymerases (Sirbu et al., 2013). 
 
To summarise the effect of APC on DDR, differences in the viability in response to DNA 
damaging agents were small and only slightly different than in control cells. It is possible 
that APClow and APCminimal cells recovered better from Cisplatin due to higher levels of p53 
and/or Topoisomerase II, enabling a faster/more efficient DNA repair. Alternatively, a more 
efficient nucleotide excision repair mechanism may be in effect in cells with reduced APC. 
Moreover, it is important to consider that cells with less APC may in fact not repair Cisplatin-
induced DNA adducts at all, instead continuing through the cell cycle. On the other hand, 
APClow and APCminimal cells recovered less well from Hydroxyurea than cells with WT APC 
levels. Recovery from HU-induced DNA damage requires the restarting of stalled replication 
forks. APC-reduced cells may lack or have reduced activity in some of the proteins required 
for the restart, such as a polymerase(s). Overall, much more work is needed to identify a 
more robust link between APC and DNA damage repair.  
 
6.4 Apc depleted cells are more sensitive to the combination of Taxol® and a Bcl-2 
inhibitor 
Apc deficient cells such as those found in CRC cannot be killed efficiently by Taxol® 
(Radulescu et al., 2010). They do not undergo apoptosis normally induced by a prolonged 
mitotic arrest. This is partly due to a compromised SAC in APC deficient cells leading to 
reduced mitotic arrest (Dikovskaya et al., 2007; Radulescu et al., 2010). Sensitising Apc 
depleted cells to Taxol® would allow these CRC cells to be killed and potentially alleviate 
the cancer. 
 
6.4.1 Apc deficient cells and ABT-737 treated cells have increased Bcl-2 
Experiments in this thesis identified another explanation as to why Apc deficient cells do 
not die in response to Taxol®. Human epithelial cancer cells depleted of Apc and CRC cells 
 157 
 
with mutant Apc (N-Apc) all showed an increase in the pro-life protein Bcl-2 (fig 5.1). Bcl-2 
-protects cells from apoptosis by several mechanisms. It binds the mitochondrial outer 
membrane (MOM) (Krajewski et al., 1993; Nguyen et al., 1993; de Jong et al., 1994) where 
it maintains membrane integrity, maintaining the mitochondrial membrane potential Δψm 
(Vander Heiden et al., 2000). Bcl-2 also binds to pro-apoptotic proteins, such as Bax, 
neutralising the apoptotic BH3 domain (Otlvai et al., 1993; Yin et al., 1994; Zha et al., 1996; 
Petros et al., 2001). An increase in Bcl-2 is expected to increase these functions. 
 
We were unable to establish a direct interaction between APC and Bcl-2. Ongoing mass-
spectrometry experiments in the lab also did not find an interaction between these two 
proteins. However, it is possible that the increased Bcl-2 in cells lacking Apc, is an indirect 
effect of Apc loss and is facilitated by intermediary protein(s). A role of Par-4 protein was 
ruled out as a means of increasing Bcl-2 after Apc depletion. More work is required to 
identify if protein(s) act as regulatory links between APC and Bcl-2.  
 
The question remains, what the function of increased Bcl-2 is? Bcl-2 maintains 
mitochondrial outer membrane integrity, maintaining the mitochondrial membrane potential 
(MMP). An increase in Bcl-2 is thus expected to either further protect the MMP or increase 
it. However, FACS data (fig. 5.10), showed that cells depleted of Apc (and thus expressing 
increased Bcl-2) showed a slight decrease in the membrane potential of mitochondria as 
shown by an increase in the mitochondria:MMP ratio. This MMP change is very small and 
likely not significant. Thus although the result is opposite to what is expected (based on an 
increase in Bcl-2) it is likely not a reflection on the function of increased Bcl-2. Further 
repetition of this FACS experiment, is needed to confirm this result as robust. 
 
Bcl-2 overexpression prevents the release of cytochrome c by maintaining the integrity of 
the mitochondrial membrane (Yang et al., 1997). When cytochrome c is released, it triggers 
formation of the apoptosome (fig 1.4) (Kluck et al., 1997; Yang et al., 1997). Cells with 
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increased Bcl-2 are expected to have even less cytochrome c within the cytosol than wild 
type cells (Yang et al., 1997). Moreover, a reduction in cytochrome c release may provide 
a mechanistic explanation as to why Apc deficient cells are not killed as readily by Taxol® 
– cytochrome c cannot be released due to increased Bcl-2 and a stronger mitochondrial 
membrane integrity. Therefore, apoptosis cannot be executed. Cytosolic cytochrome c 
detection by Western blot, IF or FACS in cells depleted of Apc and treated with Taxol® 
would show whether these cells have less cytochrome c in their cytoplasms. This could be 
a functional read out for increased Bcl-2 in Apc depleted cells. 
 
The observation that Apc loss leads to increased Bcl-2 ties in with a recent paper stating 
that Apc loss primes cells for apoptosis and that Bcl-2 is required for intestinal 
tumorigenesis (van der Heijden et al., 2016). Interestingly, they state that Bcl-2 increases 
at the mRNA and protein level, allowing transformation in cells with Apc loss. Inhibiting Bcl-
2 in these Apc depleted cells (even by just heterozygous mutation) impaired adenoma 
formation and tumorigenesis, even in established adenomas.  
 
In addition to Apc depletion, ABT-737 treatment also caused an increase in Bcl-2 (fig 5.3 
and S8). Fractionation experiments showed that this increase occurred in the membrane 
fraction. However, there was no Bcl-2 increase at the mitochondria or ER of U2OS cells 
treated with ABT-737 (fig 5.4). Therefore, the location(s) of this Bcl-2 increase remains 
elusive. Bcl-2 is also known to bind to the nuclear outer membrane (Akao et al., 1994) and 
the endoplasmic reticulum (Franke and Kartenbeck, 1971; Lithgow et al., 1994). So, Bcl-2 
has functions in multiple membrane compartment within the cell. In fact, these membranes 
all produce ROS (Freeman and Crapo, 1982) and it is possible that Bcl-2 is involved in an 
antioxidant pathway. An ABT-737 induced increase in membrane-associated Bcl-2 may be 
an attempt by cells to react to and minimize the damage that can result from ROS. Thus, 
examining Bcl-2 levels at the nuclear outer membrane after ABT-737 is important to 
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establish if this is where the increase occurs. An increase at the nuclear membrane may 
indeed show the cell trying to combat increased intracellular ROS levels.  
 
Alternatively, the increase in membrane-associated Bcl-2 may be attributable to Bcl-2 within 
membrane bound vesicles. Such vesicles have multiple functions including protection from 
proteolysis and transport. Transport vesicles move molecules around the cell, between 
membrane-bound compartments, for example between the rough endoplasmic reticulum 
and the Golgi apparatus. Perhaps, ABT-737 causes the transport of Bcl-2 between cellular 
compartments. Alternatively, vesicles may act to protect Bcl-2 from ABT-737, or from 
proteolytic degradation. For instance all Gram negative bacteria use such vesicles to 
protect protein cargo from a host (Bonnington and Kuehn, 2014). To test these hypotheses, 
measuring the amount of Bcl-2 in the nuclear outer membrane and membrane-bound 
vesicles, using cell fractionation and Western blots could identify the location increased Bcl-
2 induced by ABT-737. Identification of where the increased Bcl-2 localised could shed light 
on how it protects APC-deficient cells.  
 
6.4.2 Taxol®, ABT-737 and siRNA treatment activate the unfolded protein response 
Up to 30% of all eukaryotic proteins pass through the ER for folding, modification and 
assembly before being transported to other parts of the cell (Mendez et al., 2015). To 
ensure ER homeostasis is controlled, the cell has developed a mechanism to recognise 
and rectify problems in the ER and restore proteostasis, called the unfolded protein 
response (UPR). Experiments in this thesis showed that control siRNA treatment, Apc 
depletion, Taxol® and the BH3 mimetic ABT-737 activated the UPR (fig 5.6). The unfolded 
protein response is a conserved mechanism (Hollien, 2013) to alleviate ER stress caused 
by the accumulation of misfolded and/or unfolded proteins. Activation of the UPR can 
happen through intrinsic (ROS, disturbed Ca2+ homeostasis, ATP depletion, inflammation, 
oncogenic mutations) or extrinsic (hypoxia, glucose deprivation, carcinogens) stressors 
(see a review by Senft and Ronai, 2015). The UPR is activated by three sensors embedded 
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in the ER that become activated in response to ER stress (fig 1.7): IRE1α/β (Nikawa and 
Yawashita, 1992; Cox et al., 1993), PERK (Harding, Zhang and Ron, 1999) and ATF6 
(Haze et al., 1999). These sensors potentiate several signalling cascades that allow the ER 
to cope with stress and restore ER homeostasis. If the stress cannot be overcome, these 
sensors induce apoptosis. 
 
Elevated P-IRE was found in both ER fractions and whole cell lysates of U2OS cells treated 
with ABT-737 (fig 5.6a). However, ABT-737 also caused an increase in Bcl-2 in the 
membrane fraction of HCT116, CaCo2 and U2OS cells (figure 5.3 and supplemental figure 
8). It is not clear from my experiments whether ABT-737 activated the UPR directly, or 
indirectly through an increase in Bcl-2 protein levels. However, very recently, Bcl-2 over-
expression was shown to enhance the splicing of XBP-1, an IRE1 target of UPR activation 
(Chonghaile et al., 2015). This suggests that Bcl-2 can play a role in the UPR and that ABT-
737-induced UPR activation is indirect, and can involve an increase in Bcl-2. Therefore, 
both Apc depletion and ABT-737 treatment may activate the UPR via increased Bcl-2, 
although more experiments are required to establish the details. For example, using RNAi 
to knock-down Bcl-2 in Apc depleted and ABT-737 treated cells and measuring the relative 
amount of P-IRE. This would show whether UPR activation requires elevated Bcl-2.  
 
Treatment with ABT-737 also elicited a UPR response in other cells types. ABT-737 caused 
a 78% increase in P-IRE in HeLa cells treated with a control siRNA (fig 5.6b) and 53% in 
CaCo2 CRC cells expressing mutant Apc (N-Apc) (fig 5.6c). Therefore ABT-737 is a robust 
activator of the UPR across cell types and regardless of Apc status. 
 
6.4.3 Taxol®, ABT-737 and siRNA treatment affect mitochondrial localisation 
When using IF to examine localisation of pGFP-Bcl-2 in U2OS cells, a change in the 
subcellular localisation of mitochondria was detected in Apc depleted, Taxol®, ABT-737 
and control siRNA treated cells (fig 5.8-5.9). Normally, mitochondria are spread out widely 
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through the cytoplasm of a cell, often extending to the cellular periphery. Using the dye 
MitoTracker® to visualize mitochondria revealed mitochondria retracting to a peri-nuclear 
region, clustered around the nucleus, often skewed to one side of the cell and absent from 
the cell periphery. Consistently, biochemical experiments (fig 5.7) showed that control 
siRNA treated cells also show increased P-IRE levels indicative of UPR activation. Thus 
the siRNA procedure itself appeared to be causing cellular stress activating the UPR. This 
means that the change in mitochondrial localization in Apc knock-down cells may be due 
to the knock-down procedure, rather than Apc depletion. Moreover, the change in 
localization may be a mitochondrial response to cellular stress. Nonetheless, the clustering 
was most severe in ABT-737 treated cells. 
 
A change in the distribution of mitochondria in the cell may indicate a change in cellular 
homeostasis. The change in localization was to a more peri-nuclear position that was often 
asymmetric. This mitochondrial distribution has previously been observed during oocyte 
fertilization, Herpes simplex virus infection, and embryonic development (Al-Mehdi et al., 
2012). Other mitochondrial redistribution patterns are also known to occur (fig 6.5). The 
peri-nuclear clustering of the mitochondria did not affect mitochondrial number, (fig 5.10a) 
indicating no change in mitochondrial fission or fusion associated with the mitochondrial 
translocation. However, measuring cell area (µm2) in cells with control and Apc siRNA and 
ABT-737 showed that each treatment caused a reduction in both cell area and 
mitochondrial number. Thus, there is a positive correlation between cell size and 
mitochondria. It is possible that the shrinking in size of a cell is a stress response. The 
mTOR pathway has been shown to control cell size in response to energy stress (Sofer et 
al., 2005). Hence, the mTOR pathway may also control cell size in response to ER stress. 
Additionally, the ER chaperone GRP78 (BiP) localises to mitochondria under ER stress and 
may help to relay the UPR signal to the mitochondria (Sun et al., 2006). Therefore, GRP78 
may be involved in the redistribution of mitochondria in response to ER stress.  
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6.4.4 ABT-737 does not affect mitochondrial function 
To determine whether the severe peri-nuclear clustering of mitochondria in ABT-737 treated 
cells affected mitochondrial function, the mitochondria dye JC-1 was used to monitor MMP. 
Monomeric JC-1 accumulates in all mitochondria, but only aggregates in mitochondria with 
an active MMP. Therefore, mitochondria with depolymerized membranes, such as those 
undergoing apoptosis have no MMP, and contain no JC-1 aggregates. The data (fig 5.9) 
showed that in mitochondria of ABT-737 treated cells, the MMP is still active and resembles 
that in untreated cells. Therefore, although the mitochondria have redistributed within the 
cell, the functionality as judged by MMP is unchanged. This is consistent with Frieden et 
Fig 6.5. Different mitochondrial distributions. (a) The normal spread of mitochondria 
(shown in white) is throughout the cell and often extends to the cell periphery. (b) 
Subplasmalemmal redistribution orders the mitochondria to the plasma membrane, leaving 
much of the cytoplasm unoccupied with mitochondria. (c) Pan-cytoplasmic localization 
moves the mitochondria in close contact with the endoplasmic reticulum. (d) Asymmetrical 
peri-nuclear clustering takes the mitochondria away from the cell periphery and 
concentrates mitochondria around the nucleus, often asymmetrically.  
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al., (2004) who showed that there was no change in mitochondrial function despite 
mitochondrial relocalisation.  
 
6.4.5 ABT-737 and Apc loss affect mitochondrial structure  
Mitochondria can exist as individual organelles, filamentous structures or large spheres 
representing swollen mitochondria (Johnson et al., 1980). Untreated U2OS cells had 
filamentous mitochondria (fig 5.8 and 5.9). Cells treated with either control siRNA or Taxol® 
retained filamentous mitochondria. However, ABT-737 treated cells contained either far 
fewer, or no filamentous mitochondria. Moreover, only in Apc depleted cells did the 
mitochondria appear swollen, appearing as very large, globular structures. Based on the 
fact that Apc depleted cells have increased Bcl-2 (fig 5.1), which binds to the mitochondrial 
outer membrane to maintain its integrity, Bcl-2 seems the most likely explanation for the 
change in mitochondrial structure. However, ABT-737 treated cells also show an increase 
in Bcl-2, but do not have swollen or filamentous mitochondria. It is possible that in ABT-737 
cells, mitochondria exhibit an intermediary phenotype between filamentous structures (in 
untreated and Taxol® treated cells) and the swollen structures that result from Apc 
depletion – the filaments are broken up into smaller chains of mitochondria, or individual 
organelles (fig 6.6). Therefore, based upon the idea that an increase in Bcl-2 influences the 
structure of the mitochondria, there must be additional changes in Apc depleted cells that 
cause mitochondria to swell. 
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6.4.6 Mitochondria as a read-out for ER stress 
Experiments in this thesis showed that Taxol®, control and Apc siRNA and ABT-737 
activated the UPR (fig 5.6 and 5.7). Additionally, these treatments all caused asymmetric 
peri-nuclear mitochondrial clustering (fig 5.8 and fig 5.9). Hypoxia, a known activator of the 
UPR, also causes mitochondrial peri-nuclear clustering (Al-Mehdi et al., 2012). Taken 
together this suggested that the change in localisation of mitochondria to a more peri-
nuclear region may be a result of ER stress and UPR 
activation (as mitochondrial peri-nuclear clustering is 
already associated with the UPR activator hypoxia). 
A more robust link between UPR activation and 
 
 
 
 
mitochondrial swelling was shown by Munos et al., 
(2013). They discovered that the mitochondrial 
fusion protein Mfn-2 controls the UPR and lies 
upstream or PERK, which controls mitochondrial 
morphology and can execute mitochondrial swelling. 
Therefore, swelling of mitochondria may be a signal 
for ER stress and UPR activation. 
 
6.4.7 Combining Taxol® and ABT-737 kills intestinal organoids with mutant Apc  
Intestinal organoids were used as a more physiological, 3D system to test the effect of 
Taxol® and ABT-737 on WT or mutant Apc cells (cysts). Organoids were treated with either 
Taxol®, ABT-737 or both (ABTTAX) and the effects followed over 48 hours. As expected 
based on 2D cell culture data (Dikovskaya et al., 2007; Radulescu et al., 2010), Taxol® 
caused organoids with WT Apc to arrest in mitosis, whereas, organoids with mutant Apc 
Fig 6.6. Different mitochondrial structures associated 
with ABT-737 and siAPC. (a) Filamentous mitochondria 
(shown in white) in untreated cells, forms chains of 
mitochondria. (b) Mitochondria in ABT-737 treated cells 
are neither filamentous nor swollen, they are more like 
individual organelles or small chains of mitochondria. (c) 
The mitochondria in Apc depleted cells are large, globular 
mitochondria and appear swollen. 
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continued to grow. ABT-737 had no visible effect on WT organoids although it appeared to 
slow the growth of Apc mutant cysts. ABTTAX had a severe impact on cysts, causing death 
within several hours of treatment. It had less impact on the organoids with WT Apc. This 
may be because the cysts are already stressed due to the presence of mutant Apc and the 
addition of two more stressors (Taxol® and ABT-737) could cause cell death by an additive 
effect. Moreover, this data ties in with work done by van der Heijden et al., (2016), whom 
showed that intestinal stem cells that had lost Apc could be primed for apoptosis by 
inhibiting Bcl-2 – impairing tumorigenesis (fig 6.7).  
 
Although a conclusion cannot be drawn from my experiments as whether Apc loss causes 
ER stress - due to the control siRNA also eliciting UPR activation, a recent publications 
showed that Apc is a cellular stressor (van der Heijden et al., 2016). Here, organoids were 
assessed on their readiness to undergo apoptosis as analysed by a mitochondrial priming 
assay (Ryan, Brunelle and Letai, 2010; van der Heijden et al., 2016). This showed that in 
Apc deficient organoids, cells showed a much higher rate of membrane depolarisation 
attributable to intrinsic pathway cell death when treated with the BH3-only Bcl-2 family 
protein BID. 
 
In summary of the Bcl-2 data (fig 6.8), Apc depleted cells cannot be killed by Taxol® as 
readily as Apc WT cells and are more sensitive to the combination of Taxol® and the Bcl-2 
inhibitor ABT-737. Experiments in this thesis discovered that Apc depleted cells had 
increased Bcl-2, a pro-life protein. This may in part explain why these cells do not die as 
readily - Bcl-2 counteracts the cells being primed for apoptosis when Apc is lost (fig 6.7) 
(van der Heijden et al., 2016).  Moreover, these cells were more sensitive to the Bcl-2 
inhibitor ABT-737 (as seen by van der Heijden et al., 2016), which also increased Bcl-2 
levels. ABT-737 also depleted APC by around 50%. This APC depletion effect was similar 
to that caused by hypoxia, a known stressor on the cell (fig 6.8). This link to cell stress led 
to the discovery that Apc loss, Taxol® and ABT-737 treatment all caused ER stress and 
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activated the unfolded protein response (UPR), similar to hypoxia.  Consistently, these 
cellular treatments also resulted in the redistribution of mitochondria to a peri-nuclear 
region, suggesting that the translocation of mitochondria is a consequence of ER stress. 
However, these treatments did not affect the functionality of the mitochondria, as measured 
by the mitochondrial membrane potential (MMP) probe JC-1. Only Apc loss caused a 
significant change in the mitochondrial structure from filamentous to swollen, globular 
structures. However, ABT-737 treated cells had mitochondria akin to an 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.7. Intestinal tumorigenesis caused by Apc loss can be impaired by Bcl-2 
inhibition. (a) Apc loss in intestinal stem cells (ISC) with increased Bcl-2 leads to neoplastic 
progression and subsequent intestinal tumorigenesis. (b) Apc loss in differentiated intestinal 
cells primes them for apoptosis due to cell stress. However, a subsequent increase in Bcl-2 
allows the transformation of the differentiated cells. (c) In ISCs as in (a), when Bcl-2 is 
inhibited (by genetic of chemical methods), intestinal tumorigenesis is impaired and the cells 
are primed for apoptosis. Image taken from van den Heijden et al., (2016).  
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intermediary phenotype between filamentous and swollen structures. As both Apc loss and 
ABT-737 increased Bcl-2 levels it is plausible that elevated Bcl-2 protein levels are in part 
due to the shift away from filamentous mitochondria.  
 
Cells with mutant Apc (N-Apc) showed higher P-IRE levels when treated with Taxol®, 
although Taxol® treatment in cells with WT Apc had little effect. This suggests that the 
mutant Apc is synergizing with Taxol® to produce a higher UPR response. If Apc depletion 
is, as I have shown, an activator or the UPR (a stressor) then it is plausible that mutant Apc, 
lacking the middle and C-terminal portion of APC is also a stressor; as these cells contain 
short, mutant Apc fragments that produce dominant effects over the WT allele (Marshall et 
al., 2011; Nelson et al., 2012), and result in polyp formation (Kinzler and Vogelstein, 1996; 
Rowan et al., 2000; Radulescu et al., 2010). This means that Apc mutant cells would be 
inherently stressed (fig 6.8) and any subsequent stress to the cell such as ABT-737 or 
Taxol® treatment, would cause a higher increase that if carried out in cells with WT Apc. 
 
6.5 Summary  
To summarise my data, I propose a model, which suggests that combining specific cellular 
insults, such as losing Apc, treatment with Bcl-2 inhibitors or Taxol® can produce 
cumulative ER stress levels (fig 6.9).  In this model, cells can cope with a certain amount of 
ER stress-induced UPR activation. However, a high a level of ER stress leads to UPR-
induced cell death. This could explain why in cell culture, Apc deficient cells are more 
sensitive to the combination of Taxol® and ABT-737 than Apc WT cells.  The Apc deficiency 
is a stressor in itself. Thus, the combination of Taxol®, ABT-737 and Apc depletion 
compound the ER stress effect causing cell death. Elevated Bcl-2 in both Apc depleted and 
ABT-737 treated cells may be the one reason for UPR activation. Activation of the UPR 
leads to a mitochondrial phenotype, causing them to cluster asymmetrically in peri-nuclear 
regions. However, no measurable change in mitochondrial function is associated with this  
translocation. Importantly, the combination of ABT-737 and Taxol® was successful in killing 
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Apc mutant organoids, much more effectively than Apc WT organoids. Combining these 
agents may constitute a possible chemotherapeutic approach for treating CRC. 
Fig 6.8. The relationship between APC, Bcl-2, ABT-737 and the UPR. (a) If APC is lost 
(RNAi) in cells expressing WT Apc, there is a stress response in activation of the UPR. In 
addition there is an increase in the Bcl-2 protein, which may also activate the UPR. (b) In cells 
expressing WT Apc that are treated with ABT-737 there is a decrease in APC, which mimics 
the stress effect of hypoxia. These cells show activation of the UPR. There is also an increase 
in Bcl-2, which may also activate the UPR. (c) In cells with mutant Apc, which are treated with 
ABT-737 there is activation of the UPR (probably due to stress caused by the Apc mutation) – 
at a higher level when compared to UPR activation in WT Apc cells. These cells also show an 
increase in Bcl-2, which may also activate the UPR. 
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6.6 Graphical summary 
b 
c 
a 
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Fig 6.9. Graphical summary. Three-step model for stress-induced cell death. (a) In this 
model, it takes 3 independent stressors on the cell, to ‘tip’ the cell over the edge of what it 
can cope with and the cell dies. A normal, unstressed happy cell (i) encounters a stressor 
(represented by the lightning bolt) and becomes stressed. One more independent stressor 
a cell can survive (ii-iii). However, a third stressor is too much for the cell and it initiates 
apoptosis (iv) and dies (v). (b) When cells with WT Apc are treated with Taxol® they arrest 
in mitosis. The cell must then fix any damage before continuing on with the cell cycle. If the 
cell remains mitotically arrested, treatment with other drugs such as ABT-737 have less of 
an effect because the arrested cell is effectively on a pedestal out of reach because it has 
arrested. (c) As my experiments identified Apc depletion or mutant Apc as a stressor, cells 
with either no Apc or mutant Apc are likely to be inherently stressed, therefore they are 
already one step closer to death on the model, they lack step (i) in (a). The addition of 2 
more stressors, Taxol® and ABT-737 are too much stress for the cell and it dies.  
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Supplementary Figures 
  
Supplemental figure 1. Targeting vectors used to create (EGFP-)degron-Apc. (a) 
pEGFP-IAA17-APC. The resistance cassette Blasticidin S is inserted so as to be in the 
same transcriptional orientation as Apc after homologous recombination. (b) pIAA17-
APC. The resistance cassette Blasticidin S is inserted so as to be in the same 
transcriptional orientation as Apc after homologous recombination. 
 
a 
b 
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Supplemental figure 2. Expression vector. TIR-9Myc cDNA and degron (AID) cDNA 
to allow for expression of separate TIR and degron proteins. 
 
pAID1.2-N 
7.4kb 
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Supplemental figure 3. Auxin does not affect DT40 viability. WT DT40 cells were 
treated with varying concentrations of auxin (0-2000nM) over 24 hours and the 
percentage of viable cells was counted. 
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Supplemental figure 4. Optimising the PCR screen to identify cells transfected 
with EGFP-IAA17-APC. (a) Schematic showing the recombined allele after HR and the 
different primers used to amplify an area representative of a targeted insertion (i.e. 
primers 2R-4R are upstream of the insertion and GFP R is within the targeting vector). 
(b) Primer combinations 5R + GFP R, 4R + GFP R, 3R + GFPR, 2R + GFP R, 5R + 1F 
were tested on DT40TIR cells, the targeting vector (T.V) and 2 test clones (A2 and O4). 
5R + GFP R is a control PCR as it amplifies up the targeting vector. The black arrow 
shows the band expected for a targeted insertion. The red arrows shows the band 
representing Blasticidin, another control PCR. (c) Primer combination 2R + GFP R was 
chosen (b) and then a gradient PCR was performed to identify the optimum annealing 
temperature. DT40TIR cells and the targeting vector are shown as negative controls. 
The arrow shows the expected band for a targeted insertion. 
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Supplemental figure 5. Optimising the PCR screen to identify cells transfected with 
IAA17-APC. (a) Schematic showing the recombined allele after HR and the different 
primers used to amplify up and area representative of a targeted insertion (i.e. using 
primer 2R upstream of the insertion and primer IAA17 R within the targeting vector). (b) 
Gradient PCRs using 2R and IAA17 primers. DT40TIR cells and the targeting vector (T.V) 
were used as negative controls. Clone 1A, known to be positive for a targeted insertion 
from the previous transfection, was used as a positive control. The arrow shows the 
expected bands. 
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Supplementary figure 6. Selection of live, single cells for FACS analysis.  Cells with 
varying APC expression were treated with 500µM Taxol® for 6 hours and then incubated 
with 20µM BrdU for 20 mins. Cells were then fixed and stained with an anti-BrdU antibody 
and PI. Using FACSDiva software the live cells (P1) were selected for, when PI-stained 
cells were visible, excluding dead cells and aggregates. This was performed for untreated 
(control) and Taxol® treated DT40TIR, V5 and X4A cells. 
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Supplementary figure 7. CoIP attempt of APC-Bcl-2. APC IP using 2mg lysate from U2OS 
cells treated plus or minus 7µM ABT-737. (a) Western blot against APC. (b) Western blot of APC 
IP (a) against Bcl-2. The faint band representing Bcl-2 in the input is marked with an asterisk 
immediately below it. Molecular weights in kDa are shown on the left-hand side. 336 is a negative 
control for the APC IP. 
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Supplemental figure 8. Fractionations show Bcl-2 increase in the membrane fraction. Cells 
were treated plus/or minus 7µM ABT-737 for 24 hours. The proteins were then separated into 
cytosol (C), membrane (M), nucleus (N) and cytoskeletal (S) fraction. Western blots show the 
increase in Bcl-2 in the membrane fraction as well as proteins used as markers for each fraction. 
Beta-catenin is a representative of a good fractionation as it is present in all fractions. (a) β-catenin 
in HCT116 cells. (b) Topoisomerase II in HCT116 cells. (c) HSP60 in HCT116 cells. (d) Keratin18 
in HCT116 cells. The antibody also picks up keratin 8. (e) GAPDH in HCT116 cells. (f) Bcl-2 in 
HCT116 cells. (g) β-catenin in CaCo2 cells. (h) Topoisomerase II in CaCo2 cells. (i) HSP60 in 
CaCo2 cells. (j) Keratin 18 in CaCo2 cells. (k) GAPDH in CaCo2 cells. (l) Bcl-2 in CaCo2 cells. 
(m) β-catenin in U2OS cells. (n) Bcl-2 in U2OS cells. 
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Supplemental figure 9. qRT-PCR of Wnt target gene Cyclin D in ABT-737 treated cells. Gene 
expression was normalised to Actin (a) qRT-PCR of Apc and β-catenin from HCT116 cells treated 
plus/minus 7µM ABT-737 for 24 hours.. (b) qRT-PCR of HCT116 cells treated as in (a). Beta-
catenin target gene Cyclin D. (c) qRT-PCR of U2OS cells as in (a). (d) qRT-PCR of U2OS cells 
as in (b). 
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g  
SAMPLE PROTEIN SCORE EMPAI 
EMPAI  EMPA
I # 
MOLA
R % 
CTRL 1. Hsp60 1. Pyruvate kinase 83.5 45.5 
 2. Pyruvate 
kinase 
2. Hsp60 * 50.8 27.6 
 3. T complex 3. c14orf80 12.4 6.7 
 4. Keratin 1 4. T complex * 10.1 5.5 
 5. Ras GAP 
Binding 
protein 1 
5. Tyrosine tRNA 
ligase 
2.4 1.3 
 6. Keratin 6A 6. Keratin 1 2.3 1.2 
 7. Ribonuclear 
protein 
7. PUF60 2.2 1.2 
 8. PUF60 8. PURH 2.1 1.1 
 9. DK 2 9. EH domain 
containing proteins 
2.1 1.1 
 10. eIF2A 10. HNRPL 2.0 1.1 
 11. Chaperonin 11. Chaperonin 
containing TCP1 * 
2.0 1.1 
 12. PURH 12. DNAJ * 1.6 0.9 
 13. Arf-GAP 
domain 
13. Ser/thr kinase * 1.4 0.8 
 14. Synembryin-
A 
14. Ras GTPase-
activating protein-
binding protein 1 
1.4 0.8 
 15. EH domain 
containing 
proteins 
15. Highly similar to 
Dihydropyrimidinase
-related protein 1a 
1.3 0.7 
 16. Tyrosine 
tRNA ligase 
16. DK 2 1.3 0.7 
 17. DNAJ 17. Synembryin-A 1.3 0.7 
 18. UDP-N-c-P 18. Archain 1, isoform 
CRA 
1.2 0.7 
 19. PDI 19. Cytoplasmic dynein 
1 light intermediate 
chain 1 
1.1 0.6 
 20. Ser/the 
kinase 
20. Proteasome non-
ATPase regulatory 
subunit 3 
1.0 0.6 
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SAMPLE PROTEIN SCORE EMPAI 
EMPAI EMPA
I # 
MOLAR 
% 
ABT-737 1. Hsp60 1. Pyruvate 
kinase 
88.1 47.9 
 2. Pyruvate kinase 2. Hsp60 * 48.2 26.3 
 3. T complex 3. T complex * 10.6 5.8 
 4. Ribonuclear 
protein 
4. Ser/the kinase 
* 
3.3 1.8 
 5. Chaperonin 5. Keratin 1 3.2 1.7 
 6. Ser/the kinase 6. Tyrosine tRNA 
ligase 
3.0 1.6 
 7. Keratin 6A 7. c14orf80 3.0 1.6 
 8. Ras GAP 
Binding protein 1 
8. DPP 2.9 1.6 
 9. Synembryin-A 9. Chaperonin * 2.9 1.6 
 10. DK 2 10. Heterogeneous 
nuclear 
ribonucleoprote
in 
2.3 1.3 
 11. Tyrosine tRNA 
ligase 
11. Asparagine 
synthetase  
2.1 1.1 
 12. Keratin 1 12. PUF60 1.8 1.0 
 13. EH domain 
containing 
proteins 
13. EH domain 
containing 
proteins 
1.8 0.9 
 14. PDI 14. UAP1 1.7 0.9 
 15. eIF2A 15. Synembryin-A 1.6 0.9 
 16. DNA J 16. DNAJ 1.6 0.9 
 17. PUF60 17. Ras GTPase-
activating 
protein-binding 
protein 1 * 
1.4 0.8 
 18. UDP-N-c-P 18. Adenosylhomo
cysteinase 
1.4 0.8 
 19. Apoptosis 
inhibitor 5 
19. DK 2 1.4 0.8 
 20. Regulator or 
chromosome 
condensation 2 
20. NudC 
containing 
protein 1 
1.4 0.7 
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Supplementary Figure 10. Identifying the mystery band detected by anti-Bcl-2 
(32124). Experiments were carried out to identify the band detected by the anti-Bcl-2 
antibody. (a) U2OS and HCT116 cells were treated with either ctrl, Apc or β-catenin 
siRNAs. A Western blot of the whole (uncut) membrane with anti-Bcl-2 reveals the 
expected band for Bcl-2 at 27kDa, but also unexpected bands A, B and C. A appears to be 
inversely correlated with Bcl-2 and increases upon Apc depletion. A is running at double 
the size of Bcl-2 and raised the possibility that it is a homodimer or a heterodimer of Bcl-2 
family proteins. (b) HeLa and U2OS cells were grown plus/or minus 7µM ABT-737 for 24 
hours. Western blots shows an increase in Bcl-2, but also in the unknown protein ‘A’. (c) 
U2OS cells were treated with ctrl siRNA or varying concentrations of Bcl-2 siRNA. Band ‘A’ 
decreases upon Bcl-2 knock-down. (d) To determine if band ‘A’ was specific to epithelial 
cells, MEFs were cultured (see table 7) plus/or minus 7µM ABT-737 for 24 hours. Western 
blots reveal that band ‘A’ is present in fibroblasts as well, but in these cells it responds to 
ABT-737 differently and decreases with ABT-737. (e) To determine if bands A, B or C 
represent a complex of proteins, various protein lysing methods were used to denature any 
non-covalently associated complexes. A Western blot shows that boiling lysates in sample 
buffer (S.B.) causes band A to disappear, but there is no increase in monomeric Bcl-2, 
suggesting that Bcl-2 is not present in band ‘A’.  (f) Data from panels a-e suggest that band 
‘A’ is not related to Bcl-2. Therefore mass-spectrometry was used to identify it. U2OS cells 
were cultured with/or without 7µM ABT-737 for 24 hours, lysed and 100µg of lysate was 
run on a gel and stained with Coomassie. Proteins in the molecular weight region of interest 
were cut out and sent for LC-MS-MS analysis. (g, h) Mass-spec analysis was applied to 
identify proteins in the control (g) and ABT-737 treated samples (h) with the aim of 
identifying proteins elevated in the latter that could represent band ‘A’ using MASCOT 
software. Specifically, protein scores (sum total of the number of peptides counted per 
protein) were compared by their emPAI scores, which represents proteins enriched in the 
sample based on abundance. As larger proteins can give to rise to more peptides by tryptic 
digestions, this can skew results in favour of larger proteins. PAI accounts for this by 
calculating the number of observed peptides divided by the theoretically observable 
peptides per protein. emPAI (10PAI-1) allows the calculation of the molar fraction percentage 
of particular proteins, therefore a protein enriched in ABT-737 treated cells compared to 
untreated cells can be identified. Proteins highlighted in yellow are unique to each list.  Red 
asterisks represent proteins involved in stress responses. It is likely that band A is a stress-
related protein. 
 
 186 
 
Supplemental figure 11. The effect of GFP-Bcl-2 on cell size and mitochondria. (a) 
U2OS cells were transfected with GFP-BCL-2. The cells were then cultured with 
MitoTracker® for 45 minutes. Mitochondria were visualised using fluorescent microscopy. 
Images were then imported into the microscopy software Imaris. Using fluorescence 
detection the number of MitoTracker®-positive spots were counted and the area of the 
cells were measured. 5 cells were analysed per treatment. There is a positive correlation 
between cell size and mitochondrial number. GFP-BCL-2 cells (yellow) are the smallest 
and so have the fewest mitochondria. (b) The number of mitochondria were divided by the 
area of the cell to give a ratio of MitoTracker® positive spots: area. The bar graph shows 
that there is no difference in mitochondrial size between treatments. Error bars represent 
the standard error. 
 
 187 
 
References  
 
Adams, J. M. and Cory, S. (2007). The Bcl-2 apoptotic switch in cancer development and 
therapy. Oncogene. 26. Pp. 1324–1337. 
 
Akao, Y., Orsuki, Y., Kataoka, S., Ito, Y. and Tsujimoto, Y. (1994). Multiple Subcellular 
Localization of bcl-2: Detection in Nuclear Outer Membrane, Endoplasmic Reticulum 
Membrane, and Mitochondrial Membranes. Cancer Res. 5. Pp. 2468-2471. 
 
Ali-Osman, F., Berger, M. S., Rajagopal, S., Spence, A. and Livingston, R. B. (1993). 
Topoisomerase II Inhibition and Altered Kinetics of Formation and Repair of Nitrosourea 
and Cisplatin-induced DNA Interstrand Cross-Links and Cytotoxicity in Human 
Glioblastoma Cells. Cancer Res. 53. Pp. 5663-5668. 
 
Al-Mehdi, A-B., Pastukh, V. M., Sewiger, B. M., Reed, D. J., Patel, M. R., Bardwell, G C., 
Pastukh, V. V., Alexeyev, M. F. and Gillespie, M. N. (2012). Perinuclear Mitochondrial 
Clustering Creates an Oxidant-Rich Nuclear Domain Required for Hypoxia-Induced 
Transcription. Sci. Signal. 5:231. Doi: 10.1126/scisignal.2002712. 
 
Baca, A. M. and Hol, W. G. J. (2000). Overcoming codon bias: A method for high-level 
overexpression of Plasmodium and other AT-rich parasite genes in Escherichia coli. Int J 
Parisit. 30:2. Pp. 113–118.  
 
Baeg, G. H., Matsumine, A., Kuroda, T., Bhattacharjee, R. N., Miyashiro, I., Toyoshima, K. 
and Akiyama, T. (1995). The tumour suppressor gene product APC blocks cell cycle 
 188 
 
progression from G0/G1 to S phase. EMBO. 14:22. Pp. 5618-25. 
 
Balusu, R., Jaiswal, A. S., Armas, M. L., Kundu, C. N., Bloom, L. B. and Narayan, S. (2007). 
Structure/function analysis of the interaction of adenomatous polyposis coli 
with DNA polymerase beta and its implications for base excision repair. Biochemistry. 
46:49. Pp. 13961-74.  
 
Barker, N. (2014). Adult intestinal stem cells: critical drivers of epithelial homeostasis and 
regeneration. Nat Rev Mol Cell Biol. 15. Pp. 19–33. 
 
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, 
M., Danenberg, E., Clarke, A. R., Sansom, O. J. and Clevers, H. (2009). Crypt stem cells 
as the cells-of-origin of intestinal cancer. Nature. 457. Pp. 608-611. 
 
Behrens, J., Jerchow, B. A., Wurtele, M., Grimm, J., Asbrand, C., Wirtz, R., Kuhl, M., 
Wedlich, M. and Birchmeier, W. (1998). Functional interaction of an axin homolog, 
conductin, with beta-catenin, APC, and GSK3beta. Science. 280:5363. Pp. 596-9. 
 
Behrens, J., Von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R. and 
Birchmeier, W. (1996). Functional interaction of β-catenin with the transcription factor LEF-
1. Nature. 382. Pp. 638-642. 
 
Bennett, R. A. O., Wilson III, D. M., Wond, D. and Demple, B. (1997). Interaction of human 
apurinic endonuclease and DNA polymerase β in the base excision repair pathway. Proc 
Natl Acad Sci U S A. 94:14. Pp. 7166–7169. 
 189 
 
Berrueta, L., Kraeft, S. K., Tirnauer, J. S., Schuyler, S. C., Chen, L. B., Hill, D. E., Pellman, 
D. and Bierer, B. E. (1998). The adenomatous polyposis coli-binding protein EB1 is 
associated with cytoplasmic and spindle microtubules. Proc Natl Acad Sci U S A. 95:18. 
Pp. 10596-601. 
 
Bertolotti, A., Zhang, Y., Hendershot, L. M., Harding, H. P. and Ron, D. (2000). Dynamic 
interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell 
Biol. 2:6. Pp. 326-32. 
 
Bi, M., Naczki, C., Koritzinksy, M., Dels, D., Blais, J., Hu, N., Harding, H., Novoa, I., Varia, 
M., Raleigh, J., Scheuner, D., Kaufman, R. J., Bell, J., Ron, D., Wouters, B. G. and 
Koumenis, C. (2005). ER stress‐regulated translation increases tolerance to extreme hypoxia 
and promotes tumor growth. EMBO. 24. Pp. 3470-3481. 
 
Bjerknes, M. and Cheng, H. (1981). The stem-cell zone of the small intestinal epithelium. I. 
Evidence from Paneth cells in the adult mouse. Am J Anat. 160:1. Pp. 51-63. 
 
Bonnington, K. E. and Kuehn, M. J. (2014). Protein selection and export via outer 
membrane vesicles. Biochim Biophys Acta.. 1843:8. Pp. 1612–1619. 
 
Brocardo, M., Lei, Y., Tighe, A., Taylor, S. S., Mok, M. T. S. and Henderson, B. R. (2007). 
Mitochondrial Targeting of Adenomatous Polyposis Coli Protein Is Stimulated by Truncating 
Cancer Mutations: REGULATION OF Bcl-2 AND IMPLICATIONS FOR CELL SURVIVAL. 
J Bio Chem. 283. Pp. 5950-5959. 
 190 
 
Browne, S.J., Williams, A. C., Hague, A., Butt, A. J. and Paraskeva, C. (1994). Loss 
of APC protein expressed by human colonic epithelial cells and the appearance of a 
specific low-molecular-weight form is associated with apoptosis in vitro. Int J Cancer: 59:1. 
Pp. 56-64. 
 
Calarco, P.G. (1995). Polarization of mitochondria in the unfertilized mouse oocyte. Dev 
Genet.  16:1. Pp. 36-43 
 
Cheema, S. K., Mishra, S. K., Rangnekar, V. M., Tari, A. M., Kumar, R. and Lopez-
Berestein, G. (2003). Par-4 Transcriptionally Regulates Bcl-2 through a WT1-binding Site 
on the bcl-2Promoter. J Biol Chem. 278. Pp. 19995-20005. 
 
Chen, B. B., Glasser, J. R., Coon, T. A., Zou, C., Miller, H. L., Fenton, M., McDyer, J. F., 
Boyiadzis, M. and Mallampalli, R. K. (2012). F-box protein FBXL2 targets cyclin D2 for 
ubiquitination and degradation to inhibit leukemic cell proliferation. Blood. 119:13. Pp. 3132 – 
3141. 
 
Chen J., Young, F., Bottaro, A., Stewart, V., Smith, R. K. and Alt, F. W. (1993). Mutations 
of the intronic IgH enhancer and its flanking sequences differentially affect accessibility of 
the JH locus. EMBO. 12:12. Pp. 4635-4645. 
 
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. N., 
Day, C. L., Adams, J. M. and Huang, D. C. S. (2005). Differential Targeting of Prosurvival 
Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Mol 
Cell. 17:3. Pp. 393–403. 
 191 
 
Cheng, H. and Leblond, C.P. (1974). Origin, differentiation and renewal of the four main 
epithelial cell types in the mouse small intestine. V. Unitarian theory of the origin of the four 
epithelial cell types. Am J Anat. 141. Pp. 537–561. 
 
Chonghaile, T. N., Gupta, S., John, M., Szegezdi, E., Logue, S. E. and Samali, A., (2015). 
BCL-2 modulates the unfolded protein response by enhancing splicing of X-box binding 
protein-1.  Biochim Biophys Res Commun. 466:1. Pp. 40-45. 
 
Ciccia, A. and Elledge, S. J. (2009). The DNA Damage Response: Making It Safe to Play 
with Knives. Mol Cell. 40:2. Pp. 179-204. 
 
Clevers, H. (2013). The Intestinal Crypt, A Prototype Stem Cell Compartment. Cell. 154:2. 
Pp. 274-284. 
 
Cox, J. S. and Walter, P. (1996). A Novel Mechanism for Regulating Activity of a 
Transcription Factor That Controls the Unfolded Protein Response. Cell. 87:3. Pp. 391–
404. 
 
Cox, J. S., Shamu, C. E and Walter, P. (1993). Transcriptional induction of genes encoding 
endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell. 73. 
Pp. 1197-1206. 
 
Cristofaro, M., Contursi, A., D'Amore, S., Martelli, N., Spaziante, A. F., Moschetta, A. and 
Villani G. Adenomatous polyposis coli (APC-) induced apoptosis of HT29 colorectal cancer 
 192 
 
cells depends on mitochondrial oxidative metabolism. Biochim Biophys Acta. 1852:9. Pp. 
1719-1728. 
 
Czabotar, P. E., Lessene, G., Strasser, A. and Adams, J. M. (2014). Control of apoptosis by 
the BCL-2 protein family: implications for physiology and therapy. Nature Rev Mol Cell Biol. 15. 
Pp. 49–63. 
 
Czabotar, P.E., Westphal, D., Dewson, G., Ma, S., Hockings, C., Fairlie, W. D., Lee, E. F., 
Yao, S., Robin, A. Y., Smith, B. J., Huang, D. C. S., Kluck, R. M., Adams, J. A. and Colman, 
P. M. (2013). Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate 
Its Oligomerization to Induce Apoptosis. Cell. 152:3. Pp. 519–531. 
 
D’Angiodella, V., Donata, V., Vijayakumar, S., Saraf, A., Florens, L., Washburn, M. P., 
Dynlacht, B. and Pagano, M. (2010). SCFCyclin F controls centrosome homeostasis and mitotic 
fidelity through CP110 degradation. Nature. 466. Pp. 138–142. 
 
Damia, G., Filiberti, L., Vikhanskaya, F., Carrassa, L., Taya, Y., D’incalci, M. and Broggini, 
M. (2001). Cisplatinum and taxol induce different patterns of p53 phosphorylation. 
Neoplasia. 3:1 Pp. 10-6. 
 
De Jong D., Prins, F. A., Mason, D. Y., Reed, J. C., van Ommen, G. B. and Kluin, P. M. 
(1994). Subcellular Localization of the bcl-2 Protein in Malignant and Normal Lymphoid 
Cells. Cancer Res. 54:1. Pp. 256-260. 
 
 193 
 
Deka, J., Kuhlmann, J. and Muller, O. (1998). A domain within the tumor suppressor 
protein APC shows very similar biochemical properties as the microtubule-associated 
protein tau. Eur J Biochem. 253:3. Pp. 591-7. 
 
Dewson, G., Kratina, T., Sim, H. W., Puthalakalth, H., Adams, J. M., Colman, P. M. and 
Kluck, R. M. (2008). To Trigger Apoptosis, Bak Exposes Its BH3 Domain and 
Homodimerizes via BH3:Groove Interactions. Mol Cell. 30:3. Pp. 369–380. 
 
Diaz, F., Menendez, M. and Andreu, J. M. (1993). Thermodynamics of ligand-induced 
assembly of tubulin. Biochemistry. 32:38. Pp. 10067-10077. 
 
Dikovskaya, D., Newton, I. P. and Näthke, I. S. (2004). The adenomatous polyposis coli 
protein is required for the formation of robust spindles formed in CSF Xenopus extracts. Mol 
Biol Cell. 15. Pp. 2978–2991. 
 
Dikovskaya, D., Schiffmann, D., Newton, I. P., Oakley, A., Kroboth, K., Sansom, O., 
Jamieson, T. J., Meniel, V., Clarke, A. and Näthke, I. S. (2007). Loss of APC induces 
polyploidy as a result of a combination of defects in mitosis and apoptosis. J Cell Biol. 176:2. 
Pp. 183-195. 
 
Draviam, V. M., Shapiro, I., Aldridge, B. and Sorger, P. K. (2006). Misorientation and reduced 
stretching of aligned sister kinetochores promote chromosome missegregation in EB1‐ or APC‐
depleted cells. EMBO. 25. Pp. 2814-2827. 
 
 194 
 
Du, C., Fang, M., Li, Y., L, L. and Wang, X. (2000). Smac, a mitochondrial protein that 
promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 
102:1. Pp. 33-42. 
 
Elford, H. L. (1968). Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys 
Res Commun. 33:1. Pp. 129-35. 
 
Ellis, G. K., Gralow, J. R., Pierce, H. I., Williams, M. A. and Livingston, R. B. (1999). 
Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for 
metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-
treated patients. J Clin Oncol. 17:5. Pp. 1407-12. 
 
Fodde, R., Edelmann, W., Yang, K., van Leeuwen, C., Carlson, C., Renault, B., Breukel, 
C., Alt, E., Lipkin, M. and Khan, P. M. (1994). A targeted chain-termination mutation in the 
mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci U S A.  91:19. Pp. 
8969–8973. 
 
Fodde, R., Kuipers, J., Rosenberg, C., Smits, R., Kielman, M., Gaspar, C., van Es, J. H., 
Breukel, C., Wiegant, J., Giles, R. H. and Clevers, H. (2001). Mutations in the APC tumour 
suppressor gene cause chromosomal instability. Nat Cell Biol. 3. Pp. 433–438. 
 
Fodde, R., Smits, R. and Clevers, H. (2001). APC, signal transduction and genetic instability 
in colorectal cancer. Nat. Rev. Cancer. 1:1. Pp. 55-67. 
 
 195 
 
Franke, W. and Kartenbeck, J. (1971). Outer mitochondrial membrane continuous with 
endoplasmic reticulum. Protoplasma. 73. Pp. 35–41. 
 
Freeman, B. A. and Crapo, J. D. (1982). Biology of disease: free radicals and tissue injury. 
Lab Invest. 47:5. Pp. 412-26. 
 
Frieden, M., Dominic, J., Castelbou, C., Danckaert, A., Martinou, J-C. and Demaurex, N. 
(2004). Ca2+ Homeostasis during Mitochondrial Fragmentation and Perinuclear Clustering 
Induced by hFis1. J Biol Chem.  279. Pp. 22704-22714. 
 
Galluzzi, L., Blomgren, K. and Kromer, G. (2009). Mitochondrial membrane 
permeabilization in neuronal injury. Nat Rev Neurosci. 10. Pp. 481-494. 
 
Gerstel, L. D. U., and PHILLIPS, L.L. (1958). Segregation of synthetic amphiploids in 
Gossypium and Nicotiana. Cold Spring Harbor Symposia Quant. Biol. 23. Pp. 225-237. 
 
Gilkerson, R.W., De Vries, R. L. A., Lebot, P., Wikstrom, J. D., Torgyekes, E., Shirihai, O. 
S., Przedborski, S. and Schon, E. A. (2012). Mitochondrial autophagy in cells with mtDNA 
mutations results from synergistic loss of transmembrane potential and mTORC1 inhibition. 
Hum Mol Genet. 21:5. Pp. 978-990. 
 
Green, R. A. and Kaplan, R. B. (2003). Chromosome instability in colorectal tumor cells is 
associated with defects in microtubule plus-end attachments caused by a dominant 
mutation in APC. J. Cell Biol. 163. Pp .949–961. 
 
 196 
 
Griffiths, G. J., Dubrez, L., Morgan, C. P., Jones, N. A., Whitehouse, J., Corfe, B. M., Dive, 
C. and Hickman, J. A. (1999). Cell Damage-induced Conformational Changes of the Pro-
Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis. J Biol Chem.  144:5. 
Pp. 903-914. 
 
Grossman, L., Riazuddin, S., Haseltine, W. A. and Lindan, C. (1979). 
Nucleotide excision repair of damaged DNA. Cold Spring Harb Symp Quant Biol. 43:2. Pp. 
947-955. 
 
Hallmann, A., Milczarek, R., Lipinski, M., Kossowska, E., Spodnik, J. H., Wozniak, M., 
Wakabayashi, T. and Klimek, J. (2004). 
Fast perinuclear clustering of mitochondria in oxidatively stressed human choriocarcinom
a cells. Folia Morphol. 63:4. Pp. 407-412. 
 
Hans, F. and Dimitrov, S. (2001) Histone H3 Phosphorylation and cell division. Oncogene. 
20:24. Pp. 3021-3027. 
 
Hao, B., Oehlmann, S., Sowa, M. E., Harper, J. W. and Pavletich, N. P. (2007). Structure 
of a Fbw7-Skp1-Cyclin E Complex: Multisite-Phosphorylated Substrate Recognition by SCF 
Ubiquitin Ligases. Mol Cell. 26:1. Pp. 131–143. 
 
Hardcastle, J. D., Balfour, T. W. and Amar, S. S. (1980). Screening for symptomless 
colorectal cancer by testing for occult blood in general practice. Lancet. 315:8172. Pp. 791-
3. 
 
 197 
 
Harding, H. P., Novoa, I., Zhang, Y., Zeng, H., Wek, R., Schapira, M. and Ron, D. (2000). 
Regulated translation initiation controls stress-induced gene expression in mammalian 
cells. Mol Cell. 6:5. Pp. 1099-108. 
 
Harding, H. P. Zhang, Y, Ron, D. (1999). Protein translation and folding are coupled by 
an endoplasmic-reticulum-resident kinase. Nature.  397:6716. Pp. 271-4. 
 
Hart, M., Concordet, J-P., Lassot, I., Albert, I., del los Santos, R., Durand, H., Perret, C., 
Rubinfeld, B., Margottin F., Benarous, R. and Polakis, P. (1999). The F-box protein β-TrCP 
associates with phosphorylated β-catenin and regulates its activity in the cell. Curr Biol. 9:4. 
Pp. 207–211. 
 
Haze, K., Yoshida, H., Yanagi, H., Yura, T. and Mori, K. (1999). Mammalian transcription 
factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in 
response to endoplasmic reticulum stress. Mol Biol Cell. 10:11. Pp. 3787-99. 
 
He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., 
Vogelstein, B. and Kinzler, K. W. (1998). Identification of c-MYC as a target of 
the APC pathway. Science. 281:5382. Pp. 1509-1512. 
 
Henderson, B. R. (2000). Nuclear-cytoplasmic shuttling of APC regulates β-catenin 
subcellular localization and turnover. Nat Cell Biol. 2. Pp. 653 – 660. 
 
Hengstler, J. G., Lange, J., Kett, A., Dornhӧfer, N., Meinert, R., Arand, M., Knapstein, P. 
G., Becker, R., Oesch, F. and Tanner, B. (1999). Contribution of c-erbB-2 and 
 198 
 
topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res. 59:13. Pp. 3206-
14. 
 
Hetz, C. (2012). The unfolded protein response: controlling cell fate decisions under ER 
stress and beyond. Nat Rev Mol Cell Biol. 13. Pp. 89-102. 
 
Hetz, C., Chevet E. and Oakes S. A. (2015). Proteostasis control by the unfolded protein 
response. Nat Cell Biol. 17. Pp. 829–838. 
 
Hinck, L., Nelson, W. J. and Papkoff, J. (1994). Wnt-1 modulates cell-cell adhesion in 
mammalian cells by stabilizing beta-catenin binding to the cell adhesion protein cadherin. 
J Cell Biol. 124:5. Pp. 729-741. 
 
Hirschl, D., Bayer, P. and Muller, O. (1996). Secondary structure of and armadillo repeat 
from the APC protein. FEBS Lett. 383. Pp. 21-36. 
 
Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D. and Korsmeyer,  S. D. 
(1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell 
death. Nature.  348:6299. Pp. 334-6. 
 
Hollien, J. (2013). Evolution of the unfolded protein response. Biochim Biophys Acta. 
1833:11. Pp. 2458–2463. 
 
Hollien, J., Lin, J. H., Li, H., Stevens, N., Walter, P. and Weissman, J. S. (2009). Regulated 
 199 
 
Ire1-dependent decay of messenger RNAs in mammalian cells. J Cell Biol. 186:3. Pp. 323–
331. 
 
Horvitz, H. R. (1999). Genetic control of programmed cell death in the nematode 
Caenorhabditis elegans. Cancer Res. 59:7 Suppl. Pp. 1701s-1706s. 
 
Hoyt, M. A., Totis, A. and Roberts, T. (1991). S. cerevisiae Genes Required for Cell Cycle 
Arrest in Response to Loss of Microtubule Function. Cell. 66. Pp. 507-517. 
 
Hsu, J. Y., Sun, Z. W., Lix, X., Reuben, M., Tatchell, K., Bishop, D. K., Grushcow, J. M., 
Brame, C. J., Caldwell, J. A., Hunt, D. F., Lin, R., Smith, M. M. and Allis, C. D. (2000). 
Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 
phosphatase in budding yeast and nematodes. Cell. 102:3. Pp. 279-291. 
 
Hu, P., Han, Z., Couvillon, A. D., Kaufman, R. J. and Exton, J. H. (2006). Autocrine Tumor 
Necrosis Factor Alpha Links Endoplasmic Reticulum Stress to the Membrane Death 
Receptor Pathway through IRE1α-Mediated NF-κB Activation and Down-Regulation of 
TRAF2 Expression. Mol Cell Biol. 26:8. Pp. 3071–3084. 
 
Ideka, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S. and Kikuchi, A. (1998). Axin, 
a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta 
and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. 
EMBO. 17:5. Pp. 1371-84. 
 
 200 
 
Jaiswal, A. S., Balusu, R., Armas, M. L., Kundu, C. N. and Narayan, S. (2006). Mechanism 
of adenomatous polyposis coli (APC)-mediated blockage of long-patch base excision 
repair. Biochemistry. 45:51. Pp. 15903-14.  
 
Jaiswal, A. S., Panda, H., Pampo, C. A., Siemann, D. W., Gairola, C. G., Hromas, R. and 
Narayan, S. (2013). Adenomatous polyposis coli-mediated accumulation of 
abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation 
of normal breast epithelial cells. Neoplasia. 15:4. Pp. 454-60. 
 
Johnson, L.V., Walsh, M. L. and Chen, L.B. (1980). Localization of mitochondria in living 
cells with rhodamine 123. Proc. Natl. Acad. Sc. USA. 77:2. Pp. 990-994. 
 
Jϋrgensmeier, J. M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D. and Reed, J. C. (1998). 
Bax directly induces release of cytochrome c from isolated mitochondria. Proc. Natl. Acad. 
Sc. USA. 95:9. Pp. 4997–5002. 
 
Kaplan, K. B., Burds, A. A., Swedlow, J. R., Bekir, S. S., Sorger, P. K. and Näthke, I. S. 
(2001).  A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat 
Cell Biol. 3. Pp. 429–432. 
 
Karagianni, N., Ly, M-C., Psarras, S., Chilichlia, K., Schirrmacher, V., Gounari, F. and 
Khazaie, K. (2005). Novel adenomatous polyposis coli gene promoter is located 40 kb 
upstream of the initiating methionine. Genomics. 85:2. Pp. 231–2. 
 
 201 
 
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. 
S., Vogelstein, B. and Fornace Jr, A. J. (1992). A mammalian cell cycle checkpoint pathway 
utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71. Pp. 587–597. 
 
Kaufman, R. J. (2002). Orchestrating the unfolded protein response in health and disease. J 
Clin Invest. 110. Pp. 1389–1398. 
 
Kerr, J. F., Wyllie, A. H. and Currie, A. R. (1972). Apoptosis: a basic biological phenomenon 
with wide-ranging implications in tissue kinetics. Br J Cancer. 26:4. Pp. 239-257. 
 
Kim, I., Rodriquez-Enriquez, S. and Lemasters, J. J. (2007). Selective degradation of 
mitochondria by mitophagy. Arch Biochem Biophys. 462. Pp. 245–253. 
Kinzler, K. W. and Vogelstein, B. (1996). Lessons from Hereditary Colorectal Cancer. Cell. 
87:2. Pp. 159–170. 
 
Kinzler, K. W., Nilbert, M C., Su, L. K., Vogelstein, B., Bryan, T. M., Levy, D. B., Smith, K. 
J., Preisinger, A. C., Hedge, P. and  McKechnie, D. (1991). Identification of FAP locus 
genes from chromosome 5q21. Science. 253:5020. Pp. 661-5. 
 
Kita, K., Wittmann, T., Näthke, I. S. and Waterman-Storer, C. M. (2006). Adenomatous 
Polyposis Coli on Microtubule Plus Ends in Cell Extensions Can Promote Microtubule Net 
Growth with or without EB1. Mol Biol Cell. 17:5. Pp. 2331-2345. 
 
Kitagawa, M., Hatakeyama, S., Shirane, M., Matsumoto, M., Ishida, N. Hattori, K., 
 202 
 
Nakamichi, I., Kikuchi, A., Nakayama, K. and Nakayama, K. (1999). An F-box protein, 
FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO. 18:9. Pp. 2401-
10. 
 
Klotz, D. M., Nelson, S. A., Kroboth, K., Newton, I. P., Radulescu, S., Ridgway, R. A., 
Sansom, O. J., Appleton, P. L. and Näthke, I. S. (2012). The microtubule poison vinorelbine 
kills cells independently of mitotic arrest and targets cells lacking the APC tumour 
suppressor more effectively. J Cell Sci. 125(Pt 4). Pp. 887-95. 
 
Kluck, R. M., Bossy-Wetzel, E., Green, D. R. and Newmeyer, D. D. (1997). The Release of 
Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis. 
Science. 275:5303. Pp. 1132-1136. 
 
Klungland, A. and Lindahl, T. (1997). Second pathway for completion of human DNA base 
excision-repair: reconstitution with purified proteins and requirement for DNase IV (FEN1). 
EMBO. 16:11. Pp 3341-8. 
 
Kobe, B. and Kajava, A. V. (2001). The leucine-rich repeat as a protein recognition motif. 
Curr Opin Struct. Bio. 11:6. Pp 725–732. 
 
Konopleva, M., Watt, J., Contractor, R., Tsao, T., Harris, D., Estrov, Z., Bornmann, W., 
Kantarjian, H., Viallet, J., Samudio, I. and Andreeff, M. (2008). Mechanisms of Antileukemic 
Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax). Can. Res. 
68:9. Pp 3413-3420. 
 
 203 
 
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., 
Vogelstein, B. and Clevers, H. (1997). Constitutive Transcriptional Activation by a β-
Catenin-Tcf Complex in APC−/− Colon Carcinoma. Science. 275:5307. Pp. 1784-1787. 
 
Krajewski, S., Tanaka, S., Takayama, S., Schibler, M. J., Fenton, W. and Reed, J. C. 
(1993). Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the 
nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer 
Res. 53:19. Pp. 4701-14. 
 
Kroboth, K., Newton, I. P., Kita, K., Dikovskaya, D., Zumbrunn, J., Waterman-Storer, C. M. 
and Näthke, I. S. (2007). Lack of Adenomatous Polyposis Coli Protein Correlates with a 
Decrease in Cell Migration and Overall Changes in Microtubule Stability. Mol Biol Cell. 18:3. 
Pp. 910-918. 
 
Kroemer, G., El-Deiry, W. S., Golstein, P., Peter, M. E., Vaux, D., Vandenabeele, P., 
Zhivotovsky, B., Blagosklonny, M. V., Malorni, W., Knight, R. A., Piacentini, M., Nagata, S. 
and Melino, G. (2005). Classification of cell death: recommendations of the Nomenclature 
Committee on Cell Death. Cell Death Differ. 12. Pp. 1463–1467. 
 
 204 
 
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., 
Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., Hengartner, M., Knight, R. 
A., Kumar, S., Lipton, S. A., Malorni, W., Nunez, G., Peter, M. E., Tschopp, J., Yuan, J., 
Piacentini, M., Zhivotovsky, B. and Melino, G. (2009). Classification of cell death: 
recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 
16. Pp. 3–11. 
 
Kubota, Y., Nash, R. A., Klungland, A., Schar, P., Barnes, D. E. and Lindahl, T. (1996). 
Reconstitution of DNA base excision-repair with purified human proteins: interaction 
between DNA polymerase and the XRCC1 protein. EMBO. 15:23. Pp 6662-6670. 
 
Lallemand, Y., Luria, V., Haffner-Krausz, R. and Lonai, P. (1998). Maternally expressed 
PGK-Cre transgene as a tool for early and uniform activation of the Cre site-specific 
recombinase. Transgenic Res. 2. Pp. 105-12. 
 
Latres, E., Chjaur, D. S. and Pagano, M. (1999). The human F box protein beta-
Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. 
Oncogene. 18:4. Pp. 849-54. 
 
Lee, E., Salic, A., Kruger, R., Heinrich, R. and Kirschner, M. W. (2003). The roles of APC 
and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS 
Biol. 1. DOI: 10.1371/journal.pbio.0000010. 
 
Lee, H-C., Yin, P-H., Lu, C-Y., Chi, C-W. and Wei, W-H. (2000). Increase in mitochondria 
 205 
 
and mitochondrial DNA in response to oxidative stress in human cells. Biochem J. 348:2. 
Pp. 425-432. 
 
Lee, J. M., Lee, J. S., Kim, H., Kim, K., Park, H., Kim, J-Y., Lee, S. H., Kim, I. S., Kim, J., 
Lee, M., Chung, C. H., Seo, S-B., Yoon, J-B., Ko, E., Noh, D-Y., Jim, K. I. and Baek, S. H. 
(2012). EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 
E3 Ubiquitin Ligase Complex. Mol Cell. 48:4. Pp. 572–586. 
 
Lee, K., Tirasophon, W., Shen, X., Michalak, M., Prywes, R., Okada, T., Yoshida, H., Mori, 
K. and Kaufman, R. J. (2002). IRE1-mediated unconventional mRNA splicing and S2P-
mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein 
response. Genes Dev. 16. Pp. 452-466. 
 
Leibowitz, B., Qiu, W., Buchanan, M. E., Zou, F., Vernon, P., Moyer, M. P., Yin, Q. M., 
Schoen, R. E., Yu, J. and Zhang, L. (2014). BID mediates selective killing of APC-deficient 
cells in intestinal tumor suppression by nonsteroidal anti-inflammatory drugs. Proc Natl 
Acad Sci U S A. 111:46. Pp. 16520-16525. 
 
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S. and Korsmeyer, S. J. 
(2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving 
as prototype cancer therapeutics. Cancer Cell. 2:3. Pp. 183–192. 
 
Li, H., Zhu, H., Xu, C-J. and Yuan, J. (1998). Cleavage of BID by Caspase 8 Mediates the 
Mitochondrial Damage in the Fas Pathway of Apoptosis. Cell. 94. Pp. 491–501. 
Liao, P-C., Tan, S-K., Lieu, C-H. and Jung, H-K. (2008). Involvement of endoplasmic 
 206 
 
reticulum in paclitaxel-induced apoptosis. J Cell Biochem. 104:4. Pp. 1509–1523. 
 
Lindahl, T. (1974). An N-Glycosidase from Escherichia coli That Releases Free Uracil from 
DNA Containing Deaminated Cytosine Residues. Proc Natl Acad Sci U S A. 71:9. Pp 3649–
365. 
 
Lithgow, T., van Driel, R., Bertram, J. F. and Strasser, A. (1994). The protein product of the 
oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and 
the outer mitochondrial membrane. Cell Growth Differ. 5:4. Pp. 411-7. 
 
Liu, C. Y., Schroder, M. and Kaufman, R. J. (2000). Ligand-independent dimerization 
activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic 
reticulum. J Biol Chem. 275:32. Pp. 24881-5. 
 
Liu, C., Li, Y., Semenov, M., Han, C., Baeg, C-H., Tan, Y., Zhang, Z., Lin, X. and He, X. 
(2002). Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism. 
Cell. 108. Pp. 837–847. 
 
Liu, J., Xing, Y., Hinds, T. R., Zheng, J. and Xu, W. (2006). The third 20 amino acid repeat 
is the tightest binding site of APC for beta-catenin. J Mol Biol. 360. Pp. 133-144. 
 
Lobert, S., Vulevic, B. and Correia, J. J. (1996). Interaction of Vinca Alkaloids with Tubulin:  
A Comparison of Vinblastine, Vincristine, and Vinorelbine. Biochemistry. 35:21. Pp. 6806–
6814. 
Longely, M. J., Pierce, A. J. and Modrich, P. (1997). DNA Polymerase d Is Required for 
 207 
 
Human Mismatch Repair in Vitro. J Biol Chem. 272:16. Pp 10917–10921. 
 
Luo, X., Budihardjo, I., Zuo, H., Slaughter, C. and Wang, X. (1998). Bid, a Bcl2 Interacting 
Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of 
Cell Surface Death Receptors. Cell. 94. Pp. 481–490. 
 
Lupardus, P.J., Shen, A., Bogyo, M. and Gargia, K. C. (2008). Small Molecule-Induced 
Allosteric Activation of the Vibrio cholerae RTX Cysteine Protease Domain. Science. 322: 
5899. Pp. 265-268. 
 
Marciniak, S. J., Yun, C. Y., Oyadomari, S., Novoa, I., Zhang, Y., Jungreis, R., Nagata, K., 
Harding, H. P. and Ron, D. (2004). CHOP induces death by promoting protein synthesis 
and oxidation in the stressed endoplasmic reticulum. Genes Dev. 18. Pp. 3066-3077. 
 
Marshall, T. W., Lloyd, I. E., Delalande, J. M., Näthke, I. S. and Rosenblatt, J. (2011). The 
tumor suppressor adenomatous polyposis coli controls the direction in which a cell extrudes 
from an epithelium. Mol Biol Cell. 22:21. Pp. 3962-70. 
 
Matsumine, A., Ogai, A., Senda, T., Okumara, N., Satoh, K., Baeg, G-H., Kawahara, T., 
Kobayashi, S., Okada, M., Toyoshima, K. and Akiyama, T. (1996). Binding of APC to the 
Human Homolog of the Drosophila Discs Large Tumor Suppressor Protein. Science. 
272:5624. Pp. 1020-1023. 
 
McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P. and 
Korsmeyer, S. J. (1989). bcl-2-Immunoglobulin transgenic mice demonstrate extended B 
 208 
 
cell survival and follicular lymphoproliferation. Cell. 57:1. P.p 79–88. 
 
Mendez, A. S., Alfaro, J., Morales-Soto, M. A., Dar, A. C., McCullagh, E., Gotthardt, K., Li, 
H., Acosta-Alvear, D., Sidrauski, C., Korrenykh, A. V., Shokat, K. M and Water, P. (2015). 
Endoplasmic reticulum stress-independent activation of unfolded protein response kinases 
by a small molecule ATP-mimic. eLife. 4:e05434. 
 
Méniel, V., Megges, M., Young, M. A., Cole, A., Sansom, O. J. and Clarke, A. R. (2015). 
Apc and p53 interaction in DNA damage and genomic instability in hepatocytes. 
Oncogene. 34. Pp. 4118–4129. 
 
Merino, D., Khaw, S. L., Glaser, S. P., Anderson, D. J., Belmont, L. D., Wong, C., Yue, P., 
Robati, M., Phipson, B., Fairlie, W. D., Lee, E. F., Campbell, K. J., Vandenberg, C. J., Cory, 
S., Roberts, A. W., Ludlam, M. J. C., Huang, D. C. S., Bouillet, P. (2012). Bcl-2, Bcl-xL, and 
Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. 
Blood. 119:24. Pp. 5807-5816. 
 
Mimori-Kiyosue, Y., Shiina, N. and Tsukita, S. (2000). Adenomatous polyposis coli (APC) 
protein moves along microtubules and concentrates at their growing ends in epithelial cells. 
J Cell Biol. 148:3. Pp. 505-18. 
 
Mironov, S. L., Ivannikov, M. V. and Johansson, M. (2004). [Ca2+]i Signaling between 
Mitochondria and Endoplasmic Reticulum in Neurons Is Regulated by Microtubules FROM 
MITOCHONDRIAL PERMEABILITY TRANSITION PORE TO Ca2+-INDUCED 
Ca2+RELEASE. J Biol Chem. 280. Pp. 715-721. 
 
 209 
 
Mogensen, M. M., Tucker, J. B., Mackie, J. B., Prescott, A. R. and Näthke, I. S. (2002). The 
adenomatous polyposis coli protein unambiguously localizes to microtubule plus ends and 
is involved in establishing parallel arrays of microtubule bundles in highly polarized 
epithelial cells. J Cell Biol.  157:6. Pp. 1041-1048. 
 
Mori, Y., Nagse, H., Ando, H., Horii, A., Ichii, S., Nakatsuru, S., Aoki, T., Miki, Y., Mori, T. 
and Nakamura, Y. (1992). Somatic mutations of the APC gene in colorectal tumors: 
mutation cluster region in the APC gene. Hum Mol Genet. 1:4. Pp. 229-233. 
 
Morin, P. J., Vogelstein, B. and Kinzler, K. W. (1996). Apoptosis and APC in colorectal 
tumorigenesis. Proc Natl Acad Sci U S A.  93:15. Pp. 7950–7954. 
 
Moseley, J. B., Bartolini, F., Okada, K., Wen, Y., Gundersen, G. G. and Goode, B. L. (2007). 
Regulated Binding of Adenomatous Polyposis Coli Protein to Actin. J Biol Chem. 282. Pp. 
12661-12668. 
 
Muhua, L., Adames, N. R., Murphy, M. D., Shields, C. R. and Cooper, J. A. (1998). A 
cytokinesis checkpoint requiring the yeast homologue of an APC-binding protein. Nature. 
393:6684. Pp. 487-91. 
 
Munemitsu, S., Souza, B., Muller, O., Albert, I., Rubinfeld, B. and Polakis, P. (1994). 
The APC gene product associates with microtubules in vivo and promotes their assembly 
in vitro. Cancer Res. 54:14. Pp. 3676-81. 
 
Muῆos, J. P., Ivanova, S., Sánchez-Wandelmer, J., Martinez-Cristóbal, P., Noguera, E., 
 210 
 
Sancho, A., Diaz-Ramos, A., Hernández-Alvarez, M. I., Sebastián, D., Mauvezin, C., 
Palacin, M. and Zorzano, A. (2013). Mfn2 modulates the UPR and mitochondrial function via 
repression of PERK. EMBO. 32. Pp. 2348-2361. 
 
Nagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B. A. and Yuan, J. (2000). 
Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by 
amyloid- . Nature. 403. Pp. 98-103. 
 
Nakamura, T., Hamada, F., Ishidate, T., Anai, K-I., Kawahara, K., Toyoshima, K. and 
Akiyama, T. (1998). Axin, an inhibitor of the Wnt signalling pathway, interacts with β-
catenin, GSK-3β and APC and reduces the β-catenin level. Genes Cells. 3:6. Pp. 395–403. 
 
Narayan, S. and Jaiswal, A.S. (1997). Activation of adenomatous polyposis coli (APC) gene 
expression by the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine requires p53. 
J Biol Chem. 272:49. Pp. 30619-22. 
 
Narayan, S., Jaiswal, A. S. and Balusu, R. (2005). Tumor Suppressor APC Blocks DNA 
Polymerase-dependent Strand Displacement Synthesis during Long Patch but Not Short 
Patch Base Excision Repair and Increases Sensitivity to Methylmethane Sulfonate. J Biol 
Chem. 280:8. Pp. 6942–6949. 
 
Nash, P., Tang, X., Orlicky, S., Chen, Q., Gertler, F. B., Mendenhall, M. D., Sicheri, F., 
Pawson, T. and Myers, M. (2001). Multisite phosphorylation of a CDK inhibitor sets a 
threshold for the onset of DNA replication. Nature. 414:6863. Pp. 514-21. 
 211 
 
Nelson, S. A., Li, Z., Newton, I. P., Fraser, D., Milne, R. E., Martin, D. M., Schiffmann. D., 
Yang, X., Dormann, D., Weijer, C. J., Appleton, P. L. and Näthke, I. S. (2012). Tumorigenic 
fragments of APC cause dominant defects in directional cell migration in multiple model 
systems. Dis Model Mech. 5. Pp. 940-947. 
 
Nelson, S. and Näthke, I.S., (2013). Interactions and functions of the adenomatous 
polyposis coli (APC) protein at a glance. J Cell Sci. 126. Pp. 873-877. 
 
Neufeld, K. L. and White, R. L. (1997). Nuclear and cytoplasmic localizations of 
the adenomatous polyposis coli protein. Proc Natl Acad Sci U S A.  94:7. Pp. 3034-9. 
 
Neufeld, K. L., Nix, D. A., Bogerd, H., Kang, Y., Beckerle, M. C., Cullen, B. R. and White, 
R. L. (2000). Adenomatous polyposis coli protein contains two nuclear export signals and 
shuttles between the nucleus and cytoplasm. Proc. Natl. Acad. Sc. USA. 97:22. Pp. 12085–
12090. 
 
Newton, I. P., Kenneth, N. S., Appleton, P. L., Näthke, I. S. and Rocha, S. (2010). 
Adenomatous polyposis coli and hypoxia-inducible factor-1{alpha} have an antagonistic 
connection. Mol Biol Cell. 21:21. Pp. 3630-3638. 
 
Nguyen, M., Millar, D. G., Yong, V. W., Korsmeyer, S. J. and Shore, G. C. (1993). Targeting 
of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. 
J Biol Chem. 268. Pp. 25265-25268. 
 
Nikawa, J. and Yamashita, S. (1992). IRE1 encodes a putative protein kinase containing a 
 212 
 
membrane-spanning domain and is required for inositol phototrophy in Saccharomyces 
cerevisiae. Mol Microbiol. 6. Pp. 1441-1446. 
 
Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T. and Kanemaki, M. (2009). An 
auxin-based degron system for the rapid depletion of proteins in nonplant cells. Nat 
Methods. 6:12. Pp. 917-923. 
 
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. 
A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., Joseph, M. K., Kitada, S., 
Korsmeyer, S. J., Kunzer, A. R., Letai, A., Li, C., Mitten, M. J., Nettesheim, D. G., Ng, S., 
Nimmer, P. M., O’Connor, J. M., Oleksijew, A., Petros, A. M., Reed, J. C., Tahir, S. K., 
Thompson, C. B., Tomaselli, K. J., Wang, B., Wendt, M, D., Zhang, H., Fesik, S. W. and 
Rosenberg, S. H. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid 
tumours. Nature. 435:7042. Pp. 677-81. 
 
Oltvai, Z. N., Milliman, C. L. and Korsmeyer, S. J. (1993). Bcl-2 Heterodimerizes In Vivo 
with a Conserved Homolog, Bax, That Accelerates Programed Cell Death. Cell. 74:4. Pp. 
609-619. 
 
Oshima, M., Oshima, H., Kitagawa, K., Kobayashi, M., Itakura, C. and Taketo, M. (1995). 
Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice 
carrying a truncated Apc gene. Proc. Natl. Acad. Sci. USA. 92. Pp. 4482-4486. 
 
Penman, G. A., Leung, L. and Näthke, I. S. (2005). The adenomatous polyposis coli protein 
(APC) exists in two distinct soluble complexes with different functions. J Cell Sci.  118:20. 
Pp. 4741-50. 
 213 
 
Perez-Galan, P., Roue, G., Lopez-Guerra, M., Nguyen, M., Villamor, N., Montserrat, E., 
Shore, G. C., Campo, E. and Colomer, D. (2008). BCL-2 phosphorylation modulates 
sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction 
with bortezomib in chronic lymphocytic leukemia cells. Leukemia. 22:9. Pp 1712-20. 
 
Petros, A. M., Medek, A., Nettesheim, D. G., Kim, D. H., Yoon, H. S., Swift, K., Matayoshi, 
E. D., Oltersdorf, T. and Fesik, S. W. (2001). Solution structure of the antiapoptotic protein 
bcl-2. Proc Natl Acad Sci U S A. 9:6. Pp. 3012–3017. 
 
Polakis, P. (2012). Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 4:5. 
Doi: 10.1101/cshperspect.a008052. 
 
Porter, E.M., Bevins, C.L., Ghosh, D. and Ganz, T. (2002). The multifaceted Paneth 
cell. Cell Mol Life Sci. 59. Pp. 156–170. 
 
Potten, C. S. and Loeffler, M. (1990). Stem cells: attributes, cycles, spirals, pitfalls and 
uncertainties Lessons for and from the Crypt. Development. 110 .Pp. 1001-1020. 
 
Quintana, A., Schwarz, E. C., Schwindling, C., Lipp, P., Kaestner, L. and Hoth, M. (2006). 
Sustained Activity of Calcium Release-activated Calcium Channels Requires Translocation 
of Mitochondria to the Plasma Membrane. J Biol Chem. 281. Pp 40302-40309. 
 
Radulescu, S., Ridgway, R. A., Appleton, A., Kroboth, K., Patel, S., Woodgett, J., Taylor, 
S., Nathke, I. S. and Sansom, O. J. (2010). Defining the role of APC in the mitotic spindle 
 214 
 
checkpoint in vivo: APC-deficient cells are resistant to Taxol. Oncogene. 29:49. Pp 6418-
27.  
 
Rafelski, S. M., Viana, M. P., Zhang, Y., Chan, Y-H. M., Thorn, K. S., Yam, P., Fung, J. C., 
Li, H., Costa, L da F. and Marshall, W. F. (2012). Mitochondrial Network Size Scaling in 
Budding Yeast. Science. 338:6108. Pp. 822-824. 
 
Rao, R. V., Hermel, E., Castro-Obregon, S., del Rio, G., Ellerby, L. M., Ellerby, H. M. and 
Bredesen, D. E. (2001). Coupling Endoplasmic Reticulum Stress to the Cell Death 
Program: MECHANISM OF CASPASE ACTIVATION. J Biol Chem. 276. Pp.  33869-33874. 
 
Rao, S., Krauss, N. E., Heerding, J. M., Swindell, C. S., Ringel, I., Orr, G. A. and Horwitz, 
S. B. (1994). 3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-
tubulin. J Biol Chem. 269:5. Pp. 3132-3134. 
 
Reed, E. (1998). Platinum-DNA adduct, nucleotide excision 
repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 24:5. Pp. 331-44. 
 
Rohlin, A., Engwall, Y., Fritzell, K., Gӧransson, K., Bergsten, A., Einbeigi, Z., Nilbert, M., 
Karlsson, P., Bjӧrk, J. and Nordling, M. (2011). Inactivation of promoter 1B of APC causes 
partial gene silencing: evidence for a significant role of the promoter in regulation and 
causative of familial adenomatous polyposis. Oncogene.  30:50. Pp. 4977-89. 
 
Rouschop, K. M., van den Beucken, T., Dubois, L., Niessen, H., Bussink, J., Savelkouls, J., 
Keulers, T., Mujcic, H., Landuyt, W., Vonckem J. W., Lambin, P., van der Kogel, A. J., 
 215 
 
Koritzinsky, M. and Wouters, B. G. (2009). 
The unfolded protein response protects human tumor cells during hypoxia through regulat
ion of the autophagy genes MAP1LC3B and ATG5. J Clin Invest. 120:1. Pp. 127-141. 
Rouse, J. and Jackson, S. P. (2002). Interfaces between the detection, signaling, and repair 
of DNA damage. Science. 297:5581. Pp. 547-51. 
 
Rowan, A. J., Lamlum, H., Ilyas, M., Wheeler, J., Straub, J., Papadopoulou, A., Bicknell, 
D., Bodmer, W. F. and Tomlinson, I. P. M. (2000). APC mutations in sporadic colorectal 
tumors: A mutational ‘‘hotspot’’ and interdependence of the ‘‘two hits’’. Proc Natl Acad Sci 
U S A. 97:7. Pp. 3352-3357. 
 
Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S. and Polakis, P. (1996). Binding 
of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly. Science. 
272:5264. Pp. 1023-1026. 
 
Rubinfeld, B., Souza, B., Albert, I., Muller, O., Chamberlain, S.H., Masiarz, F.R., 
Munemitsu, S. and Polakis, P. (1993). Association of the APC gene product with beta-
catenin. Science. 262:5140. Pp. 1731–1734. 
 
Rubinfeld, B., Tice, D. A. and Polakis, P. (2001). Axin-dependent phosphorylation of the 
Adenomatous Polyposis Coli protein mediated by casein kinase 1ϵ. J Biol Chem. 276. Pp. 
39037–39045. 
 
Ryan, J. A., Brunelle, J. K. and Letai, A. (2010). Heightened mitochondrial priming is the 
basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc. Natl Acad. Sci. 
USA. 107. Pp. 12895–12900. 
 216 
 
Santoro, I. M. and Groden, J. (1997). Alternative splicing of the APC gene and its 
association with terminal differentiation. Cancer Res.  57:3. Pp. 488-94. 
 
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van 
Es, J. H., Abo, A., Kujala, P., Peters, P.J. and Clevers, H. (2009).  Single Lgr5 stem cells 
build crypt–villus structures in vitro without a mesenchymal niche. Nature. 459:7244. Pp. 
262-5 
 
Schendel, S. L., Montal, M. and Reed, J. C. (1998). Bcl-2 family proteins as ion-channels. 
Cell Death Differ. 5. Pp. 372-380. 
 
Schendel, S. L., Xie, Z., Montal, M. O., Matsuyama, S., Montal, M. and Reed, J. C. (1997). 
Channel formation by antiapoptotic protein Bcl-2. Proc. Natl. Acad. Sci. USA. 94. Pp. 5113–
5118. 
 
Schiff, P. B., Fant, J. and Horwitz, S. B. (1979).  
Promotion of microtubule assembly in vitro by taxol. Nature. 277:2598. Pp. 665-667. 
 
Schiff, P. B. and Horwitz, S. B. (1980). Taxol stabilizes microtubules in mouse fibroblast 
cells. Proc Natl Acad Sci U S A. 77. Pp. 1561–1565. 
 
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., 
Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J., Hartenstein, 
V., Eliceiri, K., Tomancak, P. and Cardona, A. (2012). Fiji: an open-source platform for 
biological-image analysis. Nat Methods.  9:7. Pp. 676-82.  
 
 217 
 
Schindler, A. J. and Schekman, R. (2009). In vitro reconstitution of ER-stress induced ATF6 
transport in COPII vesicles. Proc Natl Acad Sci U S A. 106:42. Pp. 17775-80. 
 
Schlesinger, P. H., Gross, A., Yin, X. M., Yamamoto, K., Saito, M., Waksman, G. and 
Korsmeter, S. J. (1997). Comparison of the ion channel characteristics of proapoptotic BAX 
and antiapoptotic BCL-2. Proc Natl Acad Sci USA. 94. Pp. 11357-11362. 
 
Sena, P., Saviano, M., Monni, S., Losi, L., Roncucci, L., Marzona, L. and De Pol, A. (2006). 
Subcellular localization of beta-catenin and APC proteins in colorectal preneoplastic and 
neoplastic lesions. Cancer Lett. 241:2. Pp. 203-12. 
 
Senft, D. and Ronai, Z. A. (2015). UPR, autophagy, and mitochondria crosstalk underlies 
the ER stress response. Trend. Biochem Sci. 40:3. Pp. 141–148. 
 
Shamu, C. E. and Walter, P. (1996). Oligomerization and phosphorylation of the Ire1p 
kinase during intracellular signaling from the endoplasmic reticulum to the nucleus. EMBO. 
15:12. Pp. 3028–3039. 
 
Sheridan, R. B. 3rd and Huang, P. C. (1977). Single strand breakage and repair in 
eukaryotic DNA as assayed by S1 nuclease. Nucleic Acids Res. 4:2. Pp. 299-318. 
 
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R. and Ben-
Ze’Ev, A. (1999). The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc 
Natl Acad Sci U S A.  96:10. Pp. 5522-5527. 
 218 
 
Siddik, K. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. 
Oncogene. 22. Pp. 7265–7279. 
 
Sirbu, B. M., McDonald, W. H., Dungrawala, H., Badu-Nkansah, A., Kavanaugh, G. M., 
Chen, Y., Tabb, D. L. and Cortez, D. (2013). Identification of Proteins at Active, Stalled, and 
Collapsed Replication Forks Using Isolation of Proteins on Nascent DNA (iPOND) Coupled 
with Mass Spectrometry. J Biol Chem. 288:44. Pp. 31458–31467. 
 
Skaar, J.R., Pagan, J. K. and Pagano, M. (2013). Mechanisms and function of substrate 
recruitment by F-box proteins. Nat Rev Mol Cell. Biol. 14. Pp. 369-381. 
 
Smaili, S. S., Hsu, Y. T., Sanders, K. M., Russell, J. T. and Youle, R. J. (2001). 
Bax translocation to mitochondria subsequent to a rapid loss of mitochondrial membrane 
potential. Cell Death Differ. 8:9. Pp. 909-20. 
 
Smiley, S.T., Reers, M., Motolla-Hartshorn, C., Lin, M., Chen, A., Smith, T. W., Steele Jr, 
J. D., Chen, L. B. (1991). Intracellular heterogeneity in mitochondrial membrane potentials 
revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A. 88:9. 
Pp. 3671-5. 
 
Smith, K. J., Levy, D. B., Maupin, P., Pollard, T. D., Vogelstein, B. and Kinzler, K. W. (1994). 
Wild-type but not mutant APC associates with the microtubule cytoskeleton. Cancer 
Res. 54:14. Pp. 3672-5. 
 
 219 
 
Sofer, A., Lei, K., Johannessen, C. M. and Ellisen, L. W. (2005). Regulation of mTOR and 
Cell Growth in Response to Energy Stress by REDD1. Mol Cell Biol. 25:14. Pp. 5834–5845. 
 
Song, J. H., Kandasamy, K., Zemskova, M., Lin, Y-W. and Kraft, A. S. (2011). The BH3 
Mimetic ABT-737 Induces Cancer Cell Senescence. Cancer Res. 71:2. Pp. 506–515. 
 
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., 
Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., Huang, D. C., Hymowitz, S. 
G., Jin, S., Khaw, S. L., Kovar, P. J., Lam, L. T., Lee, J., Maecker, H. L., Marsh, K. C., 
Mason, K. D., Mitten, M. J., Nimmer, P. M., Oleksijew, A., Park, C. H., Park, C. M., Phillips, 
D. C., Roberts, A.W., Sampath, D., Seymour, J. F., Smith, M. L., Sullivan, G. M., Tahir, S. 
K., Tse, C., Wendt, M. D., Xiao, Y., Xue, J. C., Zhang, H., Humerickhouse, R.A., Rosenberg, 
S. H. and Elmore, S. W. (2013). Nat Med.19:2. Pp.202-208. 
 
Srivastava, S. P., Davies, M. V. and Kaufman, R. J. (1995). Calcium Depletion from the 
Endoplasmic Reticulum Activates the Double-stranded RNA-dependent Protein Kinase 
(PKR) to Inhibit Protein Synthesis. J Biol Chem. 270. Pp. 16619-16624. 
 
Steffensen, I. L., Paulsen, J. E., Eide, T. J. and Alexander, J. (1997) 2-Amino-l-methyl-6-
phenylimidazo[4,5-b]pyridine increases the numbers of tumors, cystic crypts and aberrant 
crypt foci in multiple intestinal neoplasia mice. Carcinogenesis. 18. Pp. 1049–1054. 
 
 220 
 
Stephens, S. G. (1961). 
Recombination between Supposedly Homologous Chromosomes of Gossypium Barbade
nse L. and G.Hirsutum L. Genetics. 11. Pp. 1483-1500. 
 
Strasser, A., Harris, A. W. and Cory, S. (1991). Bcl-2 transgene inhibits T cell death and 
perturbs thymic self-censorship. Cell. 67. Pp. 889–899. 
 
Su, L. K., Kinzler, K. W., Vogelstein, B., Preisinger, A. C., Moser, A. R., Luongo, C., Gould, 
K. A. and Dove, W. F. (1992). Multiple intestinal neoplasia caused by a mutation in the 
murine homolog of the APC gene. Science. 256:5057. Pp. 668-670. 
 
Su, L. K., Vogelstein, B and Kinzler, K. W. (1993). Association of the APC tumor suppressor 
protein with catenins. Science 262:5140. Pp. 1734–1737.  
 
Su, L-K., Johnson, K. A., Smith, K. J., Hill, D. E., Vogelstein, B., Kinzler, K. W. (1993). 
Association between Wild Type and Mutant APC Gene Products. Cancer Res. 53. Pp. 
2728-2731. 
 
Sudhakar, A., Ramachandran, A., Ghosh, S., Hasnain, S. E., Kaufman, R. J. and Ramaiah, 
K. V. (2000). Phosphorylation of serine 51 in initiation factor 2 alpha (eIF2 alpha) promotes 
complex formation between eIF2 alpha(P) and eIF2B and causes inhibition in the guanine 
nucleotide exchange activity of eIF2B. Biochemistry. 39:42. Pp. 12929-38. 
 
Sun, F-C., Wei, S., Li, C-W., Chang, Y-S., Chao, C-C. and Lai, Y-K. (2006). Localization of 
 221 
 
GRP78 to mitochondria under the unfolded protein response. Biochem J. 396. Pp. 31–39. 
 
Swiger, B., Patel, M., Pastukh, V., Gillespie, M. N. and Al-Mehdi, A. B. (2008). Hypoxia 
causes perinuclear mitochondrial clustering and nuclear oxidant stress in pulmonary artery 
endothelial cells (PAECS) via a dynein-dependent molecular motor. FASEB J. 22. Pp. 
1174-1176. 
 
Tameire, F., Verginadis, I. I. and Koumenis, C. (2015). Cell intrinsic and extrinsic activators 
of the unfolded protein response in cancer: Mechanisms and targets for therapy. Semin 
Cancer Biol. 33. Pp. 3–15. 
 
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M. 
and Zheng, N. (2007). Mechanism of auxin perception by the TIR1 ubiquitin ligase. 
Nature. 446. Pp. 640-645. 
 
Tartaglia, L. A., Ayres, T. M., Wong, G. H. W. and Goeddel, D. V. (1993). A novel domain 
within the 55 kd TNF receptor signals cell death. Cell. 74:5. Pp. 845–853. 
 
Tetsu, O. and McCormick, F. (1999). Beta-catenin regulates expression of cyclin D1 in 
colon carcinoma cells. Nature. 398:6726. Pp. 422-426. 
 
Thliveris, A., Samowitz, W., Matsunami, N., Groden, J. and White, R. (1994). 
Demonstration of promoter activity and alternative splicing in the region 5' to exon 1 of 
the APC gene. Cancer Res. 54:11. Pp. 2991-5. 
 
 222 
 
Thode, S., Schafer, A., Pfeiffer, P. and Vielmetter, W. (1990). A novel pathway of DNA end-
to-end joining. Cell. 60:6. Pp. 921-928. 
 
Tibbetts, R. S., Brumbaugh, G. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S. 
Y., Taya, Y., Prives, C. and Abraham, R. T. (1999). A role for ATR in the DNA damage-
induced phosphorylation of p53. Genes Dev. 13:2. Pp. 152-7. 
 
Tickenbrock, L., Kossmeier, K., Rehmann, H., Herrmann, C. and Muller, O. (2003). 
Differences between the interaction of beta-catenin with non-phosphorylated and single-
mimicked phosphorylated 20-amino acid residue repeats of the APC protein. J Mol 
Biol. 327: 359–367.  
 
Trudel, S., Li, Z. H., Rauw, J, Tiedemann, R. E., Wen, X. Y. and Stewart, A. K. (2007).  
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. 
Blood. 109:12. Pp 5430-8. 
 
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., 
Marsh, K. C., Mitten, M. J., Nimmer, P., Roberts, L., Tahir, S. K., Xiao, Y., Yang, X., Zhang, 
H., Fesik, S., Rosenberg, S. H. and Elmore, S. W. (2008). ABT-263: A Potent and Orally 
Bioavailable Bcl-2 Family Inhibitor. Can. Res. 68. Pp 3421. 
 
 
Vaillant, F., Merino, D., Lee, L., Breslin, K., Pal, B., Ritchie, M. E., Smyth. G. K., Christie, 
M., Phillipson, L. J., Burns, C. J., Mann, G. B., Visvader, J. E. and Lindeman, G. J. (2013). 
 223 
 
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast 
Cancer. Cancer Cell. 24:1. Pp 120–129.  
 
Van de Wetering, M., Cavallo, R., Dooijes, D., van Beest, M., van Es, J., Loureiro, J., Ypma, 
A., Hursh, D., Jones, T., Bejsovec, A., Peifer, M., Mortin, M. and Clevers, H. (1997). 
Armadillo Coactivates Transcription Driven by the Product of the Drosophila Segment 
Polarity Gene dTCF. Cell. 88. Pp. 789–799. 
 
Van der Heijden, M., Zimberlin, C. D., Nicholson, A. M., Colak, S., Kemp. R., Meijer, S. L., 
Medema, J. P., Gretan, F. R., Jansen, M., Winton, D. J. and Vermeulen, L. (2016). Bcl-2 is 
a critical mediator of intestinal transformation. Nat Commun. 7:10916. DOI: 
10.1038/ncomms10916. 
 
Vander Heiden, M. G., Chandel, N. S., Li, X. X., Schumaker, P. T., Colombini, M. amd 
Thompson, C. B. (2000). Outer mitochondrial membrane permeability can regulate coupled 
respiration and cell survival. Proc Natl Acad Sci U S A. 97:9. Pp. 4666–4671. 
 
Vazquez, G., Wedel, B. J., Bird, G. J., Joseph, S. K. and Putney, J. W. (2002). An inositol 
1,4,5‐trisphosphate receptor‐dependent cation entry pathway in DT40 B lymphocytes. EMBO. 
21:17. Pp. 4393 – 4748. 
 
Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, 
R. L., Simpson, R. J. and Vaux, D.L. (2000) Identification of DIABLO, a mammalian protein 
that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 102. Pp. 43–53. 
 224 
 
Villunger, A., Michalak, E. M., Coultas, L., Mullauer, F., Bock, G., Ausserlechner, M. J., 
Adams, J. M. and Strasser, A. (2003). p53- and Drug-Induced Apoptotic Responses 
Mediated by BH3-Only Proteins Puma and Noxa. Science. 302:5647. Pp. 1036-1038. 
 
Walker, I. G. and Sridhar, R. (1976). The formation and repair of single-strand breaks in 
DNA of cultured mammalian cells treated with UV-light, methylating agents or 4-
nitroquinoline-1-oxide. Chem Biol Interact. 12. Pp. 229-39. 
 
Wang, Y., Azuma, Y., Moore, D., Osheroff, N. and Neufeld, K. L. (2008). Interaction 
between tumor suppressor adenomatous polyposis coli and topoisomerase IIalpha: 
implication for the G2/M transition. Mol Biol Cell. 19:10. Pp. 4076-4085. 
 
Wang, Y., Coffey, R. J., Osheroff, N., Neufeld, K. L. (2010). Topoisomerase IIalpha binding 
domains of adenomatous polyposis coli influence cell cycle progression and aneuploidy. 
PLoS One. 5:4. e9994. 
 
Wildenberg, J. and Meselson, M. (1975). Mismatch repair in heteroduplex DNA. Proc Natl 
Acad Sci U S A. 72:6. Pp. 2202-2206 
 
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C, Y., Elledge, S. J. and Harper, J. W. 
(1999). The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with 
phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates 
IkappaBalpha ubiquitination in vitro. Genes Dev. 13:3. Pp. 270-83. 
 
Wolter, K. G., Hsu, Y. T., Smith, C. L., Nechushtan, A., Si, X. G. and Youle, R. J. (1997). 
 225 
 
Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol. 139:5. Pp. 
1281-92. 
 
Wroblewski, D., Jiang, C. C., Croft, A., Farrelly, M. L., Zhang, X. D. and Hersey, P. (2013). 
OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that 
limit induction of apoptosis. PLoS ONE. 8:12. e84073. doi:10.1371/journal.pone.0084073. 
 
Xing, Y., Clements, W. K., Le Trong, I., Hinds, T. R., Stenkamp, R., Kimelman, D. and Xu, 
W. (2004). Crystal structure of a beta-catenin/APC complex reveals a critical role for APC 
phosphorylation in APC function. Mol Cell. 15:4. Pp. 523-533. 
 
Yamamoto, K., Sato, T., Matsui, T., Okada, T., Yoshida, H., Harada, A. and Mori, K. (2007). 
Transcriptional Induction of Mammalian ER Quality Control Proteins Is Mediated by Single 
or Combined Action of ATF6α and XBP1. Dev Cell. 13:3. Pp. 365–376. 
 
Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T. I., Jones, D. P. and 
Wang, X. (1997). Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from 
Mitochondria Blocked. Science. 275:5303. Pp .1129-1132. 
 
Ye, J., Rawson, R. B., Komuro, R., Chen, X., Dave, U. P., Prywes, R., Brown, M. S. and 
Goldstein, J. L. (2000). ER stress induces cleavage of membrane-bound ATF6 by the same 
proteases that process SREBPs. Mol Cell. 6:6. Pp. 1355-64. 
 
Yen, H-C. S., Xu, G., Chou, D. M., Zhao, Z. and Elledge, S. J. (2008). Global Protein 
Stability Profiling in Mammalian Cells. Science. 322:5903. Pp. 918-923. 
 226 
 
Yilmaz, G. and Arslanyolu, M. (2015). Efficient expression of codon-adapted affinity 
tagged super folder green fluorescent protein for synchronous protein localization 
and affinity purification studies in Tetrahymena thermophila. BMC Biotechnology. 
15:22. doi: 10.1186/s12896-015-0137-9. 
 
Yin, X-M., Oltvai, Z. N and Korsmeyer, S.J. (1994). BH1 and BH2 domains of Bcl-2 are 
required for inhibition of apoptosis and heterodimerization with Bax. Nature. 369. Pp. 321 – 
323. 
 
Yoshida, H., Matsui, T., Yamamoto, A., Okada, T. and Mori, K. (2001). XBP1 mRNA Is 
Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active 
Transcription Factor. Cell. 107:7. Pp. 881–891. 
 
Yoshida, Y., Chiba, T., Tokunaga, F., Kawasaki, H., Iwai, K., Suzuki, T., Ito, Y., Matsuoka, 
K., Yoshida M., Tanaka K. and Tadaski, T. (2002). E3 ubiquitin ligase that recognizes sugar 
chains. Nature. 418. Pp. 438-442. 
 
Zha, H., Aimé-Sempé, C., Sato, T. and Reed, J, C. (1996). Proapoptotic Protein Bax 
Heterodimerizes with Bcl-2 and Homodimerizes with Bax via a Novel Domain (BH3) Distinct 
from BH1 and BH2. J Biol Chem. 271. Pp. 7440-7444. 
 
Zhang, J. H. and Xu, M. (2000). DNA fragmentation in apoptosis. Cell Res. 10. Pp. 205–
211. 
 
Zinszner, H., Kuroda, M., Wang, X. Z., Batchvarova, N., Lightfoot, R. T., Remotti, H., 
 227 
 
Stevens, J. L. and Ron, D. (1998). CHOP is implicated in programmed cell death in 
response to impaired function of the endoplasmic reticulum. Genes Dev. 12. Pp. 982-995. 
Zumbrunn, J., Kinoshita, K., Hyman, A. A. and Näthke, I. S. (2001). Binding of the 
adenomatous polyposis coli protein to microtubules increases microtubule stability and is 
regulated by GSK3β phosphorylation. Curr Biol. 11:1. Pp. 44–49. 
  
 228 
 
Appendix 
 
Appendix A 
 
Wnt Target Genes – Nusse lab, Stanford (June 2015) 
 Gene  Organism/system  Direct? Transcription  Reference(s) 
Axin-2 human colon cancer yes up 
Yan, 2001 
Lustig, 2002 
Jho, 2002 
betaTrCP   
Independent of 
transcription 
up 
 Spiegelman 
2000 
BMP4 human colon cancer ? up Kim, 2002  
BMP4 Xenopus ? down Baker, 1999  
Brachyury  Mouse (Wnt-3A) yes up 
Yamaguchi, 1999 
Arnold, 2000 
c-jun human colon cancer yes up Mann B, 1999  
c-myc human colon cancer yes up He, 1998  
c-myc binding 
protein 
human colon cancer yes up Jung, 2005  
Cacna1g Neuron  up Wisniewska, 2010  
CCN1/Cyr61 Osteoblasts  up Si, 2006  
CD44 human colon cancer ? up Wielenga, 1999  
Cdx1 Mouse embryo   Pilon, 2007  
Cdx1 Mouse Wnt-3A yes up  Lickert, 2000  
Cdx4 Mouse Wnt-3A   Pilon, 2006  
Cdx4 Zebrafish HSC ? up Davidson, 2003  
claudin-1 human colon cancer yes up Miwa, 2002  
connexin 30 Xenopus ?  McGrew, 1999  
connexin43 Xenopus, Mouse yes up 
van der Heyden, 
1999  
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connexin43 rat cardiomyocytes ? up Ai, 2000  
CTLA-4 Melanomas yes up Shah, 2008  
Cyclin D human colon cancer yes up 
Tetsu, 1999 
Shtutman, 1999 
Disputed 
by Sansom, 2005 
cyclooxygena
se-2 
mouse (Wnt-1) ? up 
Howe, 1999 
Haertel-
Wiesmann, 2000 
Delta-like 1 somites   
Galceran, 2004 
Hofmann, 2004 
Dfrizzled2 Drosophila ? down Cadigan, 1998  
dharma/bozoz
ok 
Zebrafish yes up Ryu, 2001  
Dickkopf Various cells, tumours  up 
Niida, 2004 
Gonzalez-
Sancho, 2004 
Chamorro, 2004 
Dpp Drosophila yes down Yang, 2000  
E-cadherin Mouse hair follicle yes down Jamora, 2003  
E-cadherin ES/EB  down Ten Berge, 2008  
Eda (TNF-
related) 
Mouse hair follicle ? up 
Laurikkala, 2002 
Durmowicz, 2002 
EGF receptor Liver  up Tan, 2005  
endothelin-1 human colon cancer  up Kim, 2004  
Engrailed Drosophila ? up Hooper, 1994  
engrailed-2 Xenopus yes up McGrew, 1999  
EphB/ephrin-
B 
human colon cancer ? up/down Batlle, 2002  
FGF18 human colon cancer yes up Shimokawa, 2003  
FGF20 Various cells, tumours   Chamorro, 2004  
FGF4 Mouse tooth bud yes up Kratochwil, 2002  
FGF9 
ovarian endometrioid 
adenocarcinoma 
 up Hendrix, 2006LB 
 230 
 
Fibronectin ES/EB  up Ten Berge, 2008  
Fibronectin Mouse lung  up De Langhe, 2005  
fibronectin Xenopus yes up Gradl, 1999  
Follistatin EC cells, ovary yes up 
Willert, 2002 
Yao, 2004 
FoxN1 thymus ? yes Balciunaite, 2002  
fra-1 human colon cancer yes up Mann B, 1999  
Frizzled 7 EC cells yes up Willert, 2002  
Gastrin human colon cancer ? up Koh, 2000  
Gbx2 Neural Crest yes up Li, 2009  
Gremlin fibroblasts  up 
Klapholz-Brown, 
2007  
Hath1 human colon cancer .. down Leow, 2004  
Id2 human colon cancer yes up 
Rockman, 2001 
Willert, 2002 
Interleukin8 Endothelial cells   
Masckauchan, 
2005  
Irx3 and Six3 Mouse brain   Braun, 2003  
Islet1 Cardiac cells  up Lin, 2007  
ITF-2 human colon cancer yes up Kolligs, 2002  
Jagged human colon cancer  up Rodilla, 2009  
Jagged1 Mouse hair follicle  up Estrach, 2006  
Keratin Mouse hair follicle yes up Dasgupta, 1999  
L1 neural 
adhesion 
human colon cancer  up Gavert, 2005  
LBH breast cancer  up Rieger, 2010  
LEF1 human colon cancer yes up 
Hovanes, 2001 
Filali, 2002 
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LGR5/GPR49 Intestine yes up Barker, 2007  
matrix 
metalloprotein
ase MMP-7 
human colon cancer yes up 
Brabletz, 1999 
Crawford, 1999 
matrix 
metalloprotein
ase-26 
Human   Marchenko, 2002  
mBTEB2  Mouse 
Independent β-
catenin 
up Ziemer, 2001  
Met human colon cancer  up Boon, 2002  
MITF/nacre Zebrafish yes up 
Dorsky, 2000 
Saito, 2002 
Yasumoto, 2002 
MMP2, MMP9 T cells   Wu, 2007  
movo1 Mouse hair follicle yes up Li, 2002  
Msl1 human colon cancer  up Spears, 2011 
myogenic 
bHLH 
Xenopus ? up 
Munsterberg, 
1995  
n-myc mesenchyme limbs  up Ten Berge, 2008  
nanog ES   
Pereira, 2006 
Cole, 2008 
Nemo     
NeuroD1 Mouse Brain yes up Kuwabara, 2009  
neurogenin 1 Mouse brain yes up 
Hirabayashi, 
2004  
Nitric Oxide 
Synthase 2 
Hepg2 cells  up Du, 2006  
Nkx2.2 Neural tube yes down Lei, 2006  
Nr-CAM human colon cancer yes up 
Conacci-Sorrell, 
2002  
Oct 4 ES  up Cole, 2008  
Osteocalcin Mouse yes down Kahler, 2003  
Osteoprotege
rin 
Osteoblasts  up Glass, 2005  
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P16ink4A Melanocytes yes down Delmas, 2007  
periostin Mouse Wnt-3 
not through β-
catenin? 
down 
 Haertel-
Wiesmann, 2000 
PTTG 
oesophageal squamous 
cell carcinoma 
  Zhou, 2004  
Pitx2 pituitary yes up Kioussi, 2002  
PPARdelta human colon cancer yes up He TC, 1999  
Proglucagon Mouse ? up Ni, 2003  
RANK ligand Osteoblasts  down Spencer, 2006  
ret rat PC12 ? up Zheng, 1996  
retinoic acid 
receptor 
gamma 
Xenopus ?  McGrew, 1999  
Runx2 chondrocytes  up Dong, 2006  
SALL4    Bohm, 2006  
sFRP-2 Mouse (Wnt-4) ? up Lescher, 1998  
shavenbaby Drosophila ? down Payre, 1999  
Siamois Xenopus yes up Brannon, 1997  
snail ES/EB  up Ten Berge, 2008  
Sox17 gastrointestinal tumours  up Du, 2009  
Sox2 Xenopus retina  up Van Raay, 2005  
Sox9 Intestine  up Blache, 2004  
Sox9 mesenchyme  down 
Hill, 2005 
Day, 2005 
Yano, 2005 
SP5 Mouse brain yes up 
Weidinger, 2005 
Fujimura, 2007 
Stra6 
Wnt-1 transformed 
mouse cells 
? 
co-induced by 
Wnt plus RA 
up Szeto, 2001  
stripe Drosophila yes down Piepenburg, 2000  
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Stromelysin 
Wnt-1 transformed 
mouse cells 
 up Prieve, 2003  
Survivin human colon cancer  up Zhang, 2001  
Tcf-1 human colon cancer yes up Roose, 1999  
Telomerase ES, other stem yes up Hoffmyer, 2012  
Tiam1 Colon tumours   Malliri, 2005  
TNF family 
41BB ligand, 
ephrinB1, 
Stra6, 
autotaxin and 
ISLR 
Wnt-1 transformed 
mouse cells 
By Wnt plus 
retinoic acid 
up Tice, 2002  
Tnfrsf19 Somitic mesoderm yes up Buttitta, 2003  
twin Xenopus yes up Laurent, 1997  
Twist 
Wnt1 induced mammary 
cancer 
 up Howe, 2003  
Ubx Drosophila yes up or down Riese, 1997  
uPAR human colon cancer ? up Mann B, 1999  
VEGF human colon cancer yes up Zhang, 2001  
versican 
vascular smooth muscle 
cells 
yes up Rahmani, 2005  
wingless Drosophila ? up or down Yu, 1998  
WISP 
Wnt-1 transformed 
mouse cells 
yes, but not 
through TCF 
(Xu, 2000) 
up Xu, 2000  
WISP-1, 
WISP-2, IGF-
II , Proliferin-
2, Proliferin-3, 
Emp, IGF-I, 
VEGF-C, 
MDR1, COX-
2, IL-6 
3T3-L1 Preadipocytes ? up Longo, 2002  
Wnt3a EC cells   Zhang, 2009  
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Wrch-1 
Wnt-1 transformed 
mouse cells 
? 
Not through TCF 
up Tao, 2001  
Xnr3 Xenopus yes up McKendry, 1997  
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Appendix B. APC amino acid sequence alignment. Chicken APC (cAPC) amino acid 
sequenced is aligned with human APC (hAPC) amino acid sequence and shows 84% 
sequence homology. Matched amino acids are shown with a line. Alternating exons are 
shown in black and red. Red represents a residue overlap splice site. 
